Anthony Lucci, M.D.

Peer-Reviewed Articles

1. Hasanov M, Kiany S, Forget MA, Bassett R, Davies MA, Diab A, Gershenwald JE, Glitza IC, Lee JE, Lucci A, McQuade JL, Patel SP, Ross MI, Tawbi HA, Wargo JA, Wong MK, Bernatchez C, Hwu P, Haymaker C, Amaria RN. Lymphodepletion, tumor-infiltrating lymphocytes, and high versus low dose IL-2 followed by pembrolizumab in patients with metastatic melanoma. Oncoimmunology 14(1):2546402, 2025. e-Pub 2025. PMID: 40815607.
2. Iwase T, Sridhar N, Kai M, Dong W, Shen Y, Krishnamurthy S, Lucci A, Le-Petross HTC, Nasrazadani A, Saleem S, Layman RM, Valero V, Tripathy D, Woodward WA, Cheng YC, Nakhlis F, Bellon JR, Lynce F, Ueno NT. Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective study. Breast Cancer Res Treat 214(1):69-77, 2025. e-Pub 2025. PMID: 40753318.
3. Mohan SC, Chen JH, Tidwell RSS, Kai M, Lucci A, Woodward WA, Johnson HM. Investigating the Prognostic Impact of Postpartum Diagnosis in Women with De Novo Stage IV Inflammatory Breast Cancer. Ann Surg Oncol 32(11):8353-8364, 2025. e-Pub 2025. PMID: 40705265.
4. Chen JH, Slack Tidwell RS, Kai M, Lucci A, Woodward WA, Johnson HM. Impact of Postpartum Diagnosis on Survival of Women with Inflammatory Breast Cancer. Cancer Epidemiol Biomarkers Prev, 2025. e-Pub 2025. PMID: 40938309.
5. Melo SA, Sugimoto H, O'Connell JT, Kato N, Villanueva A, Vidal A, Qiu L, Vitkin E, Perelman LT, Melo CA, Lucci A, Ivan C, Calin GA, Kalluri R. Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis. Cancer Cell 43(9):1776, 2025. e-Pub 2025. PMID: 40930611.
6. Hsiang J, Kang A, Maristany A, Malik F, Botwinick A, Lucci A, Bez Y, Coffey B. Chronic Catatonia in an Adolescent: A Case of Functional Decline and Relapse. J Child Adolesc Psychopharmacol, 2025. e-Pub 2025. PMID: 40779407.
7. Huynh VD, Mouabbi J, Kuerer HM, Wanis KN, Abdel-Salam HM, Gutierrez AM, Johnson HM, Lucci A, Hunt KK, Arun BK. Characterization of the Germline Pathogenic Mutational Landscape and Oncologic Outcomes Among 877 Patients with Invasive Lobular Carcinoma. Ann Surg Oncol 32(8):5477-5488, 2025. e-Pub 2025. PMID: 40314901.
8. Goktepe B, Demirors B, Senol K, Ozbas S, Sezgin E, Lucci A, Soran A. A Pragmatic Grouping Model for Bone-Only De Novo Metastatic Breast Cancer (MetS Protocol MF22-03). Cancers (Basel) 17(12), 2025. e-Pub 2025. PMID: 40563682.
9. Goktepe B, Demirors B, Senol K, Ozbas S, Sezgin E, Lucci A, Soran A. A Pragmatic Grouping Model for Bone-Only De Novo Metastatic Breast Cancer (MetS Protocol MF22-03). Cancers (Basel) 17(12):1-15, 2025.
10. Kouzy R, Kai M, Huong T Le-Petross, Saleem S, Cancer Team MIB, Woodward WA. Use of natural language processing to identify patients with inflammatory breast cancer across a health-care system, 2025. e-Pub 2025.
11. Kouzy, R, Kai, M, Le-Petross, HT, Saleem, S, Layman, RM, Lim, B, Nasrazadani, A, Saleem, S, Valero, V, Stauder, MC, Lucci, A, Sun, SX, Whitman, GJ, Patel, MM, Le-Petross, H, Lu, Y, Marx, AN, Alexander, A, Yajima, C, Kai, M, Villareal, L, Lopez, H, Woodward, W. Use of natural language processing to identify patients with inflammatory breast cancer across a health-care system. JNCI Cancer Spectrum 9(3), 2025. e-Pub 2025. PMID: 40493814.
12. Goktepe, B, Demirors, B, Senol, K, Ozbas, S, Sezgin, E, Lucci, A, Soran, A. A Pragmatic Grouping Model for Bone-Only De Novo Metastatic Breast Cancer (MetS Protocol MF22-03) †. Cancers 17(12), 2025. e-Pub 2025.
13. Kuerer HM, Valero V, Smith BD, Krishnamurthy S, Diego EJ, Johnson HM, Lin H, Shen Y, Lucci A, Shaitelman SF, Mitchell MP, Boughey JC, White RL, Hunt KK, Yang WT, Rauch GM. Selective Elimination of Breast Surgery for Invasive Breast Cancer: A Nonrandomized Clinical Trial. JAMA Oncol 11(5):529-534, 2025. e-Pub 2025. PMID: 40152443.
14. Glencer AC, Wanis KN, Brown S, Lucci A, Sun SX, Adesoye T, DeSnyder SM, Layman R, Woodward WA, Hunt KK, Teshome M. Self-Reported Management of Inflammatory Breast Cancer Among the American Society of Breast Surgeons Membership: Consensus and Opportunities. Ann Surg Oncol 31(11):7326-7334, 2024. e-Pub 2024. PMID: 39034365.
15. Lucci A. Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA, 2024. e-Pub 2024.
16. Chen JH, Addanki S, Roy D, Bassett R, Kalashnikova E, Spickard E, Kuerer HM, Meas S, Sarli VN, Korkut A, White JB, Rauch GM, Tripathy D, Arun BK, Barcenas CH, Yam C, Sethi H, Rodriguez AA, Liu MC, Moulder SL, Lucci A. Monitoring response to neoadjuvant chemotherapy in triple negative breast cancer using circulating tumor DNA. BMC Cancer 24(1):1016, 2024. e-Pub 2024. PMID: 39148033.
17. Wanis KN, Kuerer HM, Sun SX, Hunt KK, Glencer AC, Teshome M, Lucci A, Weiser R, Johnson H, Smith BD, Gutierrez AM, Shaitelman SF, Arun BK. Clinical Outcomes for BRCA Pathogenic Variant Carriers With Breast Cancer Undergoing Breast Conservation. JAMA Netw Open 7(6):e2418486, 2024. e-Pub 2024. PMID: 38916888.
18. Kim Y, Ganduglia-Cazaban C, Tamirisa N, Lucci A, Krause TM. Correction: Contemporary Analysis of Reexcision and Conversion to Mastectomy Rates and Associated Healthcare Costs for Women Undergoing Breast-Conserving Surgery. Ann Surg Oncol 31(6):3956, 2024. e-Pub 2024. PMID: 38520584.
19. Kim Y, Ganduglia-Cazaban C, Tamirisa N, Lucci A, Krause TM. Contemporary Analysis of Reexcision and Conversion to Mastectomy Rates and Associated Healthcare Costs for Women Undergoing Breast-Conserving Surgery. Ann Surg Oncol 31(6):3649-3660, 2024. e-Pub 2024. PMID: 38319511.
20. Szabo Yamashita T, Shirali AS, Meas S, Sarli V, Clemente-Gutierrez UE, Chiang YJ, Silva-Figueroa A, Vodopivec DM, Williams M, Fisher SB, Graham PH, Grubbs EG, Lucci A, Busaidy N, Perrier ND. Is there a role for liquid biopsy in the surveillance of parathyroid carcinoma?. Surgery 175(1):193-198, 2024. e-Pub 2024. PMID: 37993289.
21. Lucci A, Kim LS, Golshan M, King TA. Great Debate: The Surgeon's Role in Locoregional Management of Stage IV Breast Cancer. Ann Surg Oncol 30(12):7000-7007, 2023. e-Pub 2023. PMID: 37596450.
22. Zaveri S, Everidge S, FitzSullivan E, Hwang R, Smith BD, Lin H, Shen Y, Lucci A, Teshome M, Sun SX, Hunt KK, Kuerer HM. ASO Visual Abstract: Extremely Low Incidence of Local-Regional Recurrences Observed among T1-2N1 (one or two Positive SLNs) Breast Cancer Patients Receiving Upfront Mastectomy without Completion Axillary Node Dissection. Ann Surg Oncol 30(12):7141-7142, 2023. e-Pub 2023. PMID: 37612547.
23. Zaveri S, Everidge S, FitzSullivan E, Hwang R, Smith BD, Lin H, Shen Y, Lucci A, Teshome M, Sun SX, Hunt KK, Kuerer HM. Extremely Low Incidence of Local-Regional Recurrences Observed Among T1-2 N1 (1 or 2 Positive SLNs) Breast Cancer Patients Receiving Upfront Mastectomy Without Completion Axillary Node Dissection. Ann Surg Oncol 30(12):7015-7025, 2023. e-Pub 2023. PMID: 37458948.
24. Adesoye T, Lucci A. ASO Author Reflections: Low Rates of Local-Regional Recurrence in Inflammatory Breast Cancer Patients After Contemporary Trimodal Therapy. Ann Surg Oncol 30(10):6243-6244, 2023. e-Pub 2023. PMID: 37610486.
25. Adesoye T, Everidge S, Chen J, Sun SX, Teshome M, Valero V, Woodward WA, Lucci A. Low Rates of Local-Regional Recurrence Among Inflammatory Breast Cancer Patients After Contemporary Trimodal Therapy. Ann Surg Oncol 30(10):6232-6240, 2023. e-Pub 2023. PMID: 37479842.
26. Johnson HM, Lin H, Shen Y, Diego EJ, Krishnamurthy S, Yang WT, Smith BD, Valero V, Lucci A, Sun SX, Shaitelman SF, Mitchell MP, Boughey JC, White RL, Rauch GM, Kuerer HM, Study Group ER. Patient-Reported Outcomes of Omission of Breast Surgery Following Neoadjuvant Systemic Therapy: A Nonrandomized Clinical Trial. JAMA Netw Open 6(9):e2333933, 2023. e-Pub 2023. PMID: 37707811.
27. Asare EA, Fisher SB, Chiang YJ, Haydu LE, Patel SH, Keung EZ, Lucci A, Wargo J, Gershenwald JE, Ross MI, Lee JE. Melanoma metastatic to the adrenal gland: An update on the role of adrenalectomy in multidisciplinary management. J Surg Oncol 128(2):313-321, 2023. e-Pub 2023. PMID: 37010038.
28. Adesoye T, Everidge S, Chen J, Sun SX, Teshome M, Valero V, Woodward WA, Lucci A. ASO Visual Abstract: Low Rates of Local-Regional Recurrence in Inflammatory Breast Cancer Patients After Contemporary Trimodal Therapy. Ann Surg Oncol. e-Pub 2023. PMID: 37578608.
29. Johnson HM, Valero V, Yang WT, Smith BD, Krishnamurthy S, Shen Y, Lin H, Lucci A, Rauch GM, Kuerer HM. Eliminating Breast Surgery for Invasive Cancer with Exceptional Response to Neoadjuvant Systemic Therapy: Prospective Multicenter Clinical Trial Planned Initial Feasibility Endpoint. J Am Coll Surg 237(1):101-108, 2023. e-Pub 2023. PMID: 36856291.
30. Lucci A, Addanki S, Chiang YJ, Meas S, Sarli VN, Upshaw JR, Manchem M, Patel SP, Wargo JA, Gershenwald JE, Ross MI. Presence of Circulating Tumor Cells Predates Imaging Detection of Relapse in Patients with Stage III Melanoma. Cancers (Basel) 15(14), 2023. e-Pub 2023. PMID: 37509290.
31. Drula R, Pardini B, Fu X, De Los Santos MC, Jurj A, Pang L, El-Daly SM, Fabris L, Knutsen E, Dragomir MP, Bayraktar R, Li Y, Chen M, Del Vecchio F, Berland L, Dae J, Fan D, Shimizu M, Tran AM, Barzi M, Pioppini C, Gutierrez AM, Ivan C, Meas S, Hall CS, Alahari SK, Berindan-Neagoe I, Fabbri M, Lucci A, Arun B, Anfossi S, Calin GA. 17β-estradiol promotes extracellular vesicle release and selective miRNA loading in ERα-positive breast cancer. Proc Natl Acad Sci U S A 120(23):e2122053120, 2023. e-Pub 2023. PMID: 37252969.
32. Singh B, Sarli VN, Milligan RD, Kinne HE, Shamsnia A, Washburn LJ, Addanki S, Lucci A. Sensitization of Resistant Cells with a BET Bromodomain Inhibitor in a Cell Culture Model of Deep Intrinsic Resistance in Breast Cancer. Cancers (Basel) 15(7), 2023. e-Pub 2023. PMID: 37046697.
33. Amaria RN, Postow M, Burton EM, Tetzlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto VG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi HA. Author Correction: Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature 615(7953):E23, 2023. e-Pub 2023. PMID: 36894629.
34. Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA. Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. e-Pub 2023. PMID: 36627494.
35. Kuerer HM, Smith BD, Krishnamurthy S, Yang WT, Valero V, Shen Y, Lin H, Lucci A, Boughey JC, White RL, Diego EJ, Rauch GM, Trials Group ERC. Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial. Lancet Oncol 23(12):1517-1524, 2022. e-Pub 2022. PMID: 36306810.
36. Cobb AN, Diao K, Teshome M, Lucci A, Ueno NT, Stauder M, Layman RM, Kuerer HM, Woodward WA, Sun SX. ASO Visual Abstract: Long-Term Oncologic Outcomes in Patients with Inflammatory Breast Cancer with Supraclavicular Nodal Involvement. Ann Surg Oncol 29(Suppl 3):620-621, 2022. e-Pub 2022. PMID: 36104531.
37. Singh B, Sarli VN, Kinne HE, Shamsnia A, Lucci A. Correction: Evaluation of 6-mercaptopurine in a cell culture model of adaptable triple-negative breast cancer with metastatic potential. Oncotarget 13:1272, 2022. e-Pub 2022. PMID: 36395366.
38. Amaria RN, Postow M, Burton EM, Tezlaff MT, Ross MI, Torres-Cabala C, Glitza IC, Duan F, Milton DR, Busam K, Simpson L, McQuade JL, Wong MK, Gershenwald JE, Lee JE, Goepfert RP, Keung EZ, Fisher SB, Betof-Warner A, Shoushtari AN, Callahan M, Coit D, Bartlett EK, Bello D, Momtaz P, Nicholas C, Gu A, Zhang X, Korivi BR, Patnana M, Patel SP, Diab A, Lucci A, Prieto VG, Davies MA, Allison JP, Sharma P, Wargo JA, Ariyan C, Tawbi HA. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Nature. e-Pub 2022. PMID: 36289334.
39. Farley CR, Irwin S, Adesoye T, Sun SX, DeSnyder SM, Lucci A, Shaitelman SF, Chang EI, Ueno NT, Woodward WA, Teshome M. Lymphedema in Inflammatory Breast Cancer Patients Following Trimodal Treatment. Ann Surg Oncol 29(10):6370-6378, 2022. e-Pub 2022. PMID: 35854031.
40. Cobb AN, Diao K, Teshome M, Lucci A, Ueno NT, Stauder M, Layman RM, Kuerer HM, Woodward WA, Sun SX. Long-term Oncologic Outcomes in Patients with Inflammatory Breast Cancer with Supraclavicular Nodal Involvement. Ann Surg Oncol 29(10):6381-6392, 2022. e-Pub 2022. PMID: 35834145.
41. Farley CR, Irwin S, Adesoye T, Sun SX, DeSnyder SM, Lucci A, Shaitelman SF, Chang EI, Ueno NT, Woodward WA, Teshome M. ASO Visual Abstract: Lymphedema in Inflammatory Breast Cancer Patients Following Trimodal Treatment. Ann Surg Oncol. e-Pub 2022. PMID: 36030283.
42. Wang Y, Ramachandran V, Sui D, Xu K, Haydu LE, Fang S, McQuade JL, Fisher SB, Lucci A, Keung EZ, Wargo J, Gershenwald JE, Ross MI, Lee JE. Evaluation of Plasma IL-6 in Patients with Melanoma as a Prognostic and Checkpoint Immunotherapy Predictive Biomarker. J Invest Dermatol 142(7):2046-2049.e3, 2022. e-Pub 2022. PMID: 34952092.
43. Vellano CP, White MG, Andrews MC, Chelvanambi M, Witt RG, Daniele JR, Titus M, McQuade JL, Conforti F, Burton EM, Lastrapes MJ, Ologun G, Cogdill AP, Morad G, Prieto P, Lazar AJ, Chu Y, Han G, Khan MAW, Helmink B, Davies MA, Amaria RN, Kovacs JJ, Woodman SE, Patel S, Hwu P, Peoples M, Lee JE, Cooper ZA, Zhu H, Gao G, Banerjee H, Lau M, Gershenwald JE, Lucci A, Keung EZ, Ross MI, Pala L, Pagan E, Segura RL, Liu Q, Borthwick MS, Lau E, Yates MS, Westin SN, Wani K, Tetzlaff MT, Haydu LE, Mahendra M, Ma X, Logothetis C, Kulstad Z, Johnson S, Hudgens CW, Feng N, Federico L, Long GV, Futreal PA, Arur S, Tawbi HA, Moran AE, Wang L, Heffernan TP, Marszalek JR, Wargo JA. Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. Nature. e-Pub 2022. PMID: 35705814.
44. Singh B, Sarli VN, Lucci A. Sensitization of Resistant Breast Cancer Cells with a Jumonji Family Histone Demethylase Inhibitor. Cancers (Basel) 14(11), 2022. e-Pub 2022. PMID: 35681611.
45. Adesoye T, Sun SX, Schaverien MV, Woodward WA, Lucci A. Immediate Breast Reconstruction in Inflammatory Breast Cancer: Are We There Yet?. Ann Surg Oncol. e-Pub 2022. PMID: 35471749.
46. Witt RG, Cope B, Chiang YJ, Newhook T, Lillemoe H, Tzeng CD, Chen IB, Fisher SB, Lucci A, Wargo JA, Lee JE, Ross MI, Gershenwald JE, Robinson J, Keung EZ. Utilization and evolving prescribing practice of opioid and non-opioid analgesics in patients undergoing lymphadenectomy for cutaneous malignancy. J Surg Oncol 125(4):719-729, 2022. e-Pub 2022. PMID: 34904258.
47. Masuda H, Harano K, Miura S, Wang Y, Hirota Y, Harada O, Jolly MK, Matsunaga Y, Lim B, Wood AL, Parinyanitikul N, Jin Lee H, Gong G, George JT, Levine H, Lee J, Wang X, Lucci A, Rao A, Schweitzer BL, Lawrence OR, Seitz RS, Morris SW, Hout DR, Nakamura S, Krishnamurthy S, Ueno NT. Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy. JCO Precis Oncol 6:e2000368, 2022. e-Pub 2022. PMID: 35294223.
48. Sosa A, Lei X, Woodward WA, Chavez Mac Gregor M, Lucci A, Giordano SH, Nead KT. Trends in Sentinel Lymph Node Biopsies in Patients With Inflammatory Breast Cancer in the US. JAMA Netw Open 5(2):e2148021, 2022. e-Pub 2022. PMID: 35147686.
49. Postlewait LM, Teshome M, Adesoye T, DeSnyder SM, Lim B, Kuerer HM, Bedrosian I, Sun SX, Woodward WA, Le-Petross HT, Valero V, Ueno NT, Lucci A. Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer. Ann Surg Oncol 28(13):8610-8621, 2021. e-Pub 2021. PMID: 34125346.
50. Adesoye T, Babayemi O, Postlewait LM, DeSnyder SM, Sun SX, Woodward WA, Ueno NT, Hunt K, Lucci A, Teshome M. ASO Visual Abstract: Inflammatory Breast Cancer at the Extremes of Age. Ann Surg Oncol. e-Pub 2021. PMID: 34743277.
51. Elmore LC, Kuerer HM, Barcenas CH, Smith BD, Miggins MV, Lucci A, Caudle AS, Meric-Bernstam F, Hunt KK, Teshome M. ASO Visual Abstract: Clinical Course of Breast Cancer Patients with Local Regional Progression During Neoadjuvant Systemic Therapy. Ann Surg Oncol. e-Pub 2021. PMID: 34743278.
52. Elmore LC, Kuerer HM, Barcenas CH, Smith BD, Miggins MV, Lucci A, Caudle AS, Meric-Bernstam F, Hunt KK, Teshome M. Clinical Course of Breast Cancer Patients with Local-Regional Progression During Neoadjuvant Systemic Therapy. Ann Surg Oncol 28(10):5477-5485, 2021. e-Pub 2021. PMID: 34247335.
53. Roy D, Lucci A, Ignatiadis M, Jeffrey SS. Cell-free circulating tumor DNA profiling in cancer management. Trends Mol Med 27(10):1014-1015, 2021. e-Pub 2021. PMID: 34312074.
54. Adesoye T, Lucci A. Current Surgical Management of Inflammatory Breast Cancer. Ann Surg Oncol 28(10):5461-5467, 2021. e-Pub 2021. PMID: 34346020.
55. Adesoye T, Babayemi O, Postlewait LM, DeSnyder SM, Sun SX, Woodward WA, Ueno NT, Hunt KK, Lucci A, Teshome M. Inflammatory Breast Cancer at the Extremes of Age. Ann Surg Oncol 28(10):5626-5634, 2021. e-Pub 2021. PMID: 34292426.
56. White MG, Lee A, Vicente D, Hall C, Kim MP, Katz MHG, Lee JE, Ikoma N, Lucci A, Tzeng CD. Measurement of Portal Vein Blood Circulating Tumor Cells is Safe and May Correlate With Outcomes in Resected Pancreatic Ductal Adenocarcinoma. Ann Surg Oncol 28(8):4615-4622, 2021. e-Pub 2021. PMID: 33415562.
57. Adesoye T, Lucci A. ASO Visual Abstract: Current Surgical Management of Inflammatory Breast Cancer. Ann Surg Oncol. e-Pub 2021. PMID: 34386917.
58. Partain N, Postlewait LM, Teshome M, Rosso K, Hall C, Song J, Meas S, DeSnyder SM, Lim B, Valero V, Woodward W, Ueno NT, Kuerer H, Lucci A. The Role of Mastectomy in De Novo Stage IV Inflammatory Breast Cancer. Ann Surg Oncol 28(8):4265-4274, 2021. e-Pub 2021. PMID: 33403525.
59. Mitra D, Ologun G, Keung EZ, Goepfert RP, Amaria RN, Ross MI, Gershenwald JE, Lucci A, Fisher SB, Davies MA, Lee JE, Bishop AJ, Farooqi AS, Wargo J, Guadagnolo BA. Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era. Ann Surg Oncol 28(7):3480-3489, 2021. e-Pub 2021. PMID: 33856603.
60. Kilgore LJ, Murphy BL, Postlewait LM, Liang DH, Bedrosian I, Lucci A, Kuerer HM, Hunt KK, Teshome M. Impact of the early COVID-19 pandemic on Breast Surgical Oncology fellow education. J Surg Oncol. e-Pub 2021. PMID: 34328640.
61. Postlewait LM, Lucci A. ASO Author Reflections: Metastasis of Inflammatory Breast Cancer to the Contralateral Axilla: A Finding Meriting Further Study. Ann Surg Oncol. e-Pub 2021. PMID: 34076808.
62. Postlewait LM, Teshome M, Adesoye T, DeSnyder SM, Lim B, Kuerer HM, Bedrosian I, Sun SX, Woodward WA, Le-Petross HT, Valero V, Ueno NT, Lucci A. ASO Visual Abstract: Contralateral Axillary Metastasis in Patients with Inflammatory Breast Cancer. Ann Surg Oncol. e-Pub 2021. PMID: 34052918.
63. Singh B, Sarli VN, Lucci A. Inhibition of resistant triple-negative breast cancer cells with low-dose 6-mercaptopurine and 5-azacitidine. Oncotarget 12(7):626-637, 2021. e-Pub 2021. PMID: 33868584.
64. Postlewait LM, Lucci A. ASO Author Reflections: The Multidisciplinary Approach to de Novo Metastatic Inflammatory Breast Cancer: A Combined Systemic and Locoregional Strategy. Ann Surg Oncol. e-Pub 2021. PMID: 33404772.
65. Postlewait LM, Lucci A. ASO Author Reflection: Axillary Dissection for Negative Lymph Nodes in Inflammatory Breast Cancer-Need for Clinical Trials to Reassess Standard of Care. Ann Surg Oncol 27(Suppl 3):676-677, 2020. e-Pub 2020. PMID: 32737697.
66. Postlewait LM, Teshome M, DeSnyder SM, Lim B, Kuerer HM, Bedrosian I, Woodward WA, Ueno NT, Lucci A. Factors Associated with Pathological Node Negativity in Inflammatory Breast Cancer: Are There Patients Who May be Candidates for a De-Escalation of Axillary Surgery?. Ann Surg Oncol 27(12):4603-4612, 2020. e-Pub 2020. PMID: 32710271.
67. Grindel BJ, Engel BJ, Hall CG, Kelderhouse LE, Lucci A, Zacharias NM, Takahashi TT, Millward SW. Mammalian expression and in situ biotinylation of extracellular protein targets for directed evolution. ACS Omega 5(39):25440-25455, 2020. e-Pub 2020. PMID: 33043224.
68. Kida K, Hess KR, Lim B, Iwase T, Chainitikun S, Valero V, Lucci A, Le-Petross HC, Woodward WA, Krishnamurthy S, Hortobagyi GN, Tripathy D, Ueno NT. Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer. Cancers (Basel) 12(11), 2020. e-Pub 2020. PMID: 33114311.
69. Singh P, Tevis SE, Hall CS, Meas S, Hwang RF, Lucci A. Correlation of circulating or disseminated tumor cells with the Oncotype DX Recurrence Score. Breast Cancer Res Treat. e-Pub 2020. PMID: 32888140.
70. Haydu LE, Lo SN, McQuade JL, Amaria RN, Wargo J, Ross MI, Cormier JN, Lucci A, Lee JE, Ferguson SD, Saw RPM, Spillane AJ, Shannon KF, Stretch JR, Hwu P, Patel SP, Diab A, Wong MKK, Glitza Oliva IC, Tawbi H, Carlino MS, Menzies AM, Long GV, Lazar AJ, Tetzlaff MT, Scolyer RA, Gershenwald JE, Thompson JF, Davies MA. Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. J Clin Oncol 38(13):1429-1441, 2020. e-Pub 2020. PMID: 31990608.
71. Iwase T, Harano K, Masuda H, Kida K, Hess KR, Wang Y, Dirix L, Van Laere SJ, Lucci A, Krishnamurthy S, Woodward WA, Layman RM, Bertucci F, Ueno NT. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. BMC Cancer 20(1):430, 2020. e-Pub 2020. PMID: 32423453.
72. Lucci A, Hall CS, Patel SP, Narendran B, Bauldry JB, Royal RE, Karhade M, Upshaw JR, Wargo JA, Glitza IC, Wong MKK, Amaria RN, Tawbi HA, Diab A, Davies MA, Gershenwald JE, Lee JE, Hwu P, Ross MI. Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. Clin Cancer Res 26(8):1886-1895, 2020. e-Pub 2020. PMID: 32015020.
73. Ueno NT, Tahara RK, Fujii T, Reuben JM, Gao H, Saigal B, Lucci A, Iwase T, Ibrahim NK, Damodaran S, Shen Y, Liu DD, Hortobagyi GN, Tripathy D, Lim B, Chasen BA. Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer. Cancer Med 9(3):1025-1032, 2020. e-Pub 2020. PMID: 31849202.
74. Helmink BA, Reddy SM, Gao J, Zhang S, Basar R, Thakur R, Yizhak K, Sade-Feldman M, Blando J, Han G, Gopalakrishnan V, Xi Y, Zhao H, Amaria RN, Tawbi HA, Cogdill AP, Liu W, LeBleu VS, Kugeratski FG, Patel S, Davies MA, Hwu P, Lee JE, Gershenwald JE, Lucci A, Arora R, Woodman S, Keung EZ, Gaudreau PO, Reuben A, Spencer CN, Burton EM, Haydu LE, Lazar AJ, Zapassodi R, Hudgens CW, Ledesma DA, Ong S, Bailey M, Warren S, Rao D, Krijgsman O, Rozeman EA, Peeper D, Blank CU, Schumacher TN, Butterfield LH, Zelazowska MA, McBride KM, Kalluri R, Allison J, Petitprez F, Fridman WH, Sautès-Fridman C, Hacohen N, Rezvani K, Sharma P, Tetzlaff MT, Wang L, Wargo JA. B cells and tertiary lymphoid structures promote immunotherapy response. Nature 577(7791):549-555, 2020. e-Pub 2020. PMID: 31942075.
75. Singh B, Sarli VN, Lucci A. Potential of 6-mercaptopurine and 5-azacitidine in halting progression of poor prognosis residual disease in triple-negative breast cancer modeled in cell culture. Oncotarget, 2020. e-Pub 2020.
76. Liang DH, Hall C, Lucci A. Circulating Tumor Cells in Breast Cancer. Tumor Liquid Biopsies 215:127-145, 2020. e-Pub 2020. PMID: 31605227.
77. Masuda H, Harano K, Miura S, Wang Y, Hirota Y, Harada O, Jolly MK, Matsunaga Y, Lim B, Wood AL, Parinyanitikul N, Lee HJ, Gong G, George JT, Levine H, Lee J, Wang X, Lucci A, Rao A, Schweitzer BL, Lawrence OR, Seitz RS, Morris SW, Hout DR, Nakamura S, Krishnamurthy S, Ueno NT. Changes in triple-negative breast cancer molecular subtype in patients without pathological complete response after neoadjuvant systemic therapy. Breast Cancer Research, 2020. e-Pub 2020.
78. Sun S, van la Parra RFD, Rauch GM, Checka C, Tadros AB, Lucci A, Teshome M, Black D, Hwang RF, Smith BD, Krishnamurthy S, Valero V, Yang WT, Kuerer HM. Patient Selection for Clinical Trials Eliminating Surgery for HER2-Positive Breast Cancer Treated with Neoadjuvant Systemic Therapy. Ann Surg Oncol 26(10):3071-3079, 2019. e-Pub 2019. PMID: 31342361.
79. Li Y, Chen M, Pardini B, Dragomir MP, Lucci A, Calin GA. The role of radiotherapy in metaplastic breast cancer: a propensity score-matched analysis of the SEER database. J Transl Med 17(1):318, 2019. e-Pub 2019. PMID: 31547814.
80. Park KU, Lucci A. Nipple sparing mastectomy for melanoma metastatic to the breast. Breast J 25(4):741, 2019. e-Pub 2019. PMID: 31074069.
81. Vicente D, Lee AJ, Hall CS, Lucci A, Lee JE, Kim MP, Katz MH, Hurd MW, Maitra A, Rhim Md AD, Tzeng CD. Circulating Tumor Cells and Transforming Growth Factor Beta in Resected Pancreatic Adenocarcinoma. J Surg Res 243:90-99. e-Pub 2019. PMID: 31170555.
82. Singh B, Sarli VN, Kinne HE, Shamsnia A, Lucci A. Evaluation of 6-mercaptopurine in a cell culture model of adaptable triple-negative breast cancer with metastatic potential. Oncotarget 10(38):3681-3693, 2019. e-Pub 2019. PMID: 31217902.
83. Anand K, Roszik J, Gombos D, Upshaw J, Sarli V, Meas S, Lucci A, Hall C, Patel S. Pilot Study of Circulating Tumor Cells in Early-Stage and Metastatic Uveal Melanoma. Cancers (Basel) 11(6), 2019. e-Pub 2019. PMID: 31226786.
84. Stecklein SR, Rosso KJ, Nuanjing J, Tadros AB, Weiss A, DeSnyder SM, Kuerer HM, Teshome M, Buchholz TA, Stauder MC, Ueno NT, Lucci A, Woodward WA. Excellent Locoregional Control in Inflammatory Breast Cancer with a Personalized Radiotherapy Approach. Pract Radiat Oncol. e-Pub 2019. PMID: 31132433.
85. Tevis SE, Bassett R, Bedrosian I, Barcenas CH, Black DM, Caudle AS, DeSnyder SM, Fitzsullivan E, Hunt KK, Kuerer HM, Lucci A, Meric-Bernstam F, Mittendorf EA, Park K, Teshome M, Thompson AM, Hwang RF. OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative Breast Cancer Patients. Ann Surg Oncol 26(3):815-820, 2019. e-Pub 2019. PMID: 30556120.
86. Tadros AB, Smith BD, Shen Y, Lin H, Krishnamurthy S, Lucci A, Barcenas CH, Hwang RF, Rauch G, Santiago L, Strom EA, DeSnyder SM, Yang WT, Black DM, Albarracin CT, Chavez-MacGregor M, Hunt KK, Kuerer HM. Ductal Carcinoma In Situ and Margins <2?mm: Contemporary Outcomes With Breast Conservation. Ann Surg 269(1):150-157, 2019. e-Pub 2019. PMID: 28742682.
87. Ning J, Fouad TM, Lin H, Sahin AA, Lucci A, Woodward WA, Krishnamurthy S, Tripathy D, Ueno NT, Shen Y. The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancer. J Cancer 10(12):2635-2642, 2019. e-Pub 2019. PMID: 31258771.
88. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24(12):1942, 2018. e-Pub 2018. PMID: 30361511.
89. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24(12):1941, 2018. e-Pub 2018. PMID: 30361510.
90. Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, Diab A, Wong MK, Royal R, Gross N, Weber R, Lai SY, Ehlers R, Blando J, Milton DR, Woodman S, Kageyama R, Wells DK, Hwu P, Patel SP, Lucci A, Hessel A, Lee JE, Gershenwald J, Simpson L, Burton EM, Posada L, Haydu L, Wang L, Zhang S, Lazar AJ, Hudgens CW, Gopalakrishnan V, Reuben A, Andrews MC, Spencer CN, Prieto V, Sharma P, Allison J, Tetzlaff MT, Wargo JA. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 24(11):1649-1654, 2018. e-Pub 2018. PMID: 30297909.
91. DeSnyder SM, Hunt KK, Dong W, Smith BD, Moran MS, Chavez-MacGregor M, Shen Y, Kuerer HM, Lucci A. American Society of Breast Surgeons' Practice Patterns After Publication of the SSO-ASTRO-ASCO DCIS Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation. Ann Surg Oncol 25(10):2965-2974, 2018. e-Pub 2018. PMID: 29987598.
92. Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clin Cancer Res 24(18):4416-4428, 2018. e-Pub 2018. PMID: 29848573.
93. Ng SP, Bahig H, Wang J, Cardenas CE, Lucci A, Hall CS, Meas S, Sarli VN, Yuan Y, Urbauer DL, Ding Y, Ikner S, Dinh V, Elgohari BA, Johnson JM, Skinner HD, Gunn GB, Garden AS, Phan J, Rosenthal DI, Morrison WH, Frank SJ, Hutcheson KA, Mohamed ASR, Lai SY, Ferrarotto R, MacManus MP, Fuller CD. Predicting treatment Response based on Dual assessment of magnetic resonance Imaging kinetics and Circulating Tumor cells in patients with Head and Neck cancer (PREDICT-HN): matching 'liquid biopsy' and quantitative tumor modeling. BMC Cancer 18(1):903, 2018. e-Pub 2018. PMID: 30231854.
94. Matsuda N, Wang X, Lim B, Krishnamurthy S, Alvarez RH, Willey JS, Parker CA, Song J, Shen Y, Hu J, Wu W, Li N, Babiera GV, Murray JL, Arun BK, Brewster AM, Reuben JM, Stauder MC, Barnett CM, Woodward WA, Le-Petross HTC, Lucci A, DeSnyder SM, Tripathy D, Valero V, Ueno NT. Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer. JAMA Oncol 4(9):1207-1213, 2018. e-Pub 2018. PMID: 29879283.
95. Hall CS, Ross M, Bowman Bauldry JB, Upshaw J, Karhade MG, Royal R, Patel S, Lucci A. Circulating Tumor Cells in Stage IV Melanoma Patients. J Am Coll Surg 227(1):116-124, 2018. e-Pub 2018. PMID: 29746918.
96. Bidard FC, Michiels S, Riethdorf S, Mueller V, Esserman LJ, Lucci A, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothé F, Smerage J, Muinelo-Romay L, Stebbing J, Viens P, Magbanua MJM, Hall CS, Engebraaten O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, Taran FA, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf DM, Bauldry JB, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Mathiesen RR, Tokiniwa H, Llombart-Cussac A, Meddis A, Blanche P, d'Hollander K, Cottu P, Park JW, Loibl S, Latouche A, Pierga JY, Pantel K. Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis. J Natl Cancer Inst 110(6):560-567, 2018. e-Pub 2018. PMID: 29659933.
97. Woodward WA, Ueno NT, Kuerer HM, Lucci A, Shen Y. Reply to 'A standard mastectomy should not be the only recommended breast surgical treatment for non-metastatic inflammatory breast cancer: A large population-based study in the Surveillance, Epidemiology, and End Results database 18'. Breast 39:148-149, 2018. e-Pub 2018. PMID: 29729725.
98. van la Parra RFD, Tadros AB, Checka CM, Rauch GM, Lucci A, Smith BD, Krishnamurthy S, Valero V, Yang WT, Kuerer HM. Baseline factors predicting a response to neoadjuvant chemotherapy with implications for non-surgical management of triple-negative breast cancer. Br J Surg 105(5):535-543, 2018. e-Pub 2018. PMID: 29465744.
99. Amaria RN, Prieto PA, Tetzlaff MT, Reuben A, Andrews MC, Ross MI, Glitza IC, Cormier J, Hwu WJ, Tawbi HA, Patel SP, Lee JE, Gershenwald JE, Spencer CN, Gopalakrishnan V, Bassett R, Simpson L, Mouton R, Hudgens CW, Zhao L, Zhu H, Cooper ZA, Wani K, Lazar A, Hwu P, Diab A, Wong MK, McQuade JL, Royal R, Lucci A, Burton EM, Reddy S, Sharma P, Allison J, Futreal PA, Woodman SE, Davies MA, Wargo JA. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol 19(2):181-193, 2018. e-Pub 2018. PMID: 29361468.
100. Singh B, Sarli VN, Washburn LJ, Raythatha MR, Lucci A. A usable model of 'decathlon winner" cancer cells in triple-negative breast cancer: survival of resistant cancer cells in quiescence. Oncotarget 9(13):11071-11082, 2018. e-Pub 2018. PMID: 29541397.
101. DeSnyder SM, Mittendorf EA, Le-Petross C, Krishnamurthy S, Whitman GJ, Ueno NT, Woodward WA, Kuerer HM, Akay CL, Babiera GV, Yang W, Lucci A. Prospective Feasibility Trial of Sentinel Lymph Node Biopsy in the Setting of Inflammatory Breast Cancer. Clin Breast Cancer 18(1):e73-e77, 2018. e-Pub 2018. PMID: 28755879.
102. Fouad TM, Ueno NT, Yu RK, Ensor JE, Alvarez RH, Krishnamurthy S, Lucci A, Reuben JM, Yang W, Willey JS, Valero V, Bondy ML, Cristofinalli M, Shete S, Woodward WA, El-Zein R. Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center. PLoS One 13(9):e0204372, 2018. e-Pub 2018. PMID: 30248155.
103. Ueno NT, Espinosa Fernandez JR, Cristofanilli M, Overmoyer B, Rea D, Berdichevski F, El-Shinawi M, Bellon J, Le-Petross HT, Lucci A, Babiera G, DeSnyder SM, Teshome M, Chang E, Lim B, Krishnamurthy S, Stauder MC, Parmar S, Mohamed MM, Alexander A, Valero V, Woodward WA. International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference. J Cancer 9(8):1437-1447, 2018. e-Pub 2018. PMID: 29721054.
104. Alvarado M, Lucci A, Manders J. Best practices for multidisciplinary integration of a DCIS genomic assay into clinical practice. J Surg Oncol 116(8):1016-1020, 2017. e-Pub 2017. PMID: 28833159.
105. Rosso KJ, Tadros AB, Weiss A, Warneke CL, DeSnyder S, Kuerer H, Ueno NT, Stecklein SR, Woodward WA, Lucci A. Improved Locoregional Control in a Contemporary Cohort of Nonmetastatic Inflammatory Breast Cancer Patients Undergoing Surgery. Ann Surg Oncol 24(10):2981-2988, 2017. e-Pub 2017. PMID: 28766220.
106. Fayanju OM, Hall CS, Bauldry JB, Karhade M, Valad LM, Kuerer HM, DeSnyder SM, Barcenas CH, Lucci A. Body mass index mediates the prognostic significance of circulating tumor cells in inflammatory breast cancer. Am J Surg 214(4):666-671, 2017. e-Pub 2017. PMID: 28720217.
107. Rosso KJ, Ueno NT, Woodward WA, Lucci A. In response to "outcomes of patients with inflammatory breast cancer treated by breast conserving surgery": the argument against breast conservation and sentinel lymph node biopsy in IBC. Breast Cancer Res Treat 165(3):779-781, 2017. e-Pub 2017. PMID: 28674763.
108. Tadros AB, Yang WT, Krishnamurthy S, Rauch GM, Smith BD, Valero V, Black DM, Lucci A, Caudle AS, DeSnyder SM, Teshome M, Barcenas CH, Miggins M, Adrada BE, Moseley T, Hwang RF, Hunt KK, Kuerer HM. Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. JAMA Surg 152(7):665-670, 2017. e-Pub 2017. PMID: 28423171.
109. Matsuda N, Lim B, Wang Y, Krishnamurthy S, Woodward W, Alvarez RH, Lucci A, Valero V, Reuben JM, Meric-Bernstam F, Ueno NT. Identification of frequent somatic mutations in inflammatory breast cancer. Breast Cancer Res Treat 163(2):263-272, 2017. e-Pub 2017. PMID: 28243898.
110. Kuerer HM, Rauch GM, Krishnamurthy S, Adrada BE, Caudle AS, DeSnyder SM, Black DM, Santiago L, Hobbs BP, Lucci A, Gilcrease M, Hwang RF, Candelaria RP, Chavez-MacGregor M, Smith BD, Arribas E, Moseley T, Teshome M, Miggins MV, Valero V, Hunt KK, Yang WT. A Clinical Feasibility Trial for Identification of Exceptional Responders in Whom Breast Cancer Surgery Can Be Eliminated Following Neoadjuvant Systemic Therapy. Ann Surg. e-Pub 2017. PMID: 28549010.
111. Fouad TM, Barrera AMG, Reuben JM, Lucci A, Woodward WA, Stauder MC, Lim B, DeSnyder SM, Arun B, Gildy B, Valero V, Hortobagyi GN, Ueno NT. Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system. Lancet Oncol 18(4):e228-32, 2017. e-Pub 2017. PMID: 28368261.
112. Woodward WA, Cristofanilli M, Merajver SD, Van Laere S, Pusztai L, Bertucci F, Berditchevski F, Polyak K, Overmoyer B, Devi GR, Sterneck E, Schneider R, Debeb BG, Wang X, van Golen KL, El-Zein R, Rahal OM, Alexander A, Reuben JM, Krishnamurthy S, Lucci A, Ueno NT. Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference. J Cancer 8(17):3607-3614, 2017. e-Pub 2017. PMID: 29667990.
113. Carter SA, Lyons GR, Kuerer HM, Bassett RL, Oates S, Thompson A, Caudle AS, Mittendorf EA, Bedrosian I, Lucci A, DeSnyder SM, Babiera G, Yi M, Baumann DP, Clemens MW, Garvey PB, Hunt KK, Hwang RF. Operative and Oncologic Outcomes in 9861 Patients with Operable Breast Cancer: Single-Institution Analysis of Breast Conservation with Oncoplastic Reconstruction. Ann Surg Oncol 23(10):3190-8, 2016. e-Pub 2016. PMID: 27406093.
114. Hall CS, Karhade MG, Bowman Bauldry JB, Valad LM, Kuerer HM, DeSnyder SM, Lucci A. Prognostic Value of Circulating Tumor Cells Identified Before Surgical Resection in Nonmetastatic Breast Cancer Patients. J Am Coll Surg 223(1):20-9, 2016. e-Pub 2016. PMID: 27049782.
115. Fang S, Sui D, Wang Y, Liu H, Chiang YJ, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Wargo J, Hu MI, Gardner JM, Reveille JD, Bassett RL, Wei Q, Amos CI, Lee JE. Association of Vitamin D Levels With Outcome in Patients With Melanoma After Adjustment For C-Reactive Protein. J Clin Oncol 34(15):1741-7, 2016. e-Pub 2016. PMID: 27001565.
116. Janni WJ, Rack B, Terstappen LW, Pierga JY, Taran FA, Fehm T, Hall C, de Groot MR, Bidard FC, Friedl TW, Fasching PA, Brucker SY, Pantel K, Lucci A. Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer. Clin Cancer Res 22(10):2583-93, 2016. e-Pub 2016. PMID: 26733614.
117. Atkinson RL, El-Zein R, Valero V, Lucci A, Bevers TB, Fouad T, Liao W, Ueno NT, Woodward WA, Brewster AM. Epidemiological Risk Factors Associated with Inflammatory Breast Cancer Subtypes. Cancer Causes Control 27(3):359-66, 2016. e-Pub 2016. PMID: 26797453.
118. Singh B, Kinne HE, Milligan RD, Washburn LJ, Olsen M, Lucci A. Important Role of FTO in the Survival of Rare Panresistant Triple-Negative Inflammatory Breast Cancer Cells Facing a Severe Metabolic Challenge. PLoS One 11(7):e0159072, 2016. e-Pub 2016. PMID: 27390851.
119. Hall C, Karhade M, Laubacher B, Anderson A, Kuerer H, DeSynder S, Lucci A. Circulating Tumor Cells After Neoadjuvant Chemotherapy in Stage I-III Triple-Negative Breast Cancer. Ann Surg Oncol 22 Suppl 3:552-8, 2015. e-Pub 2015. PMID: 25968619.
120. Hall CS, Karhade M, Laubacher BA, Kuerer HM, Krishnamurthy S, DeSnyder S, Anderson AE, Valero V, Ueno NT, Li Y, Su X, Lucci A. Circulating tumor cells and recurrence after primary systemic therapy in stage III inflammatory breast cancer. J Natl Cancer Inst 107(11), 2015. e-Pub 2015. PMID: 26374427.
121. DeSnyder SM, Hunt KK, Smith BD, Moran MS, Klimberg S, Lucci A. Assessment of Practice Patterns Following Publication of the SSO-ASTRO Consensus Guideline on Margins for Breast-Conserving Therapy in Stage I and II Invasive Breast Cancer. Ann Surg Oncol 22(10):3250-6, 2015. e-Pub 2015. PMID: 26202554.
122. Cromwell KD, Chiang YJ, Armer J, Heppner PP, Mungovan K, Ross MI, Gershenwald JE, Lee JE, Royal RE, Lucci A, Cormier JN. Is surviving enough? Coping and impact on activities of daily living among melanoma patients with lymphoedema. Eur J Cancer Care (Engl) 24(5):724-33, 2015. e-Pub 2015. PMID: 25809989.
123. Fang S, Wang Y, Chun YS, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Reveille JD, Chen W, Sui D, Bassett RL, Wang LE, Wei Q, Amos CI, Lee JE. Association of Common Genetic Polymorphisms with Melanoma Patient IL-12p40 Blood Levels, Risk and Outcomes. J Invest Dermatol 135(9):2266-72, 2015. e-Pub 2015. PMID: 25848976.
124. Roland CL, Ross MI, Hall CS, Laubacher B, Upshaw J, Anderson AE, Lucci A. Detection of circulating melanoma cells in the blood of melanoma patients: a preliminary study. Melanoma Res 25(4):335-41, 2015. e-Pub 2015. PMID: 26011119.
125. Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Chavez-MacGregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera G, Buchholz TA, Valero V, Ueno NT. Erratum to: Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis. Breast Cancer Res Treat 152(2):417, 2015. e-Pub 2015. PMID: 26092296.
126. Fouad TM, Kogawa T, Liu DD, Shen Y, Masuda H, El-Zein R, Woodward WA, Chavez-MacGregor M, Alvarez RH, Arun B, Lucci A, Krishnamurthy S, Babiera G, Buchholz TA, Valero V, Ueno NT. Overall Survival Differences Between Patients with Inflammatory and Noninflammatory Breast Cancer Presenting with Distant Metastasis at Diagnosis. Breast Cancer Res Treat 152(2):407-16, 2015. e-Pub 2015. PMID: 26017070.
127. Tsai CJ, Li J, Gonzalez-Angulo AM, Allen PK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Yang W, Cristofanilli M, Valero V, Buchholz TA. Outcomes after Multidisciplinary Treatment of Inflammatory Breast Cancer in the Era of Neoadjuvant HER2-directed Therapy. Am J Clin Oncol 38(3):242-7, 2015. e-Pub 2015. PMID: 23648437.
128. Fang S, Wang Y, Sui D, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Gardner JM, Reveille JD, Bassett RL, Wang LE, Wei Q, Amos CI, Lee JE. C-reactive protein as a marker of melanoma progression. J Clin Oncol 33(12):1389-96, 2015. e-Pub 2015. PMID: 25779565.
129. Fang S, Wang Y, Chun YS, Liu H, Ross MI, Gershenwald JE, Cormier JN, Royal RE, Lucci A, Schacherer CW, Reveille JD, Sui D, Bassett RL, Wang LE, Wei Q, Amos CI, Lee JE. The relationship between blood IL-12p40 level and melanoma progression. Int J Cancer 136(8):1874-80, 2015. e-Pub 2015. PMID: 25196740.
130. Moossdorff M, van Roozendaal LM, Strobbe LJ, Aebi S, Cameron DA, Dixon JM, Giuliano AE, Haffty BG, Hickey BE, Hudis CA, Klimberg VS, Koczwara B, Kühn T, Lippman ME, Lucci A, Piccart M, Smith BD, Tjan-Heijnen VC, van de Velde CJ, Van Zee KJ, Vermorken JB, Viale G, Voogd AC, Wapnir IL, White JR, Smidt ML. Maastricht Delphi Consensus on event definitions for classification of recurrence in breast cancer research. J Natl Cancer Inst 106(12), 2014. e-Pub 2014. PMID: 25381395.
131. Melo SA, Sugimoto H, O'Connell JT, Kato N, Villanueva A, Vidal A, Qiu L, Vitkin E, Perelman LT, Melo CA, Lucci A, Ivan C, Calin GA, Kalluri R. Cancer Exosomes Perform Cell-Independent MicroRNA Biogenesis and Promote Tumorigenesis. Cancer Cell 26(5):707-21, 2014. e-Pub 2014. PMID: 25446899.
132. Karhade M, Hall C, Mishra P, Anderson A, Kuerer H, Bedrosian I, Krishnamurthy S, Lucci A. Circulating Tumor Cells in Non-metastatic Triple Negative Breast Cancer. Breast Cancer Res Treat 147(2):325-33, 2014. e-Pub 2014. PMID: 25164970.
133. Mosalpuria K, Hall C, Krishnamurthy S, Lodhi A, Hallman DM, Baraniuk MS, Bhattacharyya A, Lucci A. Cyclooxygenase-2 expression in non-metastatic triple-negative breast cancer patients. Mol Clin Oncol 2(5):845-850, 2014. e-Pub 2014. PMID: 25054056.
134. Bertucci F, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, Marsan M, Iwamoto T, Krishnamurthy S, Masuda H, Van Dam P, Woodward WA, Cristofanilli M, Reuben JM, Dirix L, Viens P, Symmans WF, Birnbaum D, Van Laere SJ. Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. Ann Oncol 25(2):358-65, 2014. e-Pub 2014. PMID: 24299959.
135. Singh B, Shamsnia A, Raythatha MR, Milligan RD, Cady AM, Madan S, Lucci A. Highly Adaptable Triple-Negative Breast Cancer Cells as a Functional Model for Testing Anticancer Agents. PLoS One 9(10):e109487, 2014. e-Pub 2014. PMID: 25279830.
136. Woodward WA, Krishnamurthy S, Lodhi A, Xiao L, Gong Y, Cristofanilli M, Buchholz TA, Lucci A. Aldehyde dehydrogenase1 immunohistochemical staining in primary breast cancer cells independently predicted overall survival but did not correlate with the presence of circulating or disseminated tumors cells. J Cancer 5(5):360-7, 2014. e-Pub 2014. PMID: 24799954.
137. Fitzsullivan E, Lari SA, Smith B, Caudle AS, Krishnamurthy S, Lucci A, Mittendorf EA, Babiera GV, Black DM, Wagner JL, Bedrosian I, Woodward W, Gainer SM, Hwang R, Meric-Bernstam F, Hunt KK, Kuerer HM. Incidence and Consequence of Close Margins in Patients with Ductal Carcinoma in Situ Treated with Mastectomy: Is Further Therapy Warranted?. Ann Surg Oncol 20(13):4103-12, 2013. e-Pub 2013. PMID: 23975313.
138. Giordano A, Gao H, Cohen EN, Anfossi S, Khoury J, Hess K, Krishnamurthy S, Tin S, Cristofanilli M, Hortobagyi GN, Woodward WA, Lucci A, Reuben JM. Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients. Ann Oncol 24(10):2515-21, 2013. e-Pub 2013. PMID: 23798614.
139. Van Laere SJ, Ueno NT, Finetti P, Vermeulen P, Lucci A, Robertson FM, Marsan M, Iwamoto T, Krishnamurthy S, Masuda H, van Dam P, Woodward WA, Viens P, Cristofanilli M, Birnbaum D, Dirix L, Reuben JM, Bertucci F. Uncovering the molecular secrets of Inflammatory Breast Cancer biology: An integrated analysis of three distinct Affymetrix gene expression data sets. Clin Cancer Res 19(17):4685-4696, 2013. e-Pub 2013. PMID: 23396049.
140. Hyngstrom JR, Chiang YJ, Cromwell KD, Ross MI, Xing Y, Mungovan KS, Lee JE, Gershenwald JE, Royal RE, Lucci A, Armer JM, Cormier JN. Prospective Assessment of Lymphedema Incidence and Lymphedema-associated Symptoms Following Lymph Node Surgery for Melanoma. Melanoma Res 23(4):290-7, 2013. e-Pub 2013. PMID: 23752305.
141. Krishnamurthy S, Bischoff F, Ann Mayer J, Wong K, Pham T, Kuerer H, Lodhi A, Bhattacharyya A, Hall C, Lucci A. Discordance in HER2 Gene Amplification in Circulating and Disseminated Tumor Cells in Patients with Operable Breast Cancer. Cancer Med 2(2):226-33, 2013. e-Pub 2013. PMID: 23634290.
142. Hall C, Laubacher B, Lucci A. Detection and prognostic significance of circulating tumor cells in nonmetastatic breast cancer patients. Breast Cancer Manage 2(4):295-309, 2013. e-Pub 2013.
143. Krishnamurthy S, Woodward W, Yang W, Reuben JM, Tepperberg J, Ogura D, Niwa S, Huo L, Gong Y, El-Zein R, Gonzalez-Angulo AM, Chavez-Macgregor M, Alvarez R, Lucci A, Valero V, Ueno NT. Status of the Anaplastic Lymphoma Kinase (ALK) gene in Inflammatory Breast Carcinoma. Springerplus 2:409, 2013. e-Pub 2013. PMID: 24156086.
144. Radvanyi LG, Bernatchez C, Zhang M, Fox PS, Miller P, Chacon J, Wu R, Lizee G, Mahoney S, Alvarado G, Glass M, Johnson VE, McMannis JD, Shpall E, Prieto V, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Patel S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Davies MA, Mansaray R, Fulbright OJ, Toth C, Ramachandran R, Wardell S, Gonzalez A, Hwu P. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 18(24):6758-70, 2012. e-Pub 2012. PMID: 23032743.
145. Card A, Crosby MA, Liu J, Lindstrom WA, Lucci A, Chang DW. Reduced Incidence of Breast Cancer-related Lymphedema following Mastectomy and Breast Reconstruction versus Mastectomy Alone. Plast Reconstr Surg 130(6):1169-78, 2012. e-Pub 2012. PMID: 22878475.
146. Alvarado R, Lari SA, Roses RE, Smith BD, Yang W, Mittendorf EA, Arun BK, Lucci A, Babiera GV, Wagner JL, Caudle AS, Meric-Bernstam F, Hwang RF, Bedrosian I, Hunt KK, Kuerer HM. Biology, treatment, and outcome in very young and older women with DCIS. Ann Surg Oncol 19(12):3777-84, 2012. e-Pub 2012. PMID: 22622473.
147. Cromwell KD, Ross MI, Xing Y, Gershenwald JE, Royal RE, Lucci A, Lee JE, Cormier JN. Variability in melanoma post-treatment surveillance practices by country and physician specialty: a systematic review. Melanoma Res 22(5):376-85, 2012. e-Pub 2012. PMID: 22914178.
148. Gainer SM, Hunt KK, Beitsch P, Caudle AS, Mittendorf EA, Lucci A. Changing behavior in clinical practice in response to the ACOSOG Z0011 trial: a survey of the American Society of Breast Surgeons. Ann Surg Oncol 19(10):3152-8, 2012. e-Pub 2012. PMID: 22820938.
149. Caudle AS, Hunt KK, Tucker SL, Hoffman K, Gainer SM, Lucci A, Kuerer HM, Meric-Bernstam F, Shah R, Babiera GV, Sahin AA, Mittendorf EA. American College of Surgeons Oncology Group (ACOSOG) Z0011: Impact on Surgeon Practice Patterns. Ann Surg Oncol 19(10):3144-51, 2012. e-Pub 2012. PMID: 22847123.
150. Gainer SM, Lodhi AK, Bhattacharyya A, Krishnamurthy S, Kuerer HM, Lucci A. Invasive lobular carcinoma predicts micrometastasis in breast cancer. J Surg Res 177(1):93-6, 2012. e-Pub 2012. PMID: 22482764.
151. Lucci A, Hall C. Circulating tumour cells in early breast cancer - Authors' reply. Lancet Oncol 13(9):e371, 2012. e-Pub 2012. PMID: 22935236.
152. Walker GV, Niikura N, Yang W, Rohren E, Valero V, Woodward WA, Alvarez RH, Lucci A, Ueno NT, Buchholz TA. Pretreatment Staging Positron Emission Tomography/Computed Tomography in Patients With Inflammatory Breast Cancer Influences Radiation Treatment Field Designs. Int J Radiat Oncol Biol Phys 83(5):1381-6, 2012. e-Pub 2012. PMID: 22284689.
153. Lucci A, Hall CS, Lodhi AK, Bhattacharyya A, Anderson AE, Xiao L, Bedrosian I, Kuerer HM, Krishnamurthy S. Circulating tumour cells in non-metastatic breast cancer: a prospective study. Lancet Oncol 13(7):688-95, 2012. e-Pub 2012. PMID: 22677156.
154. Kuerer HM, Lari SA, Arun BK, Hu CY, Brewster A, Mittendorf EA, Albarracin CT, Babiera GV, Caudle AS, Wagner JL, Litton JK, Bedrosian I, Meric-Bernstam F, Lucci A, Hunt KK. Biologic Features and Prognosis of Ductal Carcinoma in Situ are Not Adversely Impacted by Initial Large Body Mass. Breast Cancer Res Treat 133(3):1131-41, 2012. e-Pub 2012. PMID: 22392043.
155. Yi M, Meric-Bernstam F, Kuerer HM, Mittendorf EA, Bedrosian I, Lucci A, Hwang RF, Crow JR, Luo S, Hunt KK. Evaluation of a Breast Cancer Nomogram for Predicting Risk of Ipsilateral Breast Tumor Recurrences in Patients with Ductal Carcinoma in Situ after Local Excision. J Clin Oncol 30(6):600-7, 2012. e-Pub 2012. PMID: 22253459.
156. Mego M, Mani SA, Lee BN, Li C, Evans KW, Cohen EN, Gao H, Jackson SA, Giordano A, Hortobagyi GN, Cristofanilli M, Lucci A, Reuben JM. Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. Int J Cancer 130(4):808-16, 2012. e-Pub 2012. PMID: 21387303.
157. Hall C, Krishnamurthy S, Lodhi A, Bhattacharyya A, Anderson A, Kuerer H, Bedrosian I, Singh B, Lucci A. Disseminated Tumor Cells Predict Survival after Neoadjuvant Therapy in Primary Breast Cancer. Cancer 118(2):342-8, 2012. e-Pub 2012. PMID: 21717428.
158. Singh B, Tai K, Madan S, Raythatha MR, Cady AM, Braunlin M, Irving LR, Bajaj A, Lucci A. Selection of metastatic breast cancer cells based on adaptability of their metabolic state. PLoS One 7(5):e36510, 2012. e-Pub 2012. PMID: 22570721.
159. Yamauchi H, Woodward WA, Valero V, Alvarez RH, Lucci A, Buchholz TA, Iwamoto T, Krishnamurthy S, Yang W, Reuben JM, Hortobágyi GN, Ueno NT. Inflammatory Breast Cancer: What We Know and What We Need to Learn. Oncologist 17(7):891-9, 2012. e-Pub 2012. PMID: 22584436.
160. Gong Y, Huo L, Liu P, Sneige N, Sun X, Ueno NT, Lucci A, Buchholz TA, Valero V, Cristofanilli M. Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer 117(24):5476-84, 2011. e-Pub 2011. PMID: 21713757.
161. Krishnamurthy S, Lucci A. Anti-cytokeratin CAM5.2 (BD Sciences) and CK8 Give No Remarkable Advantages to the Pancytokeratin Cocktail of Antibodies (AE1/AE3, CAM5.2, MNF116, CK8, and CK18) in Detecting Disseminated Tumor Cells in Biologic Subtypes of Stage I-III Breast Cancer Patients. Ann Surg Oncol 18 Suppl 3:263-4, 2011. e-Pub 2011. PMID: 21057878.
162. Roses RE, Arun BK, Lari SA, Mittendorf EA, Lucci A, Hunt KK, Kuerer HM. Ductal Carcinoma In Situ of the Breast with Subsequent Distant Metastasis and Death. Ann Surg Oncol 18(10):2873-8, 2011. e-Pub 2011. PMID: 21476105.
163. Caudle AS, Hunt KK, Kuerer HM, Meric-Bernstam F, Lucci A, Bedrosian I, Babiera GV, Hwang RF, Ross MI, Feig BW, Hoffman K, Litton JK, Sahin AA, Yang W, Hortobagyi GN, Buchholz TA, Mittendorf EA. Multidisciplinary Considerations in the Implementation of the Findings from the American College of Surgeons Oncology Group (ACOSOG) Z0011 Study: A Practice-Changing Trial. Ann Surg Oncol 18(9):2407-12, 2011. e-Pub 2011. PMID: 21327455.
164. Joseph RW, Peddareddigari VR, Liu P, Miller PW, Overwijk WW, Bekele NB, Ross MI, Lee JE, Gershenwald JE, Lucci A, Prieto VG, McMannis JD, Papadopoulos N, Kim K, Homsi J, Bedikian A, Hwu WJ, Hwu P, Radvanyi LG. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res 17(14):4882-91, 2011. e-Pub 2011. PMID: 21632855.
165. Reuben JM, Lee BN, Gao H, Cohen EN, Mego M, Giordano A, Wang X, Lodhi A, Krishnamurthy S, Hortobagyi GN, Cristofanilli M, Lucci A, Woodward WA. Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44 (+) CD24 (lo) cancer stem cell phenotype. Eur J Cancer 47(10):1527-36, 2011. e-Pub 2011. PMID: 21334874.
166. Singh B, Cook KR, Vincent L, Hall CS, Martin C, Lucci A. Role of COX-2 in tumorospheres derived from a breast cancer cell line. J Surg Res 168(1):e39-49, 2011. e-Pub 2011. PMID: 20462604.
167. De Giorgi U, Cohen EN, Gao H, Mego M, Lee BN, Lodhi A, Cristofanilli M, Lucci A, Reuben JM. Mesenchymal stem cells expressing GD2 and CD271 correlate with breast cancer-initiating cells in bone marrow. Cancer Biol Ther 11(9):812-5, 2011. e-Pub 2011. PMID: 21358274.
168. Sharma R, Rourke LL, Kronowitz SJ, Oh JL, Lucci A, Litton JK, Robb GL, Babiera GV, Mittendorf EA, Hunt KK, Kuerer HM. Management of local-regional recurrence following immediate breast reconstruction in patients with early breast cancer treated without postmastectomy radiotherapy. Plast Reconstr Surg 127(5):1763-72, 2011. e-Pub 2011. PMID: 21532405.
169. Yi M, Kronowitz SJ, Meric-Bernstam F, Feig BW, Symmans WF, Lucci A, Ross MI, Babiera GV, Kuerer HM, Hunt KK. Local, regional, and systemic recurrence rates in patients undergoing skin-sparing mastectomy compared with conventional mastectomy. Cancer 117(5):916-24, 2011. e-Pub 2011. PMID: 20945319.
170. Krishnamurthy S, Lucci A. Reply to detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer. e-Pub 2011. PMID: 21437895.
171. Dawood S, Merajver SD, Viens P, Vermeulen PB, Swain SM, Buchholz TA, Dirix LY, Levine PH, Lucci A, Krishnamurthy S, Robertson FM, Woodward WA, Yang WT, Ueno NT, Cristofanilli M. International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment. Ann Oncol 22(3):515-23, 2011. e-Pub 2011. PMID: 20603440.
172. Yi M, Buchholz TA, Meric-Bernstam F, Bedrosian I, Hwang RF, Ross MI, Kuerer HM, Luo S, Gonzalez-Angulo AM, Buzdar AU, Symmans WF, Feig BW, Lucci A, Huang EH, Hunt KK. Classification of Ipsilateral Breast Tumor Recurrences after Breast Conservation Therapy can Predict Patient Prognosis and Facilitate Treatment Planning. Ann Surg 253(3):572-9, 2011. e-Pub 2011. PMID: 21209588.
173. Iwamoto T, Bianchini G, Qi Y, Cristofanilli M, Lucci A, Woodward WA, Reuben JM, Matsuoka J, Gong Y, Krishnamurthy S, Valero V, Hortobagyi GN, Robertson F, Symmans WF, Pusztai L, Ueno NT. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Res Treat 125(3):785-95, 2011. e-Pub 2011. PMID: 21153052.
174. Hall C, Lucci A. How heterogeneous cell populations, cancer cell dormancy, and minimal residual disease influence the natural history of cancers. Oncology (Williston Park) 25(1):47, 50, 2011. e-Pub 2011. PMID: 21361243.
175. Kuerer HM, Buzdar AU, Mittendorf EA, Esteva FJ, Lucci A, Vence LM, Radvanyi L, Meric-Bernstam F, Hunt KK, Symmans WF. Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast. Cancer 117(1):39-47, 2011. e-Pub 2011. PMID: 20740500.
176. Li J, Gonzalez-Angulo AM, Allen PK, Yu TK, Woodward WA, Ueno NT, Lucci A, Krishnamurthy S, Gong Y, Bondy ML, Yang W, Willey JS, Cristofanilli M, Valero V, Buchholz TA. Triple-Negative Subtype Predicts Poor Overall Survival and High Locoregional Relapse in Inflammatory Breast Cancer. Oncologist 16(12):1675-83, 2011. e-Pub 2011. PMID: 22147002.
177. Hall C, Krishnamurthy S, Lodhi A, Mosalpuria K, Kuerer HM, Meric-Bernstam F, Bedrosian I, Hunt KK, Lucci A. Disseminated tumor cells in biologic subtypes of Stage I-III breast cancer patients. Ann Surg Oncol 17(12):3252-3258, 2010. e-Pub 2010. PMID: 20559739.
178. Sharma R, Bedrosian I, Lucci A, Hwang RF, Rourke LL, Qiao W, Buchholz TA, Kronowitz SJ, Krishnamurthy S, Babiera GV, Gonzalez-Angulo AM, Meric-Bernstam F, Mittendorf EA, Hunt KK, Kuerer HM. Present-Day Locoregional Control in Patients with T1 or T2 Breast Cancer with 0 and 1 to 3 Positive Lymph Nodes After Mastectomy Without Radiotherapy. Ann Surg Oncol 17(11):2899-908, 2010. e-Pub 2010. PMID: 20443145.
179. Kang T, Yi M, Hunt KK, Mittendorf EA, Babiera GV, Kuerer H, Bedrosian I, Hwang RF, Lucci A, Meric-Bernstam F. Does blue dye contribute to success of sentinel node mapping for breast cancer?. Ann Surg Oncol 17(Suppl 3):280-5, 2010. e-Pub 2010. PMID: 20853047.
180. Chang SB, Askew RL, Xing Y, Weaver S, Gershenwald JE, Lee JE, Royal R, Lucci A, Ross MI, Cormier JN. Prospective assessment of postoperative complications and associated costs following inguinal lymph node dissection (ILND) in melanoma patients. Ann Surg Oncol 17(10):2764-72, 2010. e-Pub 2010. PMID: 20336388.
181. Singh B, Irving LR, Tai K, Lucci A. Overexpression of COX-2 in celecoxib-resistant breast cancer cell lines. J Surg Res 163(2):235-43, 2010. e-Pub 2010. PMID: 20691996.
182. Dawood S, Gong Y, Broglio K, Buchholz TA, Woodward W, Lucci A, Valero V, Gonzalez-Angulo AM, Hortobagyi GN, Cristofanilli M. Trastuzumab in Primary Inflammatory Breast Cancer (IBC): High Pathological Response Rates and Improved Outcome. Breast J 16(5):529-32, 2010. e-Pub 2010. PMID: 20626396.
183. Gainer SM, Lee E, Lucci A. The suture scaffold technique for improved cosmesis in partial mastectomy defects. J Surg Oncol 102(2):184-6, 2010. e-Pub 2010. PMID: 20648592.
184. Debeb BG, Zhang X, Krishnamurthy S, Gao H, Cohen E, Li L, Rodriguez AA, Landis MD, Lucci A, Ueno NT, Robertson F, Xu W, Lacerda L, Buchholz TA, Cristofanilli M, Reuben JM, Lewis MT, Woodward WA. Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells. Mol Cancer 9(1):180, 2010. e-Pub 2010. PMID: 20615238.
185. Krishnamurthy S, Cristofanilli M, Singh B, Reuben J, Gao H, Cohen EN, Andreopoulou E, Hall CS, Lodhi A, Jackson S, Lucci A. Detection of minimal residual disease in blood and bone marrow in early- stage breast cancer. Cancer 116(14):3330-3337, 2010. e-Pub 2010. PMID: 20564098.
186. Robertson FM, Simeone AM, Lucci A, McMurray JS, Ghosh S, Cristofanilli M. Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4. Cancer 116(11 Suppl):2806-14, 2010. e-Pub 2010. PMID: 20503412.
187. Dominici LS, Negron Gonzalez VM, Buzdar AU, Lucci A, Mittendorf EA, Le-Petross HT, Babiera GV, Meric-Bernstam F, Hunt KK, Kuerer HM. Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer 116(12):2884-9, 2010. e-Pub 2010. PMID: 20564395.
188. Xing Y, Chang GJ, Hu CY, Askew RL, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Lucci A, Cormier JN. Conditional survival estimates improve over time for patients with advanced melanoma: results from a population-based analysis. Cancer 116(9):2234-41, 2010. e-Pub 2010. PMID: 20187100.
189. Singh B, Cook KR, Martin C, Huang EH, Mosalpuria K, Krishnamurthy S, Cristofanilli M, Lucci A. Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer. Clin Exp Metastasis 27(4):233-40, 2010. e-Pub 2010. PMID: 20229045.
190. Debeb BG, Xu W, Mok H, Li L, Robertson F, Ueno NT, Reuben J, Lucci A, Cristofanilli M, Woodward WA. Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions. Int J Radiat Oncol Biol Phys 76(3):889-895, 2010. e-Pub 2010. PMID: 20159363.
191. Boughey JC, Goravanchi F, Parris RN, Kee SS, Kowalski AM, Frenzel JC, Bedrosian I, Meric-Bernstam F, Hunt KK, Ames FC, Kuerer HM, Lucci A. Prospective randomized trial of paravertebral block for patients undergoing breast cancer surgery. Am J Surg 198(5):720-5, 2009. e-Pub 2009. PMID: 19427625.
192. Zhang D, LaFortune TA, Krishnamurthy S, Esteva FJ, Cristofanilli M, Liu P, Lucci A, Singh B, Hung MC, Hortobagyi GN, Ueno NT. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer. Clin Cancer Res 15(21):6639-48, 2009. e-Pub 2009. PMID: 19825949.
193. Lucci A, Krishnamurthy S, Singh B, Bedrosian I, Meric-Bernstam F, Reuben J, Broglio K, Mosalpuria K, Lodhi A, Vincent L, Cristofanilli M. Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow. Breast Cancer Res Treat 117(1):61, 2009. e-Pub 2009. PMID: 18663571.
194. Boughey JC, Goravanchi F, Parris RN, Kee SS, Frenzel JC, Hunt KK, Ames FC, Kuerer HM, Lucci A. Improved Postoperative Pain Control using Thoracic Paravertebral Block for Breast Operations. Breast J 15(5):483-8, 2009. e-Pub 2009. PMID: 19624418.
195. Huang EH, Singh B, Cristofanilli M, Gelovani J, Wei C, Vincent L, Cook KR, Lucci A. A CXCR4 antagonist CTCE-9908 inhibits primary tumor growth and metastasis of breast cancer. J Surg Res 155(2):231-6, 2009. e-Pub 2009. PMID: 19482312.
196. Boughey JC, Wagner J, Garrett BJ, Harker L, Middleton LP, Babiera GV, Meric-Bernstam F, Lucci A, Hunt KK, Bedrosian I. Neoadjuvant Chemotherapy in Invasive Lobular Carcinoma May Not Improve Rates of Breast Conservation. Ann Surg Oncol 16(6):1606-11, 2009. e-Pub 2009. PMID: 19280264.
197. Xing Y, Badgwell BD, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Lucci A, Cormier JN. Lymph node ratio predicts disease-specific survival in melanoma patients. Cancer 115(11):2505-13, 2009. e-Pub 2009. PMID: 19309746.
198. Krishnamurthy S, Meric-Bernstam F, Lucci A, Hwang RF, Kuerer HM, Babiera G, Ames FC, Feig BW, Ross MI, Singletary E, Hunt KK, Bedrosian I. A prospective study comparing touch imprint cytology, frozen section analysis, and rapid cytokeratin immunostain for intraoperative evaluation of axillary sentinel lymph nodes in breast cancer. Cancer 115(7):1555-62, 2009. e-Pub 2009. PMID: 19195040.
199. Lang JE, Mosalpuria K, Cristofanilli M, Krishnamurthy S, Reuben J, Singh B, Bedrosian I, Meric-Bernstam F, Lucci A. HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer. Breast Cancer Res Treat 113(3):501-7, 2009. e-Pub 2009. PMID: 18327638.
200. Yi M, Meric-Bernstam F, Ross MI, Akins JS, Hwang RF, Lucci A, Kuerer HM, Babiera GV, Gilcrease MZ, Hunt KK. How many sentinel lymph nodes are enough during sentinel lymph node dissection for breast cancer?. Cancer 113(1):30-37, 2008. e-Pub 2008. PMID: 18457326.
201. Yi M, Krishnamurthy S, Kuerer HM, Meric-Bernstam F, Bedrosian I, Ross MI, Ames FC, Lucci A, Hwang RF, Hunt KK. Role of primary tumor characteristics in predicting positive sentinel lymph nodes in patients with ductal carcinoma in situ or microinvasive breast cancer. Am J Surg 196(1):81-87, 2008. e-Pub 2008. PMID: 18436181.
202. Marulanda GA, Mont MA, Lucci A, Letson GD, Khakpour N. Orthopedic surgery implications of breast cancer. Expert Rev Anticancer Ther 8(6):949-956, 2008. e-Pub 2008. PMID: 18533804.
203. Singh B, Cook KR, Vincent L, Hall CS, Berry JA, Multani AS, Lucci A. Cyclooxygenase-2 induces genomic instability BCL2 expression, doxorubicin resistance, and altered cancer initiating cell phenotype in MCF7 breast cancer cells. J Surg Res 147(2):240-6, 2008. e-Pub 2008. PMID: 18498876.
204. Mittendorf EA, Lim SJ, Schacherer CW, Lucci A, Cormier JN, Mansfield PF, Gershenwald JE, Ross MI, Lee JE. Melanoma adrenal metastasis: natural history and surgical management. Am J Surg 195(3):363-8; discussion 368-9, 2008. e-Pub 2008. PMID: 18206850.
205. Lucci A. Is axillary dissection needed when the sentinel node is positive? No: it is time to rethink axillary lymph node dissection when the sentinel node is positive. J Surg Oncol 97(3):201-2, 2008. e-Pub 2008. PMID: 18264979.
206. Mortenson MM, Xing Y, Weaver S, Lee JE, Gershenwald JE, Lucci A, Mansfield PF, Ross MI, Cormier JN. Fibrin sealant does not decrease seroma output or time to drain removal following inguino-femoral lymph node dissection in melanoma patients: a randomized controlled trial (NCT00506311). World J Surg Oncol 6:63, 2008. e-Pub 2008. PMID: 18564433.
207. Singh B, Vincent L, Berry JA, Multani AS, Lucci A. Cyclooxygenase-2 expression induces genomic instability in MCF10A breast epithelial cells. J Surg Res 140(2):220-6, 2007. e-Pub 2007. PMID: 17418864.
208. Lucci A, McCall LM, Beitsch PD, Whitworth PW, Reintgen DS, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Giuliano AE, Giuliano AE. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 25(24):3657-63. e-Pub 2007. PMID: 17485711.
209. Gonzalez RJ, Buzdar AU, Fraser Symmans W, Yen TW, Broglio KR, Lucci A, Esteva FJ, Yin G, Kuerer HM. Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin). Breast J 13(1):72-5, 2007. e-Pub 2007. PMID: 17214797.
210. Singh B, Berry JA, Shoher A, Ayers GD, Wei C, Lucci A. COX-2 involvement in breast cancer metastasis to bone. Oncogene 26(26):3789-3796, 2007. e-Pub 2007. PMID: 17213821.
211. Woodward WA, Lucci A, Cristofanilli M. A gene signature in breast cancer. N Engl J Med 356:1887-8, 2007. e-Pub 2007.
212. Wilke LG, McCall LM, Posther KE, Whitworth PW, Reintgen DS, Leitch AM, Gabram SG, Lucci A, Cox CE, Hunt KK, Herndon JE, nd, Giuliano AE. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol 13:491-500, 2006. e-Pub 2006. PMID: 16514477.
213. Singh B, Berry JA, Shoher A, Lucci A. COX-2 induces IL-11 production in human breast cancer cells. J Surg Res 131:267-275, 2006. e-Pub 2006. PMID: 16457848.
214. Rosenkranz KM, Bedrosian I, Feng L, Hunt KK, Hartman K, Lucci A, Meric-Bernstam F, Kuerer HM, Singletary ES, Hwang R, Feig B, Ross M, Ames F, Babiera GV. Breast cancer in the very elderly: treatment patterns and complications in a tertiary cancer center. Am J Surg 192:541-544, 2006. e-Pub 2006. PMID: 16978971.
215. Rosenkranz KM, Lucci A. Surgical treatment of pregnancy associated breast cancer. Breast Dis 23:87-93, 2006. e-Pub 2006. PMID: 16823171.
216. Peintinger F, Symmans WF, Gonzalez-Angulo AM, Boughey JC, Buzdar AU, Yu TK, Hunt KK, Singletary SE, Babiera GV, Lucci A, Meric-Bernstam F, Kuerer HM. The safety of breast-conserving surgery in patients who achieve a complete pathologic response after neoadjuvant chemotherapy. Cancer 107:1248-1254, 2006. e-Pub 2006. PMID: 16862596.
217. Rivera AL, Diwan A, Muylaert S, Lucci A. Intramammary lymph node presenting as the primary breast mass in infiltrating lobular carcinoma. Curr Surg 63(2):107-109, 2006. e-Pub 2006. PMID: 16520110.
218. Lambert LA, Ayers GD, Hwang RF, Hunt KK, Ross MI, Kuerer HM, Singletary SE, Babiera GV, Ames FC, Feig B, Lucci A, Krishnamurthy S, Meric-Bernstam F. Validation of a breast cancer nomogram for predicting nonsentinel lymph node metastases after a positive sentinel node biopsy. Ann Surg Oncol 13:310-320, 2006. e-Pub 2006. PMID: 16463073.
219. Newman LA, Lee CT, Parekh LP, Stewart AK, Thomas CR, Jr, Beltran RA, Lucci A, Green B, Ota D, Nelson H. Use of the National Cancer Data Base to develop clinical trials accrual targets that are appropriate for minority ethnicity patients: a report from the American College of Surgeons Oncology Group (ACOSOG) Special Population Committee. Cancer 106:188-195, 2006. e-Pub 2006. PMID: 16333856.
220. Shoher A, Diwan A, Teh BS, Lu HH, Fisher R, Lucci A. Lymphoscintigraphy does not enhance sentinel node identification or alter management of patients with early breast cancer. Curr Surg 63:207-212, 2006. e-Pub 2006. PMID: 16757375.
221. Singh B, Berry JA, Vincent LE, Lucci A. Involvement of IL-8 in COX-2-mediated bone metastases from breast cancer. J Surg Res 134:44-51, 2006. e-Pub 2006. PMID: 16678856.
222. Boughey JC, Peintinger F, Meric-Bernstam F, Perry AC, Hunt KK, Babiera GV, Singletary SE, Bedrosian I, Lucci A, Buzdar AU, Pusztai L, Kuerer HM. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Ann Surg 244:464-470, 2006. e-Pub 2006. PMID: 16926572.
223. Ramakrishnan V, Shoher A, Ehrlich M, Powell S, Lucci A. Atypical dermatofibrosarcoma protuberans in the breast. Breast J 11:217-218, 2005. e-Pub 2005. PMID: 15871713.
224. Brundage SI, Lucci A, Miller CC, Azizzadeh A, Spain DA, Kozar RA. Potential targets to encourage a surgical career. J Am Coll Surg 200:946-953, 2005. e-Pub 2005. PMID: 15922210.
225. Khakpour N, Hunt KK, Kuerer HM, Yi M, Meric-Bernstam F, Ross MI, Lucci A. Sentinel lymph node dissection provides axillary control equal to complete axillary node dissection in breast cancer patients with lobular histology and a negative sentinel node. Am J Surg 190:598-601, 2005. e-Pub 2005. PMID: 16164930.
226. Singh B, Berry JA, Shoher A, Ramakrishnan V, Lucci A. COX-2 Over-expression increases motility and invasion of breast cancer cells. Int J Oncol 26:1393-1399, 2005. e-Pub 2005. PMID: 15809733.
227. Suh YJ, Chada S, McKenzie T, Liu Y, Swisher SG, Lucci A, Hunt KK. Synergistic tumoricidal effect between celecoxib and adenoviral-mediated delivery of mda-7 in human breast cancer cells. Surgery 138:422-430, 2005. e-Pub 2005. PMID: 16213894.
228. Newman LA, Hurd T, Leitch M, Kuerer HM, Diehl K, Lucci A, Giuliano A, Hunt KK, Putnam W, Wells SA. A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the American College of Surgeons Oncology Group. J Am Coll Surg 199:644-651, 2004. e-Pub 2004. PMID: 15454152.
229. Lucci A, Shoher A, Sherman MO, Azzizadeh A. Assessment of the current Medicare reimbursement system for breast cancer operations. Ann Surg Oncol 11:1037-1044, 2004. e-Pub 2004. PMID: 15545504.
230. Shoher A, Arbab F, Lucci A, Jr. Giant pelvic schwannoma with ancient change. J Am Coll Surg 197:163, 2003. e-Pub 2003. PMID: 12831937.
231. Shoher A, Hekier R, Lucci A, Jr. Mastectomy performed with scissors following tumescent solution injection. J Surg Oncol 83:191-193, 2003. e-Pub 2003. PMID: 12827691.
232. Azizzadeh A, McCollum CH, Miller CC, rd, Holliday KM, Shilstone HC, Lucci A, Jr. Factors influencing career choice among medical students interested in surgery. Curr Surg 60:210-213, 2003. e-Pub 2003. PMID: 14972298.
233. Van Pelt AE, Mohsin S, Elledge RM, Hilsenbeck SG, Gutierrez MC, Lucci A, Jr, Kalidas M, Granchi T, Scott BG, Allred DC, Chang JC. Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results. Clin Breast Cancer 4:348-353, 2003. e-Pub 2003. PMID: 14715110.
234. Kozar RA, Lucci A, Miller CC, Azizzadeh A, Cocanour CS, Potts JR, Fischer CP, Brundage SI. Brief intervention by surgeons can influence students toward a career in surgery. J Surg Res 111:166-169, 2003. e-Pub 2003. PMID: 12842462.
235. Anstadt MP, Carwile JM, Guill CK, Conklin LD, Soltero ER, Lucci A, Kroll MH. Relapse of thrombotic thrombocytopenic purpura associated with decreased VWF cleaving activity. Am J Med Sci 323:281-284, 2002. e-Pub 2002. PMID: 12018674.
236. Haigh PI, Lucci A, Turner RR, Bostick PJ, Krasne DL, Stern SL, Morton DL. Carbon dye histologically confirms the identity of sentinel lymph nodes in cutaneous melanoma. Cancer 92:535-541, 2001. e-Pub 2001. PMID: 11505397.
237. Lucci A, Citro HW, Wilson L. Assessment of knowledge of melanoma risk factors, prevention, and detection principles in Texas teenagers. J Surg Res 97:179-183, 2001. e-Pub 2001. PMID: 11341796.
238. Lucci A, Jr, Kelemen PR, Miller C, rd, Chardkoff L, Wilson L. National practice patterns of sentinel lymph node dissection for breast carcinoma. J Am Coll Surg 192:453-458, 2001. e-Pub 2001. PMID: 11294401.
239. Feig BW, Curley S, Lucci A, Hunt KK, Vauthey JN, Mansfield PF, Cleary K, Hamilton S, Ellis V, Brame M, Berger DH. A caution regarding lymphatic mapping in patients with colon cancer. Am J Surg 182(6):707-712, 2001. e-Pub 2001. PMID: 11839343.
240. Lucci A, Han TY, Liu YY, Giuliano AE, Cabot MC. Modification of ceramide metabolism increases cancer cell sensitivity to cytotoxics. Int J Oncol 15:541-546, 1999. e-Pub 1999. PMID: 10427137.
241. Lucci A, Giuliano AE, Han TY, Dinur T, Liu YY, Senchenkov A, Cabot MC. Ceramide toxicity and metabolism differ in wild-type and multidrug-resistant cancer cells. Int J Oncol 15:535-540, 1999. e-Pub 1999. PMID: 10427136.
242. Lucci A, Turner RR, Morton DL. Carbon dye as an adjunct to isosulfan blue dye for sentinel lymph node dissection. Surgery 126:48-53, 1999. e-Pub 1999. PMID: 10418592.
243. Hsueh EC, Lucci A, Qi K, Morton DL. Survival of patients with melanoma of the lower extremity decreases with distance from the trunk. Cancer 85:383-388, 1999. e-Pub 1999. PMID: 10023706.
244. Lucci A, Han TY, Liu YY, Giuliano AE, Cabot MC. Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells. Cancer 86:300-311, 1999. e-Pub 1999. PMID: 10421266.
245. Lucci A, Cho WI, Han TY, Giuliano AE, Morton DL, Cabot MC. Glucosylceramide: a marker for multiple-drug resistant cancers. Anticancer Res 18:475-480, 1998. e-Pub 1998. PMID: 9568165.
246. Lavie Y, Cao H, Volner A, Lucci A, Han TY, Geffen V, Giuliano AE, Cabot MC. Agents that reverse multidrug resistance, tamoxifen, verapamil, and cyclosporin A, block glycosphingolipid metabolism by inhibiting ceramide glycosylation in human cancer cells. J Biol Chem 272:1682-1687, 1997. e-Pub 1997. PMID: 8999846.
247. Lucci A. A comparison of intra-operative methods to diagnose duodenal gastrinomas. Acta Chir Austriaca 26:3, 1994. e-Pub 1994.
248. Doman D, Hoffman K, Morrow PK, Arriaga L, Johnston D, Strom E, Perkins G, Tereffe W, Lucci A, Woodward W. Prospective evaluation of chronic lymphedema after axillary lymph node dissection and comprehensive irradiation. The Breast.

Invited Articles

1. Yi M, Meric-Bernstam F, Kuerer HM, Mittendorf EA, Bedrosian I, Lucci A, Hwang RF, Crow J, Sheng L, Hunt KK. Reply to K.J. Van Zee et al. J Clin Oncol 30(25):3144-3145, 2012. e-Pub 2012.
2. Lucci A. Guest Editorial: It's time to rethink axillary lymph node dissection when the sentinel node is positive. J Surg Oncol 97:201-202, 2008. e-Pub 2008.
3. Lucci A. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 98:599-609, 2006. Breast Diseases: A Yearbook Quarterly 18:181-182, 2007. e-Pub 2007.
4. Lucci A. My Commentary on Nipple-Sparing Mastectomy for Breast Cancer and Risk Reduction: Oncologic or Technical Problem?. Breast Diseases: A Year Book Quarterly 18:370-371, 2007. e-Pub 2007.
5. Lucci A. Re: Clinical implications of sentinel nodes outside the axilla and internal mammary chain in patients with breast cancer, by van Rijk MC, Tanis PJ, Nieweg OE, et al. J Surg Oncol 94(4):266-8, 2006. e-Pub 2006. PMID: 16941526.
6. Rosenkranz KM, Lucci A. Review: Surgical treatment of pregnancy associated breast cancer. Breast Diseases: A Year Book Quarterly 23:87-93, 2006. e-Pub 2006.
7. Beauchamp R, Lucci A, Stamos M. Commentary: PET scanning in malignant disease. Contemp Surg 61:499-506, 2005. e-Pub 2005.
8. Lucci A, Diwan A. Commentary: Site of primary tumor has a prognostic role in operable breast cancer: The International Breast Cancer Group Experience. Women's Oncology Review 5:175-176, 2005. e-Pub 2005.
9. Khakpour N, Lucci A. Commentary: Repeat breast-conserving surgery for in-breast carcinoma recurrence: the potential role of partial breast irradiation. Women's Oncology Review 100:2269-2280, 2004. e-Pub 2004.
10. Lucci A, Shoher A. Commentary: Clinical axillary recurrence in breast cancer patients after a negative sentinel lymph node biopsy. Women's Oncology Review 3, 2003. e-Pub 2003.
11. Lucci A, Muylaert S. Commentary Smoking as a risk factor for wound healing and infection in breast cancer surgery. Women's Oncology Review 3, 2003. e-Pub 2003.
12. Lucci A. Commentary: Factors predicting recurrence from malignant phyllodes tumor. Women's Oncology Review 2, 2002. e-Pub 2002.
13. Lucci A, Shoher A. Commentary: First results from the International Breast Cancer Interventional Study (IBIS): a randomized prevention trial. Women's Oncology Review 2, 2002. e-Pub 2002.
14. Lucci A. Commentary: Levels of consumption of meat and dairy products and risk of developing breast cancer. Women's Oncology Review 2, 2002. e-Pub 2002.
15. Lucci A. Commentary: Bracketing wires for preoperative breast needle localization. Women's Oncology Review 1, 2001. e-Pub 2001.
16. Lucci A, Sherman M. Assessment of the current medicare reimbursement system for breast cancer operations. Breast Diseases: A Year Book Quarterly, 2000. e-Pub 2000.
17. Bhattacharyya A, Lodhi A, Lucci A. Commentary on: Establishing axillary sentinel lymph node biopsy (SLNB) for early breast cancer in the United Kingdom: a survey of the national training program. Breast Diseases: A Year Book Quarterly 21.
18. DeLeonardis C, Lucci A. Axillary metastases in breast cancer patients with negative sentinel nodes: A follow-up of 3,548 cases. Breast Diseases: A Yearbook Quarterly.
19. Lucci A, Hall C. CTC's and bone marrow biopsies in breast cancer. Breast Diseases: A Year Book Quarterly 23(4).
20. Lodhi A, Lucci A. Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer. Breast Diseases: A Yearbook Quarterly.

Review Articles

1. Goodman, C, Sun, SX, Lucci, A, Stauder, MC, Woodward, W. Contemporary Locoregional Therapy for Inflammatory Breast Cancer: Don’t De-Escalate Off Protocol. Current Breast Cancer Reports 17(1), 2025. e-Pub 2025.
2. Chen JH, Geng Y, Lucci A. Applications of ctDNA testing to monitor and detect residual disease in breast cancer. Expert Rev Mol Diagn 25(6):263-274, 2025. e-Pub 2025. PMID: 40288891.
3. Addanki S, Meas S, Sarli VN, Singh B, Lucci A. Applications of Circulating Tumor Cells and Circulating Tumor DNA in Precision Oncology for Breast Cancers. Int J Mol Sci 23(14), 2022. e-Pub 2022. PMID: 35887191.
4. Adesoye T, Irwin S, Sun SX, Lucci A, Teshome M. Contemporary surgical management of inflammatory breast cancer: a narrative review. Chin Clin Oncol 10(6):57, 2021. e-Pub 2021. PMID: 35016511.
5. Menta A, Fouad TM, Lucci A, Le-Petross H, Stauder MC, Woodward WA, Ueno NT, Lim B. Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer. Surg Clin North Am 98(4):787-800, 2018. e-Pub 2018. PMID: 30005774.
6. Fayanju OM, Park KU, Lucci A. Molecular Genomic Testing for Breast Cancer: Utility for Surgeons. Ann Surg Oncol 25(2):512-519, 2018. e-Pub 2018. PMID: 29159748.
7. Hall C, Valad L, Lucci A. Circulating Tumor Cells in Breast Cancer Patients. Crit Rev Oncog 21(1-2):125-141, 2016. e-Pub 2016. PMID: 27481009.
8. Gainer SM, Lucci A. Oncoplastics: Techniques for reconstruction of partial breast defects based on tumor location. J Surg Oncol 103(4):341-7, 2011. e-Pub 2011. PMID: 21337569.
9. Robertson FM, Bondy M, Yang W, Yamauchi H, Wiggins S, Kamrudin S, Krishnamurthy S, Le-Petross H, Bidaut L, Player AN, Barsky SH, Woodward WA, Buchholz T, Lucci A, Ueno NT, Ueno N, Cristofanilli M. Inflammatory breast cancer: the disease, the biology, the treatment. CA Cancer J Clin 60(6):351-75, 2010. e-Pub 2010. PMID: 20959401.
10. Lang JE, Hall CS, Singh B, Lucci A. Significance of micrometastasis in bone marrow and blood of operable breast cancer patients: research tool or clinical application?. Expert Rev Anticancer Ther 7(10):1463-72, 2007. e-Pub 2007. PMID: 17944570.
11. Shoher A, Lucci A. Emerging patterns of practice in the implementation and application of sentinel lymph node biopsy in breast cancer patients in the United States. J Surg Oncol 83:65-67, 2003. e-Pub 2003. PMID: 12772197.
12. Singh B, Lucci A. Role of cyclooxygenase-2 in breast cancer. J Surg Res 108:173-179, 2002. e-Pub 2002. PMID: 12472107.

Other Articles

1. Melo, S, Sugimoto, H, O'Connell, JT, Kato, N, Villanueva, A, Vidal, A, Qiu, L, Vitkin, E, Perelman, LT, Melo, CA, Lucci, A, Ivan, C, Calin, GA, Kalluri, R Erratum. Cancer cell 43(9):1776, 2025.

Editorials

1. Lucci A. Editorial: Prospective studies confirm what we have thought all along - sentinel lymph node dissection really is a less morbid means of axillary staging - Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol 13:491-500, 2006. Breast Diseases: A Yearbook Quarterly 18:18, 2007.
2. Woodward WA, Lucci A, Cristofanilli M. A gene signature in breast cancer. N Engl J Med 356(18):1887-1888; author reply 1887-1888, 2007. PMID: 17479476.
3. Lucci A. Editorial: Clinical implications of sentinel nodes outside the axilla and internal mammary chain in patients with breast cancer by van Rijk MC, Tanis PJ, Nieweg OE, et al. J Surg Oncol 94:266-268, 2006.

Abstracts

1. Goodman CR, Shaitelman SF, Ramezani S, Strauss JB, Zia A, Comeaux N, Virk R, Lin R, Nead K, Mitchell MP, Hoffman KE, Strom E, Stauder M, Perkins G, Reed V, Bloom E, Joyner M, Schlembach P, Valero V, Lim B, Barcenas CH, Lucci A, Woodward WA, Smith BD. Prospective analysis of circulating tumor cell dynamics during preoperative radiotherapy in locally advanced breast cancer. Accepted for presentation at AACR Special Conference in Cancer Research: Liquid Biopsy: From Discovery to Clinical Implementation 30(21_Supplement), 2024. e-Pub 2024.
2. Chen JH, Hwang H, Dong B, Sarli VN, Upshaw JR, Meas S, Lucci A. Prognostic value of circulating tumor cells in stage III and IV melanoma: a systematic review and meta-analysis. Accepted for a poster presentation at AACR Special Conference in Cancer Research: Liquid Biopsy: From Discovery to Clinical Implementation 30(Supplement 21), 2024. e-Pub 2024.
3. Roy D, Sarli VN, Liu Y, Chen JH, Meas S, Upshaw J, Lorenzi PL, Lucci A. Comprehensive circulating cytokine/chemokine profiles for monitoring and predicting clinical outcomes in melanoma neoadjuvant immunotherapy. Accepted for presentation at ISLB Conference 5(Supplement), 2024. e-Pub 2024.
4. Chen JH, Meas S, Sarli VN, Koupaei N, Upshaw J, Lucci A. Characterization Of CTC-HER2 Status In Patients With HER2-low Invasive Breast Cancer. Accepted as a full oral presentation in the Scientific Forum at American College of Surgeons Clinical Congress. e-Pub 2024.
5. Chen J, Meas S, Koupaei N, Bassett R, Sarli V, Upshaw J, Roy D, Valero V, Woodward W, Lucci A. Is presence of molecular residual disease after pathologic complete response associated with relapse in inflammatory breast cancer?. Accepted for poster presentation ESMO Congress 2024 35(Supplement 2):S355, 2024. e-Pub 2024.
6. Glencer AC, Wanis KN, Brown S, Lucci A, Sun SX, Adesoye T, DeSnyder SM, Layman R, Woodward WA, Hunt KK, Teshome M. Self-Reported Management of Inflammatory Breast Cancer Among the American Society of Breast Surgeons Membership: Consensus and Opportunities. Accepted for presentation at Society of Surgical Oncology Annual Meeting 31:7326-7334, 2024. e-Pub 2024.
7. Soran A, Ozbas S, Dogan L, Can Trablus D, Al-Azhri J, Senol K, Goktepe B, Zaveri S, Meas S, Demirci U, Karanlik H, Soyder A, Dag A, Bilici A, Dogan M, Sendur M, Koksal H, Gulcelik M, Cabioglu N, Yeniay L, Utkan Z, Karadurmus N, Daglar G, Simsek T, Yildiz B, CUras, Tukenmez M, Ozaslan C, Karaman N, Isik A, Demirors B, Sezgin E, Ozmen V, Lucci A. Loco-regional Treatment in De Novo Bone Only Metastatic Breast Cancer; Prospective, Multi-Institutional Real-World Data, BOMETIN, Protocol MF14-1a. Accepted for Poster Presentation, Annual San Antonio Breast Cancer Symposium, December 5-9, 2023, San Antonio, TX 84(9_Supplement), 2024. e-Pub 2024.
8. Chen JH, Meas S, Sarli VN, Koupaei N, Upshaw J, Roy D, Valero V, Woodward WA, Lucci AA. Presence of molecular residual disease after pathologic complete response among patients with inflammatory breast cancer. Accepted for poster presentation American Society for Clinical Oncology 42:3044, 2024. e-Pub 2024.
9. Ma W, Zhao L, Devi G, Hsu H, Krishnamurthy S, Coffer L, Alexander S, Kai M, Wang X, Le-Petross H, Patel M, Debeb BG, Bartholomeusz C, Zhang J, Song X, Futreal A, Tumor Initiative TR, Ueno NT, Layman R, Lucci A, Wang J, Woodward WA. BUILDING GENOMIC AND TRANSCRIPTOMIC DATA AMONG AFRICAN AMERICAN AND BLACK PATIENTS WITH TRIPLE-NEGATIVE INFLAMMATORY BREAST CANCER. Accepted for Poster Presentation, Annual San Antonio Breast Cancer Symposium 84(9_Supplement), 2024. e-Pub 2024.
10. Lynce F, Niman S, Gonçalves A, Kai M, Ryan S, Troll E, Layman R, Giordano A, Nasrazadani A, Nakhlis F, Bellon J, Warren L, Block C, Schumer S, Lucci A, Krishnamurthy S, Lerebours F, Dalenc F, Levy C, Petit T, Leheurteur M, Bachelot T, Trédan O, Ladoire S, Almeida LL, Zemmour C, Tolaney S, Valero V, BERTUCCI F, Regan M, Woodward W. Pathological complete response with chemotherapy and immune checkpoint inhibition in triple negative inflammatory breast cancer (TN-IBC). Accepted for poster presentation at San Antonio Breast Cancer Symposium 84(9_Supplement), 2024. e-Pub 2024.
11. Iwase T, Nithya S, Kai M, Willey J, Dong W, Shen Y, Krishnamurthy S, Lucci A, Le-Petross H, Nasrazadani A, Saleem S, Layman R, Valero V, Tripathy D, Woodward W, Cheng YC, Nakhlis F, Bellon J, Lynce F, Ueno N. Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer (IBC): a multicenter retrospective study. Accepted for poster presentation at San Antonio Breast Cancer Symposim 84(9_Supplement), 2024. e-Pub 2024.
12. Tarantino P, Niman SM, Giordano A, Nakhlis F, Bellon J, Woodward W, Nasrazadani A, Saleem S, Lucci A, DeMeo M, Ueno N, Tolaney SM, Valero V, Regan MM, Layman RM, Lynce F. TRUDI: A Phase II Study of neoadjuvant TRastuzumab derUxtecan and Durvalumab for Stage III HER2-expressing Inflammatory Breast Cancer. Accepted for Poster Presentation, Annual San Antonio Breast Cancer Symposium 84(9_Supplement), 2024. e-Pub 2024.
13. Addanki S, Meas S, Sarli V, Almosa A, Woodward W, Roy D, Lucci A. Integrating Circulating Tumor Cells (CTCs) and Cell-free DNA (cfDNA) Signatures for Monitoring Treatment Response in Stage III/IV Inflammatory Breast Cancer. Accepted for poster presentation at San Antonio Breast Cancer Symposium 84(9_Supplement), 2024. e-Pub 2024.
14. Fernandez E, Cass S, Seo YD, Damania AV, Meng X, Sahasrabhojane PV, Liu JS, Liu W, Chen Y, Bassett RL, Shelburne S, Chang H, Somaiya KR, Mungovan KS, Malke JC, Matejka B, Fisher SB, Lucci A, Lee JE, Ross MI, Gershenwald JE, Sharma P, Ajami NJ, Roland CL, Wargo JA, Keung EZ. A single dose of perioperative cefazolin disrupts the gut microbiome and immunity in patients (pts) with early-stage melanoma. Accepted for presentation at American Association for Cancer Research Annual Meeting 84(6_Supplement), 2024. e-Pub 2024.
15. Chen JH, Meas S, Koupaei N, Roy D, Slack Tidwell RS, Woodward WA, Lucci A. Impact of Race on Cytokine Profiles in Patients with Triple-Negative Inflammatory Breast Cancer: An Exploratory Analysis. Accepted for presentation at Society of Surgical Oncology Annual Meeting. e-Pub 2024.
16. Nasrazadani A, Kai M, Layman R, Valero V, Saleem S, Debeb BG, Lucci A, Sun SX, Bopparaju S, Murphy HE, Alexander A, Marx AN, Stauder MC, Lim B, Woodward WA. High brain relapse rates in stage III triple negative inflammatory breast cancer are independent of systemic therapy. Accepted for poster presentation at American Association for Cancer Research Annual Meeting 84(6_Supplement), 2024. e-Pub 2024.
17. Hasanov M, Kiany S, Forget M, Bassett RL, Davies MA, Diab A, Gershenwald JE, Glitza IC, Lee JE, Lucci A, McQuade JL, Patel SP, Ross MI, Tawbi HA, Wargo J, Wong MK, Bernatchez C, Hwu P, Haymaker C, Amaria RN. Phase II study of pembrolizumab in conjunction with lymphodepletion, TIL ACT, and high- or low-dose IL-2 in patients with metastatic melanoma. Accepted for presentation at American Association for Cancer Research 84(6_Supplement), 2024. e-Pub 2024.
18. Singh B, Sarli VN, Lucci A. Modeling evolutionary fitness in resistant cancers based on a common adaptability trait. Accepted for presentation at American Association for Cancer Research 84(6_Supplment), 2024. e-Pub 2024.
19. ASoran, BGoktepe, BDemirors, SOzbas, Sezgin E, JAl-Azhri, SZaveri, SMeas, ALucci, McAuliffe PF. THE IMPORTANCE OF TRI-MODALITY THERAPY FOR DE NOVO STAGE IV INVASIVE LOBULAR CARCINOMA (ILC) PRESENTING WITH BONE-ONLY METASTASES. Accepted for presentation at Miami Breast Cancer Conference. e-Pub 2024.
20. Braschi E, Yang Y, Stauder M, Woodward W, Layman R, Lim B, Arnold T, Lucci A, Sun S, Saleem S, Ludmir E, Kelsey C. Rare but Relevant: Exploring Factors behind the Exclusion of Inflammatory Breast Cancer from Breast Cancer Clinical Trials. Accepted for Poster Presentation, Annual ASTRO 2024, September 29-October 2, 2024, Washington, DC, 2024. e-Pub 2024.
21. Roy D, Sarli V, Meas S, Upshaw J, Koupaei N, Almosa A, Lucci A. Blood-Based Circulating Tumor Cells and Cell-Free DNA Monitoring for Dynamic Recurrence Risk Prediction in Melanoma. Accepted for poster presentation at ISLB Conference 1:11-12, 2023. e-Pub 2023.
22. Lucci A, Addanki S, Kalashnikova E, Renner D, Kuerer HM, Meas S, Sarli VN, White JB, Rauch G, Tripathy D, Arun BK, Barcenas CH, Yam C, Rodriguez AA, Liu MC, Moulder SL. Monitoring response to neoadjuvant chemotherapy in TNBC using circulating tumor DNA. Accepted for presentation ESMO Breast Conference 8(1), 2023. e-Pub 2023.
23. Singh B, Sarli VN, Lucci A. A cell culture model of resistant cells in solid cancers that opportunistically switch between proliferation and quiescence. Accepted for presentation at American Association for Cancer Research 83(7_Supplement), 2023. e-Pub 2023.
24. Patel SP, Haymaker C, Sheth RA, Kuban JD, Weintraub J, Wehrenberg-Klee E, Novelli P, Gonsalves C, Adamo R, Honaker V, Timciuc L, Hennegan T, Amador Molina JC, Duose D, Parras Cuenta ER, Lucci A, Meas S, Sarli V, Prieto VG, LaPorte J, Hulstine A, Moody A, Cox B, Geller D, Davar D, Montazeri K, Orloff M, Katz SC, Carvajal R. PERIO-01: Initial safety experience and immunologic effects of a Class C TLR9 agonist using pressure- enabled drug delivery in a phase 1 trial of hepatic arterial infusion of SD-101 +/- checkpoint inhibition in metastatic uveal melanoma. Accepted for presentation at American Association for Cancer Research 87(7_Supplement), 2023. e-Pub 2023.
25. Tarantino P, Niman SM, Giordano A, Nakhlis F, Bellon J, Woodward W, Nasrazadani A, Saleem S, Lucci A, DeMeo M, Ueno N, Tolaney SM, Valero V, Regan MM, Layman RM, Lynce F. TRUDI: A Phase II Study of neoadjuvant TRastuzumab derUxtecan and Durvalumab for Stage III HER2-expressing Inflammatory Breast Cancer. Accepted for Poster Presentation, Annual San Antonio Breast Cancer Symposium, December 5-9, 2023, San Antonio, TX, 2023. e-Pub 2023.
26. Ma W, Zhao L, Devi G, Hsu H, Krishnamurthy S, Coffer L, Alexander S, Kai M, Wang X, Le-Petross H, Patel M, Debeb BG, Bartholomeusz C, Zhang J, Song X, Futreal A, Tumor Initiative TR, Ueno NT, Layman R, Lucci A, Wang J, Woodward WA. BUILDING GENOMIC AND TRANSCRIPTOMIC DATA AMONG AFRICAN AMERICAN AND BLACK PATIENTS WITH TRIPLE-NEGATIVE INFLAMMATORY BREAST CANCER. Accepted for Poster Presentation, Annual San Antonio Breast Cancer Symposium, December 5-9, 2023, San Antonio, TX, 2023. e-Pub 2023.
27. Patel SP, Carvajal R, Montazeri K, Reddy S, Lutzky J, Khan SA, Chmielowski B, Bhatia S, Medina T, Haymaker C, Sheth R, Kuban JD, Thornton L, Wehrenberg-Klee E, Novelli P, Lucci A, Sarli V, Meas S, Cox B, LaPorte J, Guha P, Ghosh CC, Hulstine A, Knight R, Moody A, Geller D, Katz S, Orloff M, Davar D. Clinical activity of SD-101 with immune checkpoint inhibition (ICI) in metastatic uveal melanoma liver metastasis (MUM-LM) from the PERIO-01 Phase 1 trial. Accepted for poster presentation at SITC Conference 11, 2023. e-Pub 2023.
28. Montazeri K, Davar D, Haymaker CL, Sheth R, Kuban J, Weintraub J, Wehrenberg-Klee E, Novelli PM, Gonsalves CF, Adamo RD, Lucci A, Meas S, Sarli VN, Prieto VG, Geller DA, Orloff MM, Carvajal RD, Patel SP. Safety and early biologic effects of phase 1 PERIO-01 trial of pressure-enabled drug delivery (PEDD) of TLR9 agonist SD-101 and immune checkpoint inhibition (ICI) in uveal melanoma metastatic to the liver (MUM). Accepted for presentation at American Society for Clinical Oncology Annual Meeting 41(Supplement 2521), 2023. e-Pub 2023.
29. Soran, A, Goktepe B, Ozbas S, Zaveri S, Meas S, Demirors B, Senol K, Sezgin E, Lucci A. Survival Improvement With Multimodality Treatment In HER2 Positive De Novo Bone-Only Metastatic Breast Cancer. Accepted for Oral Presentation at the 19th Annual Academic Surgical Congress to be held February 6-8, 2024 in Washington, DC(Abstract #: ASC20241373), 2023. e-Pub 2023.
30. Postlewait LM, Teshome M, DeSnyder SM, Lim B, Kuerer HM, Woodward WA, Ueno NT, Lucci A. Factors Associated with Pathologic Node Negativity in Inflammatory Breast Cancer: Are there patients who may be candidates for sentinel lymph node biopsy or targeted axillary dissection?. Accepted as a Quick Shot Presentation at the Society's 21st Annual Meeting April 29 - May 3, 2020 in Las Vegas, NV, 2020. e-Pub 2020.
31. Lucci A, Hall C, Sarli V, Upshaw J, Meas S, Narendran B, Wang F, Li Y, Ross MM. CTCs AND SENTINEL LYMPH NODE BURDEN IN MELANOMA PATIENTS. Submitted for Oral Presentation to 2020 Global Academic Program Conference, May 11-13, Melbourne, Australia, 2020. e-Pub 2020.
32. Liang D, Hall C, Meas S, Narendran B, Sarli V, Lucci A. Pilot study of circulating tumor cells before and after neoadjuvant chemotherapy in non-metastatic inflammatory breast cancer. Accepted as a Oral Presentation at the Society of Surgical Oncology 2020 International Conference on Surgical Cancer Care March 25-28 in Boston, MA, 2020. e-Pub 2020.
33. Singh B, Sarli VN, Lucci A. Potential of 6-mercaptopurine and 5-azacitidine in halting progression of poor prognosis residual disease in triple negative breast cancer. Accepted for virtual oral presentation, American Association for Cancer Research June 22-24(Abstract No. 1153), 2020. e-Pub 2020.
34. Vicente D, Lee AJ, Hall CS, Lucci A, Vreeland T, Newhook T, Lee JE, Kim MP, Katz M HG, Hurd M, Alvarez H, Maitra A, Rhim AD, Tzeng CWD. Circulating Tumor Cells and Transforming Growth Factor Beta in Pancreatic Adenocarcinoma. Accepted for Quick Shot Presentation at the 14th Annual Academic Surgical Congress, February 5-7, 2019 in Houston, TX, 2019. e-Pub 2019.
35. Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets T, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Gonzalez AM, Toth CL, Wardell S, Mansaray R, Patel V, Carpio DJ, Vaughn C, Farinas CM, Velasquez PG, Hwu WJ, Patel SP, Davies MA, Diab A, Glitza IC, Tawbi H, Wong MK, Cain S, Ross MI, Lee JE, Gershenwald JE, Lucci A, Royal R, Cormier JN, Wargo JA, Radvanyi LG, Torres-Cabala CA, Beroukhim R, Hwu P, Amaria RN, Bernatchez C. Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. Clin Cancer Res 24(18):4416-4428, 2018. e-Pub 2018. PMID: 29848573.
36. Partain N, Rosso K, Song S, Meas S, Mediget T, Hall CS, Kuerer HM, Lucci A. The Role of Mastectomy in Stage IV Inflammatory Breast Cancer. Accepted for Poster Presentation, SSO Annual Meeting, 2018. e-Pub 2018.
37. Lim B, Napa P, Hee L, Rob S, Morris S, Bailey D, Hout D, Arvind R, Lucci A, Tripathy D, Krishnamurthy S, Ueno N. Molecular subtype change of neoadjuvant chemotherapy impacts the prognosis of patients with triple-negative breast cancer. Accepted for Poster Presentation, Annual San Antonio Breast Cancer Symposium, December 4-8, 2018, San Antonio, TX, 2018, 2018. e-Pub 2018.
38. Singh B, Sarli V, Lucci A. Metabolically adaptable cancer cells as usable cell culture model of rapidly progressing poor-prognosis minimal residual disease in triple-negative breast cancer: Mechanistic insights and evaluation of a potential therapy. Poster Presentation AACR Cancer Dormany and Residual Disease, Montreal, QC, Canada, 2018. e-Pub 2018.
39. Ng S, Hall CS, Meas S, Sarli V, Bahig H, Elgohari B, Moreno A, Skinner H, Garden A, Rosenthal D, Morrison W, Phan J, Gunn GB, Frank S, Fuller C, Lucci A. Circulating Tumor Cells and cfDNA Changes During Radiotherapy in Patients with Head and Neck Cancer. The 2019 American Association for Cancer Research Annual Meeting in Atlanta, GA, March 29 - April 3, 2018. e-Pub 2018.
40. Lee AJ, Hall C, Hurd M, Lucci A, Kim M, Lee JE, Katz M, Maitra A, Rhim A, Tzeng CW. Feasibility of intraoperative CTC detection from portal vein during resection for pancreatic adenocarcinoma. Accepted for Oral Presentation at the 2019 Annual Meeting of the Americas Hepato-Pancreato-Biliary Association in Miami Beach, Florida, March 20-24, 2019, 2018. e-Pub 2018.
41. Lucci, A. Circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC). Accepted for Poster Presentation, Annual San Antonio Breast Cancer Symposium, December 4-8, 2018, San Antonio, TX, 2018, 2018. e-Pub 2018.
42. Vicente D, Lee AJ, Hall CS, Lucci A, Vreeland T, Newhook T, Lee JE, Kim MP, Katz M HG, Hurd M, Alvarez H, Maitra A, Rhim AD, Tzeng CW D. Circulating Tumor Cells and Transforming Growth Factor Beta in Pancreatic Adenocarcinoma. Quick Shot Presentation; 14th Annual Academic Surgical Congress, February 5-7, 2019, Houston, TX, 2018. e-Pub 2018.
43. Lucci A. Can Circulating Tumor Cell Monitoring Identify Optimal Candidates For Watch And Wait After Neoadjuvant Therapy For Rectal Cancer?. presentation in the Scientific Forum program at the American College of Surgeons Clinical Congress, October 21-25, 2018, 2018. e-Pub 2018.
44. Ueno NT, Tahara RK, Saigal B, Fujii T, Reuben JM, Gao H, Lucci A, Ibrahim NK, Damodaran S, Shen Y, Liu DD, Hortobagyi GN, Tripathy D, Lim B, Chasen BA. Phase II study of Ra-223 combined with hormonal therapy and denosumab for treatment of hormone receptor-positive breast cancer with bone-dominant metastasis. J Clin Oncol 36(suppl; abstr 1065), 2018. e-Pub 2018.
45. Park KU, Kyrish K, Terrell JA, Akay CL, Bedrosian I, Black DS, Caudle AS, Checka C, Feig BW, Hunt KK, Hwang RF, Kuerer HM, Lucci A, Meric-Bernstam F, Refinetti AP, Reyna C, Ross MI, Teshome M, Thompson AM, DeSnyder SM. Opioid prescriptions after breast cancer surgery: Perception and reality. J Clin Oncol 36(suppl; abstr e18799), 2018. e-Pub 2018.
46. Masuda H, Harano K, Miura S, Wang Y, Hirota Y, Harada O, Matsunaga Y, Lim B, Wood AL, Lucci A, Parinyanitikul N, Lee HJ, Gong G, Rao A, Seitz R, Hout DR, Morris SW, Nakamura S, Krishnamurthy S, Ueno NT. Molecular subtypes of triple-negative breast cancer (TNBC) tumor samples obtained before and after neoadjuvant systemic therapy (NST) and relationship between immunomodulatory (IM) gene signature and intensity of tumor-infiltrating lymphocytes (TILs). J Clin Oncol 36(suppl), 2018. e-Pub 2018.
47. Woodward WA, Cristofanilli M, Merajver SD, Van Laere S, Pusztai L, Bertucci F, Berditchevski F, Polyak K, Overmoyer B, Devi GR, Sterneck E, Schneider R, Debeb BG, Wang X, van Golen KL, El-Zein R, Rahal OM, Alexander A, Reuben JM, Krishnamurthy S, Lucci A, Ueno NT. Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference. J Cancer, 2017. e-Pub 2017. PMID: 29667990.
48. Royal R, Vence L, Wray T, Comier J, Lee J, Lucci A, Gershenwald J, Ross M, Wargo J, Amaria R, Davies M, Diab A, Glitza I, Hwu, WJ, Patel S, Woodman S, Overwijk W, Hwu P. A toll-like receptor agonist used melanoma regression as a vaccination adjuvant or by direct tumor application. Accepted for Poster Presentation at the 2017 ASCO Annual Meeting, June 2-6, Chicago, IL, 2017. e-Pub 2017.
49. Singh B, Washburn LJ, Kinne HE, Milligan RD, A L. Treatment with a Jumonji demethylase inhibitor JIB-04 sensitizes resistant breast cancer cells to chemotherapeutic drugs in an in vitro model of intrinsic resistance. Accepted for Poster Presentation at the 2016 San Antonio Breast Cancer Symposium San Antonio, TX, 2016. e-Pub 2016.
50. F-C B, Michiels S, Mueller V, Riethdorf S, Esserman LJ, A L, Naume B, Horiguchi J, Gisbert-Criado R, Sleijfer S, Toi M, Garcia-Saenz JA, Hartkopf A, Generali D, Rothe F, Smerage J, Muinelo L, Stebbing J, Viens P, Magbanua M, Hall CS, Engebråtenm O, Takata D, Vidal-Martínez J, Onstenk W, Fujisawa N, Diaz-Rubio E, F-A T, Cappelletti MR, Ignatiadis M, Proudhon C, Wolf D, Bowman Bauldry J, Borgen E, Nagaoka R, Carañana V, Kraan J, Maestro M, Brucker SY, Weber K, Reyal F, Amara D, Karhade MG, Ruud R, Tokiniwa H, Llombart-Cussac A, D'Hollander K, Cottu P, Park JW, Loibl S, J-Y P, Institut Curie PK, Paris, France, Roussy G, Villejuif, France, Hamburg-Eppendorf U, Hamburg, Germany, San Francisco UOCA, Francisco S, CA, Center MD, Houston, TX, Hospital OU, Oslo, Norway, Hospital GU, Gunma, Japan, de Vilanova HA, Valencia, Spain, Cancer Institute EM, Rotterdam, Netherlands, Hospital KU, Kyoto, Japan, San Carlos HC, Madrid, Spain, Tuebingen UO, Tuebingen, Germany, Trieste UO, Cremona, Italy, Bordet IJ, Brussels, Belgium, Cancer Center UOMC, Arbor A, MI, Universitario CH, Compostella SD, Spain, College I, London, Kingdom U, Calmette IP, Marseilles, France, Group GB, Neu-Isenburg, Germany, IDDI, Neuve LL, Belgium. IMENEO: International MEta-analysis of circulating tumor cell detection in early breast cancer patients treated by Neoadjuvant chemotherapy. Accepted for Oral Presentation at the 2016 San Antonio Breast Cancer Symposium, San Antonio, TX, 2016. e-Pub 2016.
51. Orozco J, Bustos M, Nelson N, Hsu S, Cheung G, Bostick PJ, Lucci A, DiNome M, Kelly DF, Hoon DSB, Marzese DM. DNA methylation landscape of breast cancer progression to brain metastasis: A pre-clinical study. Accepted for Poster Presentation at the 2016 Annual SABCS Meeting in San Antonio, TX, December 6-10, 2016, 2016. e-Pub 2016.
52. Hall CS, Karhade M, Bauldry J, Kuerer HK, DeSnyder S, Lucci A. Obesity and inflammatory breast cancer. Accepted for Presentation at the 2016 World Cancer Congress, Paris, France, October 31- November 3, 2016, 2016. e-Pub 2016.
53. Lucci A, Hall CS, Karhade M, Bauldry J, Ross MI. Measurement of circulating melanoma cells as an alternative for routine imaging of advanced melanoma patients. Accepted for Oral Presentation at the 2016 World Cancer Congress, Paris, France, October 31- November 3, 2016, 2016. e-Pub 2016.
54. Amaria R, Haymaker C, Bernatchez C, Forget MA, Patel V, Hwu WJ, Davies M, Pradyuman S, Diab A, Glitza I, Tawbi H, Woodman SE, Wargo J, Ross MI, Lee JE, Gershenwald JE, Cormier J, Royal RE, Lucci A, Hwu P. A phase I/II study of lymphodepletion plus adoptive cell transfer (ACT) with T cells transduced with CXCR2 and NGFR followed by high dose interleukin-2 (IL-2) in patients with metastatic melanoma (MM). Accepted as a Poster Presentation at the 2016 ASCO Annual Meeting in Chicago, IL, June 3-7, 2016, 2016. e-Pub 2016.
55. Matsuda N, Wang X, Krishnamurthy S, Alvarez R, Willey J, Lim B, Parker C, Babiera G, Booser D, Murray J, Arun B, Brewster A, Reuben JM, Stauder MC, Woodward W, Lucci A, DeSnyder S, Tripathy D, Valero V, Ueno N. Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER2-negative inflammatory breast cancer. Accepted for Poster Presentation at the 2016 ASCO Annual Meeting in Chicago, IL, June 3-7, 2016, 2016. e-Pub 2016.
56. Matsuda N, Wang X, Krishnamurthy S, Willey J, Lim B, Parker C, Babiera G, Booser D, Murray J, Arun B, Brewster A, Reuben J, Stauder M, Woodward W, Lucci A, DeSnyder S, Tripathy D, Valero V, Alvarez R, Ueno N. Phase II study of Panitumumab, Nab-paclitaxel, and Carboplatin Followed by FEC neoadjuvant chemotherapy for Patients with Primary Inflammatory Breast Cancer (HR+ or TNBC). Accepted for Poster Presentation at the 2016 ASCO Annual Meeting in Chicago, IL, June 3-7, 2016, 2016. e-Pub 2016.
57. Hall CS, Ross M, Karhade M, Bauldry JB, Valad L, Upshaw J, Royal R, Lucci A. Can Circulating Melanoma Cells be detected in the Blood of Patients with Melanoma?. Accepted for Oral Presentation at the 51st Congress of the European Society for Surgical Research in Prague, Czech Republic, May 25-28, 2016, 2016. e-Pub 2016.
58. Fayanju O, Hall CS, Bauldry J, Karhade M, Valad L, Kuerer HK, DeSnyder S, Barcenas C, Lucci A. The Impact of Body Mass Index on the Prognostic Power of Circulating Tumor Cells and Pathologic Complete Response following Neoadjuvant Chemotherapy for Breast Cancer. Accepted for Poster Presentation at the 2016 ASBS Annual Meeting, April 13-17, 2016 in Dallas, TX, 2016. e-Pub 2016.
59. Singh B, Lucci A. Important role of FTO in the survival of rare panresistant triple-negative inflammatory breast cancer cells under a severe metabolic challenge. Accepted for poster presentation at the 2016 AACR Annual Meeting in New Orleans, April 16-20, 2016, 2016. e-Pub 2016.
60. Prieto P, Cooper Z, Gopalakrishnan V, Tetzlaff M, Bassett R, Amaria R, Davies M, Diab A, Glitza I, Hwu P, Hwu WJ, Patel S, Yee C, Burton E, Simpson L, Royal R, Cormier J, Lucci A, Lee JE, Gershenwald J, Ross M, Wargo J. Treatment with neoadjuvant targeted therapy yields high response rates and pathologic complete responses in patients with respectable metastatic melanoma. Accepted as Poster Presentation at the 2016 SSO Annual Cancer Symposium in Boston, MA, March 2-5, 2016, 2016. e-Pub 2016.
61. Lucci A. Circulating Melanoma Cell levels before and after Immunotherapy in Advanced Melanoma Patients. Submitted to the Society of Surgical Oncology's 69th Annual Cancer Symposium, March 2-5, 2016, Boston, MA, 2016. e-Pub 2016.
62. Lucci A, Bauldry JB, Karhade M, Valad L, Kuerer H, DeSnyder S, Hall CS. Circulating Tumor Cells After Neoadjuvant Therapy and Relapse in Stage I-III Breast Cancer. Accepted for Oral Presentation at the 2016 SSO Annual Meeting in Boston, MA, March 2-5, 2016, 2016. e-Pub 2016.
63. Hall CS, Lucci A. Circulating melanoma cells and recurrence in stage III melanoma patients. Accepted for Oral Presentation at the 10th ISMRC International Symposium on Minimal Residual Cancer: Liquid Biopsy in Cancer Diagnostics and Treatment, March 18-21, 2016 in Hamburg, Germany, 2016. e-Pub 2016.
64. Hall C, Ross M, Karhade M, Bauldry JB, Upshaw J Royal R, Valad L, Lucci A. Circulating Tumor Cells and Relapse in Stage IV Cutaneous Melanoma Patients. Accepted for Oral Presentation at the 11th Annual Academic Surgical Congress, February 2-6, 2016, Jacksonville, FL, 2016. e-Pub 2016.
65. Boughey J, Goravanchi F, Hunt K, Parris R, Kee S, Frenzel J, Kowalski A, Kuerer H, Ames F, Lucci A. A prospective randomized controlled clinical trial of paravertebral block anesthesia for patients undergoing surgery for breast cancer. Accepted, Poster presentation for ASCO Breast Symposium, 2016. e-Pub 2016.
66. Hall C, Valad L, Karhade M, Bauldry J, Kuerer HK, DeSnyder S, Lucci A. Prognostic Value of Circulating Tumor Cells Identified Prior to Surgical Resection in Non-Metastatic Breast Cancer Patients. Accepted for Oral Presentation at the 2015 WSA Annual Meeting November 7-10, 2015, Napa Valley, CA, 2015. e-Pub 2015.
67. DeSnyder SM, Hall C, Karhade M, Kuerer K, Lucci A. Presence of Circulating Tumor Cells and Disseminated Tumor Cells does not Predict Site of Recurrent or Metastatic Disease. Accepted for Poster Presentation at the 2015 SSO's 68th Annual Cancer Symposium, March 25-28, Houston, TX, 2015. e-Pub 2015.
68. Hall CS, Laubacher B, Anderson A, Karhade M, Kuerer KM, DeSnyder S, Lucci A. Circulating Tumor Cells after Neoadjuvant Therapy in Stage I-III Triple-negative Breast Cancer. Accepted for Oral Presentation at SSO's 68th Annual Cancer Symposium, March 25-28, Houston, TX, 2015. e-Pub 2015.
69. Sauder CA, Hunt KK, Lucci A, Mittendorf EA, Kuerer HM, Caudle AS. Outcomes with Contralateral Axillary Nodal Metastases in Breast Cancer Breast Track. Accepted for Poster Presentation at the 2015 Society of Surgical Oncology Annual Meeting, Houston, TX, 2015. e-Pub 2015.
70. Lucci A, Hall C, Karhade M, Laubacher B, Bauldry J, Royal R, Upshaw J, Roland CL, Ross MI. Circulating melanoma cells and recurrence in stage III melanoma patients. Accepted for Poster Presentation at the 2015 ASCO Annual Meeting, May 29 - June 2, 2015, Chicago, IL, 2015. e-Pub 2015.
71. Hall, C, Karhade, M, Laubacher, B, Anderson, A, Kuerer, K, DeSnyder, S, Lucci A, A. Circulating tumor cells and relapse in non-metastatic triple negative breast cancer. Accepted as Poster Presentation at the Global Academic Programs 2015 Conference, April 14-16, 2015, Houston, TX, 2015. e-Pub 2015.
72. Hall C, Valad L, Karhade M, Kuerer HK, DeSnyder S, Lucci A. Circulating Tumor Cells After Neoadjuvant Therapy and Relapse in Stage I-III Breast Cancer. Accepted for Poster Presentation at the 19th International Meeting of the European Society of Gynaecological Oncology (ESGO 2015), October 24-27, 2015, Nice, France, 2015. e-Pub 2015.
73. Bauldry J, Karhade M, Hall C, Lucci A. Circulating melanoma cells predict perineural invasion. Accepted for Poster Presentation at The University of Texas MD Anderson Cancer Center Trainee Research Day, June 10, 2015, Houston, TX, 2015. e-Pub 2015.
74. Barcenas C, Sinha A, Hortobagyi G, Valero V, Ueno N, Giordano S, Chavez-Mac Gregor M, Brewster A, Lucci A, Tripathy D. Hormonal treatment (HT) and late recurrence in early-stage breast cancer (BC) patients. Accepted for Poster Presentation at the 2015 ASCO Annual Meeting, May 29 - June 2, 2015, Chicago, IL, 2015. e-Pub 2015.
75. Matsuda N, Alvarez R, Krishnamurthy S, Willey J, Wang X, Lim B, Parker C, Marx A, Babiera G, Booser D, Murray J, Arun B, Brewster A, Reuben J, Woodward W, Lucci A, Gainer SM, Tripathy D, Valero V, Ueno N. Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER-2 negative inflammatory breast cancer. Accepted for Poster Presentation at the 2015 ASCO Annual Meeting, May 29 - June 2, 2015, Chicago, IL, 2015. e-Pub 2015.
76. Amaria R, Wargo J, Cooper Z, Tetzlaff M, Reuben A, Davies M, Gershenwald J, Jiang H, Austin-Breneman J, Lee JE, Hwu P, Hwu WJ, Cormier J, Royal R, Lucci A, Patel SP, Diab A, Glitza I, Burton EM, Ross MI. Treatment with neoadjuvant BRAF Inhibition Yields Responses in Patients (pts) with High Risk Borderline Resectable Stage III Melanoma. 2015 ASCO Annual Meeting, May 29 - June 2, 2015, Chicago, IL, 2015. e-Pub 2015.
77. Karhade M, Bauldry J, Hall C, Lucci A. Circulating melanoma cells predict recurrence in stage IV melanoma patients. Accepted for Poster Presentation at The University of Texas MD Anderson Cancer Center Trainee Research Day, June 10, 2015, Houston, TX, 2015. e-Pub 2015.
78. DeSnyder S, Hunt K, Smith B, Moran M, Klimberg S, Lucci A. Assessment of Practice Patterns Following Publication of the SSO-ASTRO Consensus Guideline on Margins for Breast-Conserving Therapy with Whole Breast Irradiation in Stage I and II Invasive Breast Cancer. Accepted for Oral Presentation at the American Society of Breast Surgeons 16th Annual Meeting, April 29 - May 3, 2015, Orlando, FL, 2015. e-Pub 2015.
79. Singh B, Milligan R, Kinne H, Shamsnia A, Lucci A. Highly adaptable triple-negative breast cancer cells as a suitable model for testing epigenetic therapies. Accepted for Poster Presentation at the 2015 AACR Annual Meeting, April 18 - 22, 2015, Philadelphia, PA, 2015. e-Pub 2015.
80. Karhade M, Bauldry J, Hall C, Lucci A. Circulating Melanoma Cells Predict Recurrence In Stage IV Melanoma Patients. Accepted for Poster Presentation at the TMC Medical World Americas Conference and Expo, April 27-29, 2015, Houston, TX, 2015. e-Pub 2015.
81. Moossdorff M, Aebi S, Cameron D, Dixon JM, Giuliano A, Haffty B, Hickey B, Hudis C, Klimberg VS, Koczwara B, Kuhn T, Lippman M, Lucci A, Piccart-Gebhart M, Rutgers E, Smith BD, Tjan-Heijnen V, Van Zee K, Valentini V, van de Velde C, Vermorken J, Viale G, Voogd A, Wapnir E, White J. Maastricht Consensus on the definition of local event, second primary breast cancer, regional event, and distant event for classifying recurrence in breast cancer research. Accepted to the 9th European Breast Cancer Conference, March 17-21, 2014, Glasgow, Scotland, 2014. e-Pub 2014.
82. Singh B, Shamsnia A, Milligan R, Lucci A. Modeling the Roots of Aggressive Triple-negative Breast Cancer for Drug Discovery by Selecting Adaptable Metabolic STate in vitro. Accepted for Poster Presentation at the 2014 Keystone Symposia Conference, March 16-21, 2014, Whistler, British Columbia, 2014. e-Pub 2014.
83. Goravanchi F, Rigby D, Rebello E, Lange G, Kowalski A, Kee S, Lucci A, Caudle A, Baumann D, French K, Kuerer H. Outpatient Breast Surgery is Safe: Recent Experience With 10836 Patients at M.D. Anderson Cancer Center. Awarded Best Clinical Paper, 49th International Congress of European Society for Surgical Research (ESSR), Budapest, Hungary, 2014. e-Pub 2014.
84. You Y, Hall C, Lucci A, Rodriguez-Bigas M, Skibber JM, Bednarski B, Messick C, Chang G. Quantitative Detection of Circulating Tumor Cells in Patients With Locally Advanced Rectal Cancer: Initial Results of An On-going Prospective Longitudinal Study. Accepted for Oral Presentation at the American Society of Colon and Rectal Surgeons 2014 Meeting, April 25-29, 2014, Boston, MA, 2014. e-Pub 2014.
85. Singh B, Raythatha M, Shamsnia A, Milligan R, Lucci A. A new strategy for testing therapies to be effective against seemingly untreatable cancers. Accepted for Poster Presentation at the 2013 Annual SABCS Meeting, December 10-14, 2013, San Antonio, TX, 2013. e-Pub 2013.
86. Janni W, Rack B, Terstappen L, Pierga JY, Fehm T, Hall C, Groot M, Bidard FC, Meier-Stiegen F, Friedl T, Fasching P, Lucci A. A Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Early Breast Cancer. Accepted for Poster Presentation at the 2013 Annual SABCS Meeting, December 10-14, 2013, San Antonio, TX, 2013. e-Pub 2013.
87. Masuda H, Chavez-Mac Gregor M, Liu DD, Alvarez RH, Krishnamurthy S, Lucci A, Woodward W, Gildy B. Predictors of poor clinical outcome among patients with inflammatory breast cancer (IBC) who did and did not achieve pathological complete response (pCR) after neoadjuvant systemic chemotherapy. Accepted for Poster Presentation at the 2013 Annual SABCS Meeting, December 10-14, 2013, San Antonio, TX, 2013. e-Pub 2013.
88. Fouad T, Kogawa T, Liu D, Shen Y, Masuda H, El-Zein R, Woodward W, Arun B, Mac Gregor M, Alvarez R, Lucci A, Krishnamurthy S, Hortobagyi G, Valero V, Ueno N. Survival differences between patients with metastatic inflammatory and non-inflammatory breast cancer. Accepted for Poster Presentation at the 2013 Annual SABCS Meeting, September 10-14, 2013, San Antonio, TX, 2013. e-Pub 2013.
89. Lucci A, Hall C, Bhattacharyya A, Lodhi A, Singh B, Anderson A, Karhade M, Mishra P, Bedrosian I, Kuerer H, Krishnamurthy S. Circulating tumor cells predict survival after neoadjuvant chemotherapy in non-metastatic breast cancer. Accepted for poster presentation at the SSO 66th Annual Cancer Symposium, March 6-9, 2013, National Harbor, Maryland, 2013. e-Pub 2013.
90. Hall C, Laubacher B, Walker A, Massingill S, Lucci A. Cyclooxygenase-2 signaling in breast cancer-initiating cells. Accepted for poster presentation at the SSO 66th Annual Cancer Symposium, March 6-9, 2013, National Harbor, Maryland, 2013. e-Pub 2013.
91. Laubacher BA, Hall CS, Bhattacharyya A, Lodhi A, Anderson AE, Bedrosian I, Kuerer H, Ueno N, Lucci A. HER2 amplification in primary tumor: A potential marker for presence of circulating tumor cells in inflammatory breast cancer patients?. Accepted for Poster Presentation at the 9th International Symposium on Minimal Residual Cancer, September 25-27, 2013, Paris, France, 2013. e-Pub 2013.
92. Singh B, Raythatha M, Shamsnia A, Lucci A. Body-like Enrichment of Metastatic Breast Cancer Cells in vitro for Developing Anti-Cancer Therapies. Accepted for Poster Presentation at the Keystone Symposia on Molecular and Cellular Biology, February 24 - March 1, 2013, Keystone, CO, 2013. e-Pub 2013.
93. Rueth NM, Xing Y, Chiang YJ, Ross MI, Gershenwald JE, Lee JE, Royal RE, Lucci A, Cormier JN. Is surveillance imaging effective for detecting treatable recurrences in melanoma patients?. Accepted for poster presentation at the Society of Surgical Oncology’s 66th Annual Cancer Symposium, March 6-9, 2013, National Harbor, MD, 2013. e-Pub 2013.
94. Caudle A, Kuerer HM, Le-Petross H, Yang W, Bedrosian I, Krishnamurthy S, Lucci A, Hunt KK, Mittendorf EA. Predicting the extent of nodal disease in early breast cancer. Accepted for poster presentation at the 2013 Breast Cancer Symposium, September 7-9, 2013, San Francisco, CA, 2013. e-Pub 2013.
95. Roland CL, Ross MI, Hall CS, Laubacher B, Lucci A. Detection of circulating melanoma cells in the blood of melanoma patients: Feasibility and Preliminary Significance. Accepted for Oral Presentation at the Society of Surgical Oncology's 66th Annual Cancer Symposium, March 6-9, 2013, National Harbor, MD, 2013. e-Pub 2013.
96. Hall CS, Karhade M, Mishra P, Anderson AE, Kuerer HK, Bedrosian I, Krishnamurthy S, Lucci A. Circulating Tumor Cells in non-Metastatic Triple Negative Breast Cancer. Accepted for Oral Presentation at the 9th International Symposium on Minimal Residual Cancer, September 25-27, 2013, Paris, France, 2013. e-Pub 2013.
97. Ross MI, Hall CS, Laubacher BA, Roland CS, Upshaw JL, Anderson AE, Lucci A. Circulating Melanoma Cells in Stage I-IV Patients. Accepted for Oral Presentation at the 9th International Symposium on Minimal Residual Cancer, September 25-27, 2013, Paris, France, 2013. e-Pub 2013.
98. FitzSullivan E, Lari SA, Smith B, Caudle A, Krishnamurthy S, Lucci A, Mittendorf E, Babiera G, Black D, Wagner J, Bedrosian I, Woodward W, Gainer S, Hwang R, Meric-Bernstam F, Hunt KK, Kuerer HM. Incidence and Consequence of Close Margins for Ductal Carcinoma In Situ Treated with Mastectomy. Accepted for Oral Presentation at the SSO's 66th Annual Cancer Symposium, March 6-9, 2013, National Harbor, Maryland, 2013. e-Pub 2013.
99. Singh B, Raythatha M, Cady A, Madan S, Tai K, Irving L, Lucci A. In Vitro selection of metastatic breast cancer cells based on their adaptability. Accepted for Poster Presentation at the 2012 AACR Annual Meeting, March 31-April 4, 2012, Chicago, IL, 2012. e-Pub 2012.
100. Singh B, Madan S, Raythatha M, Cady A, |Lucci A. Selection of Metastatic Breast Cancer Cells Based on Adaptability of their Metabolic State. Accepted for Poster Presentation at the UPCP 2012 Conference, Florence, Italy, February 2-5, 2012, 2012. e-Pub 2012.
101. Gainer SM, Lohdi A, Bhattacharyya A, Hall CS, Krishnamurthy S, Kuerer HM, Lucci A. Invasive Lobular Carcinoma Predicts Micrometastatic Disease in Stage I-III Breast Cancer. Accepted for Oral Presentation at the 7th Annual Academic Surgical Congress, February 14-16, 2012, Las Vegas, NV, 2012. e-Pub 2012.
102. Gainer S, Lucci A. Use of disseminated tumor cells to predict outcome in patients with stage I-III breast cancer. Accepted for Poster Presentation at the 2012 Breast Cancer Symposium, San Francisco, CA, Sept. 13-15, 2012, 2012. e-Pub 2012.
103. Krishnamurthy S, Bischoff F, Mayer JA, Kuerer HM, Lodhi A, Bhattacharyya A, Hall CS, Wong K, Pham T, Pircher TJ, Lucci A. Detection of discordant HER2 status by FISH in circulating tumor cells and disseminated tumor cells in early stage breast cancer using a microfluidic-based cell enrichment and extraction platform (OncoCEETM). Accepted for Poster Presentation at ASCO 48th Annual Meeting, June 1-5, 2012, Chicago, IL, 2012. e-Pub 2012.
104. Alvarez RH, Cristofanilli M, Ensor J, Lucci A, Yang W, Le-Petross H, Reuben JM, Babiera G, Huo L, Gong Y, Woodward W, Parker C, Willey JS, MacEachern J, Buchholz TA, Ueno N, Valero V. Limited Efficacy and Significant Toxicities of Lapatinib (Lap) plus Chemotherapy as Neoadjuvant Therapy (NAC) for HER2-positive Inflammatory Breast Cancer (IBC) Patients (Pts). ASCO 48th Annual Meeting, June 1-5, 2012, Chicago, IL, 2012. e-Pub 2012.
105. Singh B, Cady A, Raythatha M, Lucci A. Developing a predictive in vitro assay for evaluating therapies against metastatic breast cancer. Accepted for Poster Presentation at the AACR Annual Meeting, Chicago, IL, March 31- April 4, 2012, 2012. e-Pub 2012.
106. Lucci A. Assessment of HER2 Status on Disseminated Tumor Cells in Early Stage Breast Cancer Using a Microfluidic Cell Enrichment and Extraction Technique. Accepted for Poster Presentation at the 22nd Biennial EACR Congress in Barcelona, Spain, July 7-10, 2012, 2012. e-Pub 2012.
107. Hall C, Laubacher B, Anderson A, Kuerer H, Bedrosian I, Krishnamurthy S, Lucci A. Investigating the tumorigenicity of disseminated tumor cells. Accepted for Poster Presentation at the AACR Annual Meeting, Chicago, IL, March 31-April4, 2012, 2012. e-Pub 2012.
108. Mittendorf EA, Ballman KV, McCall LM, Hansen N, Lucci A, Gabram S, Urist M, Crow J, Hurd T, Hunt KK, Giuliano AE. Evaluation of the stage IB designation of the 7th edition of the AJCC staging system: Biologic factors are more important. Accepted for Poster Presentation at the 2012 SABCS, December 4-8, 2012, San Antonio, TX, 2012. e-Pub 2012.
109. Caudle A, Hunt KK, Tucker S, Hoffman K, Gainer S, Lucci A, Kuerer H, Meric-Bernstam F, Shah R, Babiera G, Sahin A, Mittendorf EA. American College of Surgeons (ACOSOG) Z0011: Impact on Surgeon Practice Patterns. Accepted for Oral Presentation at the 13th Annual ASBS Meeting, Phoenix, AZ, May 2-6, 2012, 2012. e-Pub 2012.
110. Lucci A, Hall C, Karhade M, Mishra P, Anderson A, Bedrosian I, Kuerer H, Krishnamurthy S. Circulating tumor cells in triple negative breast cancer. Accepted for Poster Presentation at Advances in Circulating Tumor Cells (ACTC) from Basic Research to Clinical Practice, Athens, Greece, Sept. 26-29, 2012, 2012. e-Pub 2012.
111. Gainer S, Krishnamurthy S, Bhaattacharyya A, Lodhi A, Hall C, Bedrosian I, Kuerer H, Lucci A. Single Center Experience with Disseminated Tumor Cells as Predictors of Outcome in Patients with Stage I-III Breast Cancer. Accepted for Poster Presentation at SSO's 65th Annual Cancer Symposium, 2012. e-Pub 2012.
112. Lucci A. Circulating Tumor Cells After neoadjuvant Chemotherapy Predict Survival in Non-metastatic Breast Cancer. Accepted for Poster Presentation at the 22nd Biennial EACR Congress in Barcelona, Spain, July 7-10, 2012, 2012. e-Pub 2012.
113. Akay C, Ueno N, Chisholm G, Hortobagyi G, Woodward W, Alvarez R, Lucci A, Bedrosian I, Kuerer HM, Hunt KK, Huo L, Babiera G. Primary tumor resection may improve survival and local disease control in stage IV inflammatory breast cancer. Accepted for Poster Presentation at ASCO 48th Annual Meeting, June 1-5, 2012, Chicago, IL, 2012. e-Pub 2012.
114. Hall C, Lucci A, Bhattacharyya A, Lodhi A, Anderson A. An evaluation of bone marrow stromal-derived growth factor-1 and interleukin-8 levels in stage I-III breast cancer patients with disseminated tumor cells. Accepted for poster presentation, American Society of Clinical Oncology 2011 Annual Meeting, Chicago, IL, 2011. e-Pub 2011.
115. Lucci A. Disseminated and Circulating Tumor Cells. Oral presentation, American Society of Breast Surgeons 12th Annual Meeting, April 27 - May1, 2011, Washington, DC, 2011. e-Pub 2011.
116. Veerapong J, Boughey J, Mittendorf E, Harrel R, Bassett R, Yi M, Meric-Bernstam F, Ross M, Babiera G, Kuerer H, Lucci A, Bedrosian I, Brodt J, Jakub J, Hunt K, Hwang R. A validated risk assessment of sentinel lymph node involvement in breast cancer patients. Accepted, Poster Presentation at SSO 64th Annual Cancer Symposium, March 2-5, 2011, San Antonio, TX, 2011. e-Pub 2011.
117. Lucci A, Krishnamurthy S, Bischoff F. Comparison of fluorescence in situ hybridization of estrogen receptor genetic locus with protein expression in invasive breast carcinoma. AACR 102nd Annual Meeting, April 2-6, 2011, Orlando, FL, 2011. e-Pub 2011.
118. Krishnamurthy S, Bischoff FZ, Mayer JA, Wong K, Pham T, Kuerer HM, Lodhi AK, Bhattacharyya A, Hall CS, Lucci A. Detection of HER2 Gene Amplification in Circulating Tumor Cells and Disseminated Tumor Cells by Fluorescence In Situ Hybridization Using OncoCEE. Accepted for Poster presentation at the 2011 SABCS, December 6-10, 2011, San Antonio, TX, 2011. e-Pub 2011.
119. Lucci A, Singh B, Tai K, Madan S, Braunlin M, Irving LR, Bajaj A. In Vitro Selection of Metastatic Breast Cancer Cells. Accepted for Poster Presentation at the 6th Era of Hope Conference, sponsored by the Department of Defense, Breast Cancer Research Program, August 2-5, 2011, Orlando, FL, 2011. e-Pub 2011.
120. Singh B, Tai K, Irving LR, Lucci A. Lack of Serum and Attachment Selects Rare and Potentially Aggressive Subpopulations of Breast Cancer Cells. Accepted for Poster Presentation at the 6th Annual Academic Surgical Congress, February 1-3, 2011, Huntington Beach, CA, 2011. e-Pub 2011.
121. Lucci A, Krishnamurthy S, Lodhi A, Bhattacharyya A, Hall C, Anderson A, Bedrosian I, Singh B, Kuerer H. Microscopic Disease in Blood and Bone Marrow Predicts Survival in Early Stage Breast Cancer. Accepted for Poster presentation at the 2011 SABCS, December 6-10, 2011, San Antonio, TX, 2011. e-Pub 2011.
122. Gainer S, Krishnamurthy S, Bhattacharyya A, Lodhi A, Hall C, Kuerer H, Bedrosian I, Anderson A, Singh B, Lucci A. Circulating Tumor Cells After Neoadjuvant Therapy Predict Outcome in Stage I to III Breast Cancer. Accepted for Poster presentation at the 2011 SABCS, December 6-10, 2011, San Antonio, TX, 2011. e-Pub 2011.
123. Lucci A, Krishnamurthy S, Bhattacharyya A, Lodhi A, Hall C, Singh B, Anderson A, Bedrosian I, Kuerer H. Circulating Tumor Cells Predict Survival in Non-Metastatic Breast Cancer. Accepted for Poster presentation at the 2011 SABCS, December 6-10, 2011, San Antonio, TX, 2011. e-Pub 2011.
124. Bedrosian, I, Whitman G, Le-Petross H, Hunt KK, Babiera G, Meric-Bernstam F, Lucci A, Mittendorf EA, Feig B, Ross MI, Hwang R. MRI for preoperative staging of patients with invasive lobular carcinoma of the breast. Accepted for oral presentation, SSO 64th Annual Cancer Symposium, March 2-5, 2011, San Antonio, TX, 2011. e-Pub 2011.
125. Bhattacharyya A, Krishnamurthy S, Lodhi A, Hall C, Anderson A, Jackson S, Ueno N, Bedrosian I, Kuerer H, Lucci A. HER2 amplification in primary tumor: A potential marker for presence of circulating tumor cells in inflammatory breast cancer patients?. Accepted for Poster presentation at the 2011 SABCS, December 6-10, 2011, San Antonio, TX, 2011. e-Pub 2011.
126. Lucci A, Krishnamurthy S, Hall C, Lodhi A, Bhattacharyya A, Kuerer H, Bedrosian I, Anderson A, Singh B. Circulating and Disseminated Tumor Cells After Neoadjuvant Therapy in Primary Breast Cancer. Accepted for Oral Presentation at the 6th Annual Academic Surgical Congress, February 1-3, 2011, Huntington Beach, CA, 2011. e-Pub 2011.
127. Krishnamurthy S, Bischoff FZ, Mayer JA, Wong S, Mikolajczyk S, Pham T, Kuerer HM, Lodhi A, Bhattacharyya A, Hall CS, Lucci A. Detection of HER2 status of circulating tumor cells and diseminated tumor cells using a microfluidic platform (cell enrichment and extraction technology, CEE). Accepted for poster presentation, American Society of Clinical Oncology 2011 Annual Meeting, Chicago, IL, 2011. e-Pub 2011.
128. Lodhi A, Krishnamurthy S, Bhattacharyaa A, Hall C, Anderson A, Kuerer HM, Bedrosian I, Singh B, Lucci A. Disseminated Tumor Cells as Predictors of Survival in Triple-negative Breast Cancer. Accepted for Oral Presentation at the 97th Annual ACS Clinical Congress, San Francisco, CA, October 23-27, 2011, 2011. e-Pub 2011.
129. Singh B, Madan S, Braunlin M, Tai K, Irving L, Raythatha M, Lucci A. Selection of Metastatic Breast Cancer Cells Based on Adaptability of Their Metabolic State. Accepted for Poster presentation at the CPRIT 2011 Annual Conference, November 15-17, Austin, TX, 2011. e-Pub 2011.
130. Mego M, Giordano A, De Giorgi U, Hsu L, Lucci A, Dawood S, Woodward WA, Ueno NT, Valero V, Andreopoulou E, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating Tumor Cells in Newly Diagnosed Inflammatory Breast Cancer. Accepted for Poster presentation at the 2011 SABCS, December 6-10, 2011, San Antonio, TX, 2011. e-Pub 2011.
131. Bhattacharyya A, Lodhi AK, Krishnamurthy S, Hall CS, Anderson AE, Kuerer HM, Bedrosian I, Singh B, Lucci A. Which is a better predictor of outcome in stage I-III breast cancer after neoadjuvant chemotherapy: microscopic disease in bone marrow or lymph nodes?. Accepted for poster presentation, American Society of Breast Surgeons 12th Annual Meeting, April 27-May 1, 2011, Washington, DC, 2011. e-Pub 2011.
132. Hall C, Krishnamurthy S, Lodhi A, Bhattacharyya A, Anderson A, Kuerer H, Bedrosian I, Singh B, Lucci A. Circulating and Disseminated Tumor Cells after Neoadjuvant Chemotherapy in Primary Breast Cancer. Accepted for Oral Presentation at the International Conference on Surgery, Prague, Czech Republic, 2011. e-Pub 2011.
133. Lodhi A, Mosalpuria K, Krishnamurthy S, Jackson S, Hall C, Andreopoulou E, Valero V, Lucci A. Microscopic disease after neoadjuvant therapy in inflammatory breast cancer. ASCO 2010 Annual Meeting, 2010. e-Pub 2010.
134. Kwang T, Yi M, Hunt KK, Babiera GV, Kuerer H, Bedrosian I, Mittendorf EA, Hwang RF, Lucci A, Meric-Bernstam F. Does blue dye contribute to the success of sentinel node mapping for breast cancer?. American Society of Breast Surgeons, 11th Annual Meeting, May 2010, 2010. e-Pub 2010.
135. Hall CS, Singh B, Tai K, Hicks LR, Lucci A. Zoledronate inhibits proliferation and invasion of inflammatory breast cancer cells. AACR 101st Annual Meeting 2010, Washington, DC, 2010. e-Pub 2010.
136. Singh B, Tai K, Cook KR, Irving LR, and Lucci A. Differences in glutamine-dependence among breast cancer cell lines. AACR 101st Annual Meeting, Washington, DC, 2010. e-Pub 2010.
137. Hunt K, Bedrosian I, Kuerer HM, Meric-Bernstam F, Beahm E, Crosby MA, Ross MI, Hernandez M, Hwang R, Krishnamurthy S, Lucci A, Feig BW, Pantoja L, Feng L. Nipple-areola complex sparing mastectomy is technically feasible for risk reduction and early-stage breast cancer. Poster Presentation, SSO 63rd Annual Cancery Symposium, March 3-7, 2010, St. Louis, MO,, 2010. e-Pub 2010.
138. Goel N, Askew RL, XingY, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Lucci A, Royal RE, Cormier JN. Standards for lymph node ratio in dissections for melanoma patients: can they be achieved?. Poster Presentation, 63rd SSO Annual Cancer Symposium, March 3-7, 2010, St. Louis, MO, 2010. e-Pub 2010.
139. Lucci A, Krishnamurthy S, Lodhi A, Hall C, Singh B. Disseminated tumor cells in histologic subtypes of Stage I-III breast cancer patients. 63rd SSO Annual Cancer Symposium, March 3-7, 2010, St. Louis, MO, 2010. e-Pub 2010.
140. Sharma R, Bedrosian I, Lucci A, Hwang RF, Rourke LL, Buchholz TA, Qiao W, Meric-Bernstam F, GOnzalez-Angulo AM, Kronowitz SJ, Babiera GV, Mittendorf EA, Krishnamurthy S, Hunt KK, Kuerer HM. Present day local-regional recurrence rates (LRR) in patients with T1 and T2 breast cancer (BC) with 0 and 1 to 3 lymph node (LN) metastases following mastectomy without radiation. 2010 SSO Annual Cancer Symposium, St. Louis, Missouri, March 3-7, 2010, 2010. e-Pub 2010.
141. Singh B, Irving LR, Tai K, Cristofanilli M, Lucci A. Overexpression of cyclooxygenase-2 in celecoxib-resistant breast cancer cell lines. Oral Presentation, 5th Annual Academic Surgical Congress, San Antonio, TX, February 3-5, 2010, 2010. e-Pub 2010.
142. Lodhi A, Hall C, Bhattacharyya A, Krishnamurthy S, Anderson A, Jackson A, Singh B, Lucci A. Is ethnicity a predictor of micrometastatic disease in early stage breast cancer patients?. Accepted for poster presentation 33rd Annual SABCS, December 2010, 2010. e-Pub 2010.
143. Krishnamurthy S, Bischoff F, Mikolajczk S, Lucci A. Detection of circulating tumor cells and HER2 gene amplification status using a novel microfluidic platform (cell enrichment and extraction technology, CEETM). Accepted for poster presentation 33rd Annual SABCS, December 2010, 2010. e-Pub 2010.
144. Singh B, Tai K, Irving L, Cook K, Lucci A. Selection of Rare and Novel Breast Cancer Cell Variants Based on Glutamine Metabolism. Accepted for poster presentation, CPRIT Conference November 17-19, 2010, Austin, Texas, 2010. e-Pub 2010.
145. Alvarez RH, Cristofanilli M, Hsu L, Ueno NT, Alizadeh PA, Lucci A, Reuben JM, Buchholz TA, Hortobagyi GN, Valero V. Patient Characteristics and Clinical Outcome of Patients with Secondary Inflammatory Breast Cancer. Accepted for Poster Presentation, 33rd Annual SABCS, December 8-12, 2010, San Antonio, TX, 2010, 2010. e-Pub 2010.
146. Patel H, Li J, Strom EA, Perkins GH, Hoffman K, Smith B, Lucci A, Valero V, Buccholz T, Woodward W. Outcomes after locoregional recurrence in patients with inflammatory breast cancer. 33rd Annual San Antonio Breast Cancer Symposium, December 2010, 2010. e-Pub 2010.
147. Mittendorf EA, Boughey JC, Degnim AC, Harrell R, Bassett R, Yi M, Meric-Bernstam F, Ross MI, Babiera GV, Kuerer HM, Lucci A, Bedrosian I, Hunt KK, Hwang RF. Size matters: incorporation of sentinel lymph node metastasis size into a nomogram predicting positive nonsentinel lymph nodes in breast cancer patients. 33rd Annual San Antonio Breast Cancer Symposium, December 2010, 2010. e-Pub 2010.
148. Debeb BG, Xu W, Lacerda L, Hortobagyi GN, Robertson F, Ueno NT, Lucci A, Reuben JM, Buchholz TA, Woodward WA. Histone deacetylase inhibitors increase markers of the dedifferentiated cancer stem cell phenotype in human breast cancer cells. 33rd Annual San Antonio Breast Cancer Symposium, December 2010, 2010. e-Pub 2010.
149. Lodhi AK, Krishnamurthy S, Bhattacharyya A, Hall CS, Anderson AE, Lucci A. Influence of body mass index on presence of disseminated tumor cells in clinical stage I-III breast cancer patients. 33rd Annual San Antonio Breast Cancer Symposium, December 2010, 2010. e-Pub 2010.
150. Singh B, Tai K, Cook K, Irving LR, Lucci A. Selection of rare and novel breast cancer cell variants based on glutamine metabolism. 33rd Annual San Annual Breast Cancer Symposium, December 2010, 2010. e-Pub 2010.
151. Koay EJ, Tereffe W, Yu K, Perkins GH, Hoffman K, Smith B, Lucci A, Meric-Bernstam F, Brewster A, Strom EA, Buchholz TA, Woodward WA. Outcomes for breast cancer patients with isolated metastasis or recurrence in the contralateral nodal basins. 33rd Annual San Antonio Breast Cancer Symposium, December 2010, 2010. e-Pub 2010.
152. Yi M, Meric-Bernstam F, Babiera G, Ross MI, Lucci A, Thomas C, Hunt KK, Kuerer H. Risk of Ipsilateral Breast Events in Patients with Ductal Carcinoma In Situ after Local Excision. Accepted for poster presentation at 33rd Annual SABCS, December 2010, 2010. e-Pub 2010.
153. Dominici LS, Negron Gonzalez V, Buzdar AU, Lucci A, Mittendorf EA, Pusztai L, Krishnamurthy S, Le-Petross HT, Babiera G, Bedrosian I, Meric-Bernstam F, Hunt KK, Valero V, Kuerer HM. Eradication of axillary lymph node metastases occurs in 74% of patients receiving trastuzumab-based neoadjuvant systemic therapy for HER2 positive breast cancer. San Antonio Breast Cancer Symposium, December 2009, 2009. e-Pub 2009.
154. Gainer S, Lodhi A, Krishnamurthy S, Jackson S, Hall C, Andreopoulou E, Singh B, Bedrosian I, Meric-Bernstam F, Kuerer H, Hunt K, Cristofanilli M, Lucci A. Predictors of persistent micrometastatic disease after neoadjuvant chemotherapy. 32nd Annual San Antonio Breast Cancer Symposium, December 2009, 2009. e-Pub 2009.
155. Krishnamurthy S, Tang S, Wang X, Lucci A, Kuerer HM, Babiera G, Bedrosian I, Hunt KK, Meric-Bernstam F. Utility of one step nucleic acid amplification (OSNA) assay for comprehensive examination of axillary lymph nodes in breast cancer. San Antonio Breast Cancer Symposium, December 2009, 2009. e-Pub 2009.
156. Deleonardis C, Lodhi A, Le-Petross H, Singh B, Krishnamurthy S, Lucci A. Pleomorphic calcifications, tumor markers and response to therapy. 32nd Annual San Antonio Breast Cancer Symposium, 2009. e-Pub 2009.
157. Hall CS, Debeb B, Xu W, Robertson F, Rruben J, Ueno N, Cristofanilli M, Lucci A, Woodward WA. Inflammatory Breast Cancer Cell Line, MDA- IBC-1, expresses and secretes WISP3 a putative tumor suppressor in Inflammatory Breast Cancer. AACR 100th Annual Meeting, April 18-22, 2009, Denver, CO, 2009. e-Pub 2009.
158. Debeb B, Xu W, Hall CS, Ueno N, Reuben J, Robertson F, Lucci A, Buchholz TA, Hortobagyi GN, Cristofanilli M, Woodward WA. Cancer initiating cells downregulate microRNAs implicated in the regulation of Epithelial Mesenchymal Transition (EMT). AACR 100th Annual Meeting, April 18-22, 2009, Denver, CO, 2009. e-Pub 2009.
159. Hall CS, Woodward WA, Lucci A, Cristofanilli M, Robertson F. Transforming growth factorβ1 mediated invasion of inflammatory breast cancer stem cells. AACR 100th Annual Meeting, April 18-22, 2009, Denver, CO, 2009. e-Pub 2009.
160. Ueno N, LaFortune T, Hortobagyi GN, Lucci A, Singh B, Krishnamurthy S, Esteva FJ, Hung MC, Zhang D. EGFR tyrosine kinase inhibitor erlotinib exhibits antimetastatic activity against inflammatory breast cancer. AACR 100th Annual Meeting, April 18-22, 2009, Denver, CO, 2009. e-Pub 2009.
161. Singh B, Daniel C, Vincent L, Lucci A. Cyclooxygenase-2 expression up-regulates EGFR protein level and alters glucose metabolism in MCF10A breast epithelial cell line. AACR 100th Annual Meeting, April 18-22, 2009, Denver, CO, 2009. e-Pub 2009.
162. Spencer A, Krishnamurthy S, Lodhi A, Cristofanilli M, Andreopolou E, Singh B, Bedrosian I, Meric-Bernstam F, Lucci A. Evaluation of micrometastatic disease after neoadjuvant chemotherapy in stage I-III breast cancer patients. Accepted for Poster Presentation, SSO's 62nd Annual Cancer Symposium, Phoenix, AZ, 2009. e-Pub 2009.
163. Silberfein EJ, Martin C, Singh B, Cook KR, Lucci A. Evaluation of androgen receptor as a therapeutic target in breast cancer. Accepted for Oral Presentation, 4th Annual Academic Surgical Congress, Fort Meyers, FL, 2009. e-Pub 2009.
164. Xing Y, Chang GJ, Hu C, Askew RL, Ross MI, Gershenwald JE, Lee JE, Mansfield PF, Lucci A, Cormier JN. Conditional survival estimates provide better prognostic information for melanoma survivors: result from the SEER dataset 1988-2000. Accepted for Oral Presentation, 4th Annual Academic Surgical Congress, Fort Meyers, FL, 2009. e-Pub 2009.
165. Mego M, Li C, Lucci A, Mani S, Ueno NT, Cohen E, Gao H, Tin S, De Giorgi U, Hortobagyi G, Cristofanilli M, Reuben JM. Epithelial mesenchymal transition (EMT) is involved in bone marrow disseminiation of breast cancer cells. Poster presentation, AACR, April 18-22, 2009, Denver, CO, 2009. e-Pub 2009.
166. De Giorgi U, Lucci A, Cohen EN, Gao H, Mego M, Li C, Cristofanilli M, Reuben JM. Subsets of mesenchymal stem cells correlate with breast cancer-propagating cells in bone marrow. AACR, April 18-22, 2009, Denver, CO, 2009. e-Pub 2009.
167. Reuben JM, B-N L, Lucci A, Gao H, Cohen EN, Li C, Krishnamurthy S, Hortobagyi GN, Woodward WA, Cristofanilli M. Disseminated tumor cells in primary breast cancer: Higher percentage of breast cancer stem cells in bone marrow aspirates of patients receiving neoadjuvant chemotherapy. ASCO May 29-June 2, 2009, Orlando, FL, 2009. e-Pub 2009.
168. Debeb B, Xu W, Hall C, Ueno N, Reuben JM. Cancer initiating cells downregulate microRNAs implicated in the regulation of Epithelial Mesenchymal Transition (EMT). 4th Annual Symposium hosted by The University of Texas M. D. Anderson Cancer Center and Baylor College of Medicine, January 22, 2009, Houston, TX, 2009. e-Pub 2009.
169. Debeb BG, Hall CS, Xu W, Ueno NT, Reuben JM, Robertson F, Lucci A, Buchholz TA, Hortobagyi GN, Cristofanilli M, Woodward WA. Populations of cells exhibiting epithelial-mesenchymal transition (EMT) or stem cell characteristics can be propagated from a single inflammatory breast cancer (IBC) cell line based on culture conditions. San Antonio Breast Cancer Symposium, December 11-16, 2008, San Antonio, TX, 2008. e-Pub 2008.
170. Mosalpuria K, Krishnamurthy S, Singh B, Bedrosian I, Meric-Bernstam F, Cristofanilli M, Lucci A. Correlation of COX-2 expression with triple receptor negative status in human breast cancer. Accepted for oral presentation, 3rd. Annual Academic Surgical Congress, Huntington Beach, California, 2008. e-Pub 2008.
171. Dawood S, Andreopoulou E, Ueno N, Lara J, Hsu L, Buchholz TA, Lucci A, Cristofanilli M. Exploring the relationship of body mass index and obesity and leptin levels among women with inflammatory breast cancer: Apolot study. First International Inflammatory Breast Cancer Conference, December 5-7, 2008, Houston, TX, 2008. e-Pub 2008.
172. Lucci A, Krishnamurthy S, Mosalpuria K, Bedorisan I, Meric-Bernstam F, Reuben J, Singh B, Woodward W, Cristofanilli M. Global Evaluation of Minimal Residual Disease in Primary Breast Cancer Patients. Accepted for Poster Presentation, ASCO 2008 Annual Meeting, Chicago, Illinois, 2008. e-Pub 2008.
173. Singh B, Cook KR, Vincent L, Hall C, Martin C, Krishnamurth S, Woodward W, Cristofanilli M, Lucci A. Role of COX-2 in bone marrow micrometastasis and cancer initiating cell phenotype in breast cancer. First International Inflammatory Breast Cancer Conference, December 5-7, 2008, Houston, TX, 2008. e-Pub 2008.
174. Lucci A, Krishnamurthy S, Singh B, Bedrosian I, Meric-Bernstam F, Cook K, Mosalpuria K, Cristofanilli M. COX2 expression correlates with bone marrow micrometastases in patients with stage I-III breast cancer. Accepted for Oral Presentation, Era of Hope Department of Defense Breast Cancer Resaerch Program, Baltimore, Maryland, 2008, 2008. e-Pub 2008.
175. Hall CS, Debeb BG, Xu W, Ueno NT, Reuben JM, Robertson F, Lucci A, Buchholz TA, Hortobagyi GN, Cristofanilli M, Woodward WA. Novel Inflammatory Breast Cancer Cell Line, MDA- IBC-1 Expresses and Secretes WISP3, a putative tumor suppressor in Inflammatory Breast Cancer. San Antonio Breast Cancer Symposium, December 11-16, 2008, San Antonio, TX, 2008. e-Pub 2008.
176. Gao H, Lucci A, Cohen EN, Lee BN, Li C, Krishnamurthy S, Andreopoulou E, De Giorgi U, Hortobagyi GN, Cristofanilli M, Woodward WA, Reuben JM. Primary tumor size is associated with ALDHbr breast cancer initiating stem cells in bone marrow aspirates of primary breast cancer patients. Accepted for Poster Presentation, San Antonio Breast Cancer Symposium, December 11-16, 2008, San Antonio, TX, 2008. e-Pub 2008.
177. Singh B, Cook K, Vencent L, Hall C, Martin C, Lucci A. Role of COX-2 in bone marrow micrometastasis and cancer initiating cell phenotype in breast cancer. Accepted for Poster Presentation at AACR Mechanisms of Metastasis Conference, 2008. e-Pub 2008.
178. Zhang D, Lafortune TA, Hortobagyi G, Cristofanilli M, Lucci A, Singh B, M-C H, Ueno NT. Reversal of mesenchymal epithelial phenotype by EGFR tyrosine kinase inhibitor in inflammatory breast cancer. First International Inflammatory Breast Cancer Conference, December 5-7, 2008, Houston, TX, 2008. e-Pub 2008.
179. Ueno NT, Kazansky A, LaFortune T, Lucci A, Krishnamurthy S, Hortobagyi GN, Woodward W, Cristofanilli M, Zhang D. Suppression of mesenchymal phenotype in inflammatory breast cancer. Accepted for Poster Presentation, First International Inflammatory Breast Cancer Conference, 2008. e-Pub 2008.
180. Hunt K, Meric-Bernstam F, Kronowitz S, Bedrosian I, Hwang R, Ross M, Kuerer H, Feig B, Lucci A, Nayeemuddin K, Khazi M, Symmans WF, Ames F, Singletary E. Local-regional and distant recurrence rates in skin-sparing mastectomies compared with non-skin-sparing mastectomies. 31st Annual San Antonio Breast Cancer Symposium, 2008. e-Pub 2008.
181. Lee BN, Li C, Lucci A, Cohen EN, Gao H, Krishnamurthy S, Ueno NT, Hortobagyi GN, Cristofanilli M, Woodward WA, Reuben JM. Notch-1 expression is not related to the percentage of cd326+ cells in bone marrow aspirates of patients wtih primary breast cancer. 31st Annual San Antonio Breast Cancer Symposium, 2008. e-Pub 2008.
182. Mosalpuria K, KrishnamurthyS, Singh B, Bedrosian I, Meric-Bernstam F, Cristofanilli M, Lucci A. Correlation of COX-2 expression with stage I-III triple receptor negative breast cancer. Accepted for poster presentation, 61st. Annual Society of Surgical Oncology Cancer Symposium, Chicago, Illinois, 2008. e-Pub 2008.
183. Gao H, Lucci A, Cohen EN, Lee BN, Li C, Krishnamurthy S, Andrepoulou E, De Giorgi U, Hortobagyi G, Cristofanilli M, Woodward WA, Reuben JM. Primary tumor size is associate with ALDH breast cancer initiating stem cells in bone marrow aspirate of primary breast cancer patients. First International Inflammatory Breast Cancer Conference, December 5-7, 2008, Houston, TX, 2008. e-Pub 2008.
184. Hall C, DebebB, Xu W, Robertson F, Reuben JM, Ueno N, Cristofanilli M, Lucci A, Woodward W. Novel inflammatory breast cancer cell line, MDA- IBC-1 expresses and secretes Wisp3 a putative tumor suppressor in inflammatory breast cancer. First International Inflammatory Breast Cancer Conference, December 5-7, 2008, Houston, TX, 2008. e-Pub 2008.
185. Yi M, Hunt K, Buchholz T, Meric-Bernstam F, Bedrosian I, Hwang R, Roos M, Kuerer H, Feig B, Lucci A. Ipsilateral breast tumor relapse after breast conservation therapy. Accepted for Poster Presentation, 2008 Breast Cancer Symposium, 2008. e-Pub 2008.
186. Lee BN, Li C, Lucci A, Cohen EN, Gao H, Krishnamurthy S, Ueno NT, Hortobagyi G, Cristofanilli M, Woodward W, Reuben JM. Notch-1 expressing cancer initiating cells in bone marrow aspirates of patients with primary breast cancer. First International Inflammatory Breast Cancer Conference, December 5-7, 2008, Houston, TX, 2008. e-Pub 2008.
187. Debeb BG, Hall CS, Xu W, Ueno N, Reuben JM, Robertson F, Lucci A, Buchholz TA, Hortobagyi G, Cristofanilli M, Woodward W. Populations of cells exhibiting epithelial-mesenchymal transition (EMT) and stem cell characteristics can be propagated from an inflammatory breast cancer (IBC) cell line. First International Inflammatory Breast Cancer Conference, December 5-7, 2008, Houston, TX, 2008. e-Pub 2008.
188. Fournier KF, Xing Y, Ross MI, Lee JE, Gershenwald JE, Mansfield PF, Lucci A. Survival in patients with synchronous versus metachronous lymph node (LN) involvement in stage III melanoma: is there a difference?. Accepted for Oral Presentation, ASCO 2008 Annual Meeting, Chicago, Illinois, 2008. e-Pub 2008.
189. Min Y, Meric-Bernstam F, Middleton LP, Arun BK, Bedrosian I, Babiera G, Hwang RF, Feig BW, Kuerer HM, Lucci A, Ross MI, Hunt KK. Predictors of contralateral breast cancer in patients with unilateral breast cancer. Accepted for oral presentation, 2008 American Society of Breast Surgeons, New York, New York, 2008. e-Pub 2008.
190. Robertson F, A-M S, A|| L, Woodward W, Reuben J, Ueno N, Cristofanilli M. Role of the prostaglandin receptor EP3 in regulating vasculogenic mimicry of inflammatory breast cancer. San Antonio Breast Cancer Symposium, December 11-16, 2008, San Antonio, TX, 2008. e-Pub 2008.
191. Ueno NT, Kazansky A, LaFortune T, Lucci A, Krishnamurthy S, Hung MC, Hortobagyi GN, Woodward W, Reuben JM, Robertson F, Cristofanilli M, Zhang D. Suppression of mesenchymal phenotype in inflammatory breast cancer by EGFR tyrosine kinase inhibitor erlotinib: A novel approach to suppressing metastasis. San Antonio Breast Cancer Symposium, December 11-16, 2009, San Antonio, TX, 2008. e-Pub 2008.
192. Yi M, Hunt KK, Meric-Bernstam F, Bedrosian I, Hwang R, Kuerer HM, Lucci A, Ross MI, Akins J, Babiera GV. Sentinel lymph node biopsy in patients with multicentric invasive breast cancer, Accepted for poster presentation, ASCO Breast Meeting, San Francisco, California, 2007. e-Pub 2007.
193. Huang EH, Singh B, Vincent L, Cristofanilli M, Mosalpuria K, Caimiao W, Lucci A. Inhibition of primary tumor growth and distant metastasis with a CXCR4 antagonist in a mouse model of breast cancer. Accepted for oral presentation, American Association for Cancer Research, Los Angeles, California, 2007. e-Pub 2007.
194. Rourke L, Lang JE, Mosalpuria K, Yi M, Cristofanilli M, Krishnamurthy S, Singh B, Bedrosian I, Meric-Bernstam F, Lucci A. Impact of neoadjuvant chemotherapy on presence of circulating tumor cells and disseminated tumor cells in operable breast cancer. Accepted for poster presentation, American Society of Breast Surgeons, Phoenix, Arizona, 2007. e-Pub 2007.
195. Woodward WA, Arriaga L, Domain D, Strom EA, Perkins GH, Yu K, Oh J, Tereffe W, Lucci A, Buchholz TA. Prospective evaluation of late, chronic lymphedema (LE) after axillary lymph node dissection (ALND) and comprehensive irradiation. Accepted for oral presentation, American Radium Society, Amsterdam, Netherlands, 2007. e-Pub 2007.
196. Singh B, Vincent LE, Berry JA, Multani S, Lucci A. Cyclooxygenase-2 perturbs DNA damage checkpoint signaling in MCF10A breast epithelial cells. Accepted as a poster presentation, American Association for Cancer Research, Los Angeles, California, 2007. e-Pub 2007.
197. Yi M, Hunt KK, Meric-Bernstam F, Bedrosian I, Hwang R, Kuerer HM, Lucci A, Ross MI, Akins J, Babiera GV. Sentinel lymph node biopsy in patients with multicentric invasive breast cancer, Accepted for poster presentation, 30th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, 2007. e-Pub 2007.
198. Boughey J, Gorovanchi F, Parris R, Ki S, Frenzel J, Kowalski A, Hunt K, ames F, Kuerer H, Lucci A. Improved post-operative pain management of breast oncologic surgieries with paravertebral block. Accepted for poster presentation, The American Society of Regional Anesthesia, Boca Raton, Florida, 2007. e-Pub 2007.
199. Kesmodel SB, Wang Y, Vo A, Schacherer CW, Lucci A, Cormier JN, Mansfield PF, Gershenwald JE, Ross MI, Je L. Il-10 gene polymorphisms predict primary tumor ulceration and risk of recurrence in melanoma patients. 60th Annual SSO Annual Cancer Symposium, Washington, DC, Ann Surg Oncol 14:A5:3, 2007. e-Pub 2007.
200. Woodward WA, Reuben J, Gao H, Krisnamurthy S, Lucci A, Singh B, Li L, Cristofanilli M. Preliminary characterization and in vitro propagation of putative stem/progenitor cells from human inflammatory breast cancer, Accepted for oral presentation, 30th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, 2007. e-Pub 2007.
201. Yi M, Krishnamurthy S, Kuerer H, Bedrosian I, Ames F, Lucci A, Hunt K. The significance of primary tumor characteristics in predicting positive sentinel lymph node in ductal carcinoma in situ or microinvasive breast cancer. Accepted for poster presentation, American Society of Breast Surgeons, Phoenix, Arizona, 2007. e-Pub 2007.
202. Lang JE, Mosalpuria K, Cristofanilli M, Krishnamurthy S, Reuban J, Singh B, Bedrosian I, Meric-Bernstam F, Lucci A. Primary tumor characteristics and lymph node status fail to predict presence of circulating tumor cells in patients with operable breast cancer. 60th Annual SSO Cancer Symposium, Washington, DC, Ann Surg Oncol 14:P160:80, 2007. e-Pub 2007.
203. Boughey JC, Goravanchi F, Parris RN, Kee SS, Frenzel JC, Hunt KK, Ames FC, Kuerer HM, Lucci A. Improved post-operative pain control using paravertebral block for breast operations. Accepted for poster presentation, American Society of Breast Surgeons, Phoenix, Arizona, 2007. e-Pub 2007.
204. Krishnamurthy S, Cristofanilli M, Reuban J, Lucci A. Evaluation of bone marrow minimal residual tumor breast cancer: a cytomorphological and immunocytochemical study. Accepted for poster presentation, American Society of Cytology, Ontario, Canada, 2006. e-Pub 2006.
205. Wilke L, ReintgenDS, Pass H, Lucci A, Jr OJ, Ollila D, McMasters K, Burak W, Simmons R, White R, Tafra L, Whitworth P, Winchester DJ, Cox CE. Outcomes of a pilot program utilizing skilled mentors for post-residency surgeon instruction in sentinel lymph node biopsy for breast cancer. American Society of Breast Surgeons 7th Annual Meeting, Baltimore, Maryland, 2006. e-Pub 2006.
206. Wilke LG, Reintgen DS, Pass H, Lucci A, Olson Jr JA, Ollila D, McMasters K, Burbak W, Simmons R, White R, Tafra L, Whitworth P, Winchester DJ, Cox CE. Introducing new surgical technology: outcomes of a mentoring model for post-residency surgeon instruction in two procedures: sentinel node biopsy for breast cancer, and total mesorectal excision for rectal cancer. Accepted for poster presentation, American Society of Breast Surgeons, Baltimore, Maryland, 2006. e-Pub 2006.
207. Al-Refaie WB, Cormier JN, Zing Y, Hunt KK, Fearmonti G, Ghandi R, Kuerer HM, Bedrosian I, Meric-Bernstam F, Lucci A. Initial biopsy procedure for breast cancer diagnosis influences number of surgical procedures and cost of care. American Society of Clinical Oncology, Atlanta, Georgia, J Clin Oncol 24:27S, 2006. e-Pub 2006.
208. Rosenkranz KM, Hartman K, Ghonimi E, Kuerer HM, Singletary SE, Hunt KK, Meric-Bernstam F, Lucci A, Hwang R, Bedrosian I, Feig B, Ross M, Ames F, Babiera GV. Breast cancer in the very elderly: treatment patterns in a tertiary cancer center. Accepted for poster presentation, American Society of Breast Surgeons, Baltimore, Maryland, 2006. e-Pub 2006.
209. Boughey JC, Peintinger F, Meric-Bernstam F, Perry A, Hunt KK, Babiera G, Singletary ES, Bedrosian I, Lucci A, Buzdar AU, Pusztai L, Kuerer HM. Impact of preoperative versus postoperative chemotherapy on the extent and number of surgical procedures in patients treated in randomized clinical trials for breast cancer. Accepted for oral presentation, American Surgical Assocation 126th Annual Meeting, Boston, Massachusetts, 2006. e-Pub 2006.
210. Vincent LE, Berry J, Singh B, Lucci A. Involvement of IL-8 in COX-2 mediated bone metastasis from breast cancer. Accepted for oral presentation, 1st Annual Academic Surgical Congress, San Diego, California, 2006. e-Pub 2006.
211. Vincent LE, Berry J, Singh B, Lucci A. COX-2 inhibitor prevents metastases to bone in a mouse model of breast cancer. Accepted for oral presentation, 1st Annual Academic Surgical Congress, San Diego, California, 2006. e-Pub 2006.
212. Boughey JC, Ross MI, Kuerer HM, Yi M, Akins JS, Giordano SH, Babiera GV, Ames GC, Lucci A, Singletary E, Meric-Bernstam F, Bedrosian I, Hunt KK. Comparative analysis of SLN surgery in male and female breast cancer patients. Accepted for poster presentation, American Society of Breast Surgeons, Baltimore, Maryland, 2006. e-Pub 2006.
213. Lucci A, Mackie L, Beitsch P, Whitworth P, Reintgen D, Blumencranz PW, Leitch M, Saha S, Hunt KK, Giulian AE. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection, versus SLND alone in the American College of Surgeons Oncology Group (ACOSOG) Trial Z011. Society of Surgical Oncology 59th Annual Meeting, San Diego, California, Ann Surg Oncol 13:9, 2006. e-Pub 2006.
214. Boughey JC, Khakpour N, Meric-Bernstam F, Ross MI, Hwang RF, Babiera GV, Lucci A, Kuerer HM, Hunt KK, Bedrosian I. Routine use of sentinel lymph node surgery in prophylactic mastectomy is not warranted. Society of Surgical Oncology 59th Annual Meeting, San Diego, California, Ann Surg Oncol 13:64, 2006. e-Pub 2006.
215. Lucci A, Savitri K, Cristofanilli M, Broglio K, Bedrosian I, Meric-Bernstam F, Singh B. Primary tumor characteristics associated with blood and bone marrow micrometastases, 29th Annual San Antonio Breast Cancer Symposium, Poster presentation, Breast Cancer Res Treat 100:S215-S216, 2006. e-Pub 2006.
216. Lucci A, Singh B, Berry J, Shoher A. A model of COX-2 mediated bone metastasis in human breast cancer. Era of Hope 2005 - DoD Breast Cancer Researach Program in Philadelphia, Pennslyvania, 2005. e-Pub 2005.
217. Al-Refaie WB, Cormier JN, Xing Y, Hunt KK, Fearmonti G, Ghandi R, Kuerer HM, Bedrosian I, Meric-Bernstam F, Lucci A. Initial biopsy procedure for breast cancer diagnosis influences number of surgical procedures and cost of care. American Surgical Association Meeting, Boston, Massachusetts, 2005. e-Pub 2005.
218. Wilke L, McCall L, Whitworth P, Reintgen D, Leitsch A, Gabram S, Lucci A, Cox C, Hunt K, Posther K, Herndon J, Guiliano A. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Accepted for oral presentation, Society of Surgical Oncology Annual Meeting, 2005. e-Pub 2005.
219. Suh YJ, Chada S, McKenzie T, Liu Y, Swisher S, Lucci A, Hunt KK. Synergistic tumoricidal effect between celecoxib and melanoma differentiation-associated gene 7 on human breast cancer cells. The Society of University Surgeons 66th Annual Meeting in Nashville, Tennessee, 2005. e-Pub 2005.
220. Khakpour N, Beckmann K, Yi M, Lucci A. Lymphovascular invasion on core biopsy predicts metastasis in sentinel lymph nodes in early stage breast cancer patients. Society of Surgical Oncology Annual Meeting, 2005. e-Pub 2005.
221. Bedrosian I, Meric-Bernstam F, Ross MI, Kuerer H, Hunt K, Hwang R, Lucci A, Babiera G. The routine use of sentinel lymph node surgery in prophylactic mastectomy is not warranted. Accepted for poster presentation, Society of Surgical Oncology Annual Meeting, 2005. e-Pub 2005.
222. Khakpour N, Shoher A, Teh B, Lu H, Lucci A. Patients with augmented breasts are candidates for breast conservation therapy. Society of Surgical Oncology Annual Meeting, 2005. e-Pub 2005.
223. Khakpour N, Lucci A, Ross MI, Kuerer H, Hunt KK. Sentinel lymph node dissection is as effective as axillary lymph node dissection for axillary staging and control in patients with breast cancer. American Society of Clinical Oncology 2005 Annual Meetiing in Orlando, Florida, 2005. e-Pub 2005.
224. Khakpour N, Hunt K, Yi M, Lucci A. Does sentinel lymph node dissection provide axillary control equal to complete axillary dissection in breast cancer patients with lobular histology?. American Society of Breast Surgeons 6th Annual Meeting in Los Angeles, California, 2005. e-Pub 2005.
225. Berry J, Singh B, Lucci A. Cox-2 Induces Interleukin-11 production in human breast cancer cells. 38th Annual Meeting of the Association for Academic Surgery, Houston, Texas, 2004. e-Pub 2004.
226. Khakpour N, Beckmann K, Yi M, Lucci A. Should intra-operative analysis of sentinel lymph nodes with lymphovascular invasion in T1 breast cancer patients be performed?. Annual Sentinel Node Congress, Santa Monica, California, John Wayne Cancer Institute Meeting, 2004. e-Pub 2004.
227. Lu H, Schroeder T, Gomex L, Lucci A, Venta L. Lumpectomy clips: boon for planning radiation therapy, bane for MR imaging of the breast. San Antonio Breast Cancer Symposium, San Antonio, Texas, 2004. e-Pub 2004.
228. Lucci A. COX-2 overexpression increases motility and invasion of cancer cells. Oral presentation at the Society of Surgical Oncology 57th Annual Cancer Symposium, New York, New York, 2004. e-Pub 2004.
229. Lucci A. Assessment of the current medicare reimbursement system for breast cancer operations. Oral presentation at the Society of Surgical Oncology 57th Annual Cancer Symposium, New York, New York, 2004. e-Pub 2004.
230. Gomez F, Weiss H, Mohsin S, Gutierrez MC, Hilsenbeck SG, Elledge RM, Lucci A, Osborne CK, Allred DC, Chang J. A phase II study of neoadjuvant docetaxel followed by doxorubicin and cyclophosphamide in locally advanced breast cancer. Fifth Annual Lynn Sage Breast Cancer Symposium, Chicago, Illinois, 2003. e-Pub 2003.
231. Spiegel A, Marin V, Lucci A. Mini-microsurgical flaps for reconstruction of delayed partial mastectomy defects after breast conservation. The Society of Plastic and Reconstructive Surgery, 2003. e-Pub 2003.
232. Lucci A, Shoher A. COX-2 staining in lymph nodes of metastatic and non-metastic breast cancer. ASCO, Chicago, Illinois, 2003. e-Pub 2003.
233. Azzizadeh A, McCollum C, Lucci A. Factor influencing career choice among medical students interested in surgery, 2002. e-Pub 2002.
234. Kozar R, Lucci A, Asissadeh A. A brief intervention can affect career choice of medical students. Association for Academic Surgery, Boston, Massachusetts, 2002. e-Pub 2002.
235. Patten L, Feig B, Berger DH, Fagan S, Lucci A. Addition of radiocolloid to blue Dye does not increase identification of sentinel nodes in colon cancer. Society of Surgical Oncology, Denver, Colorado, 2002. e-Pub 2002.
236. Van Pelt AE, Elledge RM, Allred DC, Mohsin SK, Gutierrez MC, Lucci A, Chang J. Phase II Study of neoadjuvant Trastuzumab plus docetaxel for locally advanced or metastatic breast cancer that over-expresses Her-2: A premilinary report. San Antontio Breast Cancer Symposium, San Antonio, Texas, 2002. e-Pub 2002.
237. Feig B, Lucci A, Hunt K, Berger DH. Lymphatic mapping in patients with colon cancer; a cautionary note. Southwestern Surgical Congress, Cancun, Mexico, 2001. e-Pub 2001.
238. Assisadeh A, Lucci A. Breast conversation in patients with large breast masses. Southwestern Surgical Congress, Cancun, Mexico, 2001. e-Pub 2001.
239. Anstadt M, Guil C, Carwile J, Soltero E, Kroll M, A L, Maike J. Can the risk for recurrent thrombotic thrombocytopenic purpura be predicted preoperatively?. Southwestern Surgical Congress, Colorado Springs, Colorado, April, 2000. e-Pub 2000.
240. Lucci A, Francois-Clement B. Clinical validity of circulating tumor cell detection during neoadjuvant chemotherapy for early breast cancer: the IMENEO study. Submitted to the 2016 Annual SABCS Meeting in San Antonio, TX, December 6-10, 2016.
241. Lucci A, Hall C, Laubacher B, Karhade M, Royal R, Upshaw J, Roland C, Ross MI. Circulating melanoma cells and recurrence in stage II-IV melanoma patients. Submitted to the 2015 SSO's 68th Annual Cancer Symposium, March 25-28, Houston, TX.
242. Woodward W, Krishnamurthy S, Lodhi A, Xiao L, Cristofanilli M, Buchholz T, Lucci A. Aldehyde dehydrogenase1 immunohistochemical staining in breast cancer tumor cells is not a surrogate for circulating or disseminated tumors cells. ASTRO 53rd Annual Meeting, Oct. 2-6, 2011, Miami Beach, FL.
243. Boughey JC, Goravanchi F, Hunt KK, Parris RN, Kee S, Frenzel J, Kowalski AM, Kuerer HM, Ames FC, Lucci A. A Prospective Randomized Controlled Clinical Trial of Paravertebral Block Anesthesia for Patients Undergoing Surgery for Breast Cancer. American Surgical Association, Huntington Beach, California.
244. Matsuda N, Lucci A. Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER2-negative inflammatory breast cancer. Submitted to the 2016 ASCO Annual Meeting, June 3-7, 2016, Chicago, IL.
245. Gainer SM, Krishnamurthy S, Bhattacharyya A, Lodhi A, Hall C, Bedrosian I, Kuerer HM, Lucci A. Disseminated tumor cells predict worse outcome in patients with stage I-III breast cancer. Submitted to the 2012 Breast Cancer Symposium, September 13-15, San Francisco, CA.
246. Amaria R, Lucci A. Phase II study of pembrolizumab in conjunction with lymphodepletion (LD), tumor infiltrating lymphocytes (TILs), and high or low dose interleukin 2 (IL-2) in patients with metastatic melanoma (MM). Submitted to the 2016 ASCO Annual Meeting, June 3-7, 2016 in Chicago, IL.
247. Lucci A. Prognostic value of DTCs and CTCs in T2 and larger breast cancers. Submitted to Society of Surgical Oncology 2011 Annual Meeting.
248. Matsuda N, Alvarez R, Krishnamurthy S, Willey J, Wang X, Lim B, Parker C, Marx A, Babiera G, Booder D, Murray J, Arun B, Brewster A, Reuben J, Woodward W, Lucci A, DeSnyder S, Tripathy D, Valero V, Ueno N. Phase II Study of Panitumumab, Nab-paclitaxel, and Carboplatin Followed by FEC Neoadjuvant Chemotherapy for Patients with Primary HER-2 Negative Inflammatory Breast Cancer. Submitted to the 2015 ASCO Annual Meeting May 29 - June 2, 2015, Chicago, IL.
249. Cormier J, Cromwell K, Chiang YJ, Armer J, Mungovan K, Gershenwald J, Lee JE, Royal R, Lucci A, Ross MI. Lower Extremity Lymphedema Presents Earlier and has a Greater Impact on Quality of Life than Upper Extremity Lymphedema in Melanoma Patients. Submitted to the International Society of Lymphology 24th International Congress, September 16-20, 2013, Rome, Italy.
250. Hall CS, Walker A, Laubacher B, Singh B, Lucci A. Investigating cyclooxygenase-2 signaling in breast cancer-initiating cells. Submitted to ASCO 48th Annual Meeting, June 1-5, 2012, Chicago, IL.
251. Hall CS, Ross MI, Karhade M, Baudry J, Upshaw J, Royal R, Lucci A. Circulating Melanoma Cells Detected at Follow-up Predict Relapse in Stage III Melanoma. Submitted to the 2017 ASC 12th Annual Meeting in Las Vegas, NV.
252. Mosalpuria K, Lodhi A, Krishnamurthy S, Hallman DM, Baraniuk MS, Bhattacharyya A, Singh B, Lucci A. Cyclooxygenase-2 in early stage triple-negative breast cancer patients. The Breast.
253. Lucci A, Singh B. In vitro selection of potentially metastatic breast cancer cells. J Surg Res.
254. Naoto U, Savitri K, Lee H, Patinyanitkul N, Hout D, Seitz R, Morris S, Ying W, Arvind R, Tazawa S, Lucci, A. Apocrine morphology and LAR molecular subtype predict prognosis of TNBC patients with residual disease after neoadjuvant chemotherapy.
255. Alrwas A, Alvarado G, Bernatchez C, Wei C, Radvanyi L, Mansaray R, Fulbright O, Toth C, Ramachandran R, Wardell S, Gonzalez A, Papadopoulos N, Kim K, Bedikian A, Hwu WJ, Patel S, Woodman S, Davies M, Ross M, Lee JE, Gershenwald J, Cormier J, Lucci A, Royal R, Hwu P. Tumor-Infiltrating Lymphocytes growth as a prognostic factor in Metastatic Melanoma: A retrospective study. Submitted to the 10th International Meeting of the Society for Melanoma Research, November 17-20, 2013, Philadelphia, PA.
256. Lucci A, Hall C, Kuerer H, Anderson A, Karhade M, Laubacher B, Krishnamurthy S. Circulating and Disseminated Tumor Cells in non-Metastatic Breast Cancer. Submitted for Oral Presentation at the 49th Congress of the European Society for Surgical Research in Budapest, Hungary, May 21-24, 2014.
257. Voss RK, Cromwell KD, Chiang YJ, Armer JM, Ross MI, Lee JE, Gershenwald JE, Royal RE, Lucci A, Cormier JN. Melanoma patients have a higher incidence but later onset of upper extremity lymphedema than breast cancer patients following axillary lymph node dissection. Submitted to SSO's 68th Annual Cancer Symposium, March 25-28, Houston, TX.
258. Giordano A, Gao H, Cohen EN, Krishnamurthy S, Tin S, Lodhi A, Cristofanilli M, Hortobagyi GN, Woodward WA, Lucci A, Reuben JM. Cancer stem cells in bone marrow as prognostic factor in early breast cancer patients. ASCO 48th Annual Meeting, June 1-5, 2012, Chicago, IL.
259. Rie TK, James R, Babita S, Fujii T, Lucci A, Nuhad I, Senthil D, Shen Y, Lui D, Hortobagyi G, Tripathy D, Lim B, Chasen B. CTCs and SUV to predict the efficacy of the bone-specific radiopharmaceutical agent radium-223 dichloride combined with hormonal therapy for hormone receptor-positive bone-dominant breast cancer metastasis.
260. Kuerer HK, van la Parra R, Rauch G, Krishnamurthy S, Caudle A, DeSnyder S, Black D, Lucci A, Goravanchi F, Hobbs B, Hwang R, Adrada B, Smith B, Candelaria R, Arribas E, Moseley T, Babiera G, Santiago L, Valero V, Yang W. Clinical trials for eliminating breast cancer surgery in exceptional responders. 21st World Congress on Advances in Oncology and 19th International Symposium on Molecular Medicine, October 6-8, 2016, Metropolitan Hotel, Athens, Greece.
261. You Y, Hall CS, Lucci A, Bednarski BK, Rodriguez-Bigas MA, Messick CA, Feig BW, Skibber JM, Chang MD, MS GJ. A Prospective Study of Circulating Tumor Cells in Patients with Locally Advanced Rectal Cancer. Submitted to the ASCRS 2016 Annual Scientific Meeting in Dallas, TX, April 30-May4, 2016.
262. Singh B, Sarli VN, Lucci A. Evaluation of 6-mercaptopurine in a cell culture model of adaptable triple-negative breast cancer with metastatic potential. Submitted for Presenation at the American Association for Cancer Research in Atlanta, Georgia, March 29-April 3, 2019.
263. Singh B, Shamsnia A, Raythatha M, Lucci A. Developing a predictive cell-based assay for anti-cancer drug selection. Submitted to the AACR 2013 Annual Meeting, April 6-10, 2013, Washington, DC.
264. Singh B, Raythatha M, Amanda C, Shamsnia A, Lucci A. Breaking news/IBC Research or Discovery. Third International Inflammatory Breast Cancer Conference.
265. Kuerer HM, Rauch G, Krishnamurthy S, Diego E, Yang W, Shen Y, Lin H, Lucci A, Moseley T, Ramirez DL, Mouabbi JA, Boughey J, Shaitelman S, White R, Hunt K, Mitchell M, Teshome M, Johnson H, Smith B, Valero V. 243O Omission of breast surgery after neoadjuvant systemic therapy for invasive cancer: Three-year preplanned primary-endpoint on a phase II multicentre prospective trial. Accepted for presentation at ESMO Conference 34(Supplement 2):S280.
266. Soran A, Senol K, Bayley E, Ozbas S, Dogan L, Ain Sabih QU, Al-Azhri J, Goktepe B, Zaveri S, Meas S, Demirors B, Ozmen V, Lucci A. A Multi-Institutional Real-World Data Analysis of Overall Survival with Locoregional Therapy (LRT) in Stage IV Solitary Bone-Only Metastatic Breast Cancer (BC). Accepted for presentation at Society of Surgical Oncology Annual Meeting.
267. Chen J, Tidwell RS, Kai M, Johnson H, Lucci A, Woodward W. Impact of Postpartum Diagnosis on Survival Outcomes in Inflammatory Breast Cancer. Accepted for presentation at American Society of Breast Surgeons Annual Meeting.
268. Braschi E, Yang Y, Stauder M, Woodward W, Layman R, Lim B, Arnold T, Lucci A, Sun S, Saleem S, Ludmir E, Kelsey C. Rare but Relevant: Exploring Factors behind the Exclusion of Inflammatory Breast Cancer from Breast Cancer Clinical Trials. Accepted for Poster Presentation, Annual ASTRO 2024.
269. . Baseline circulating tumor cells (CTCs) predict for progression-free survival (PFS) after ablation on NRG-BR002, a randomized phase II/III study of ablation vs. standard systemic therapy care (SOC) for oligometastatic breast cancer (OMBC). San Antonio Breast Cancer Symposium.
270. Chen JH, Liu Y, Meas S, Kundu S, Lucci A, Zaveri S. Selective De-Escalation of Surgery: Trends in Surgical Management of de Novo Stage IV Breast Cancer Over the Past Decade. Accepted for poster presentation at San Antonio Breast Cancer Symposium.
271. Chen JH, Meas S, Bassett RL, Sarli VN, Upshaw J, Le-Petross HT, Valero V, Lim B, Woodward WA, Lucci A. Molecular Residual Disease Precedes Radiographic Confirmation of Recurrence in Patients with Stage III Inflammatory Breast Cancer. Accepted for poster presentation at San Antonio Breast Cancer Symposium.
272. Chen JH, Meas S, Slack Tidwell BS, Sarli VN, Upshaw J, Cancer Team MIB, Krishnamurthy S, Valero V, Layman RM, Nasrazadani A, Sun SX, Lim B, Woodward WA, Lucci A. Preoperative Predictors of pCR for Potential De-Escalation of Surgery in Inflammatory Breast Cancer. Accepted for poster presentation at San Antonio Breast Cancer Symposium.
273. Lucci A. Nodal imaging concordance with pathologic findings after neoadjuvant immunotherapy in patients with Stage III melanoma. Accepted for Resident/Fellow Top Poster Presentation at the SSO 2025 Annual Meeting.
274. Postlewait LM, Teshome M, DeSnyder SM, Lim B, Kuerer HM, Woodward WA, Ueno NT, Lucci A. Factors Associated with Pathologic Node Negativity in Inflammatory Breast Cancer: Are there patients who may be candidates for sentinel lymph node biopsy or targeted axillary dissection?. Accepted as a Quick Shot Presentation at the Society's 21st Annual Meeting.
275. Liang D, Hall C, Meas S, Narendran B, Sarli V, Lucci A. Pilot study of circulating tumor cells before and after neoadjuvant chemotherapy in non-metastatic inflammatory breast cancer. Accepted as a Oral Presentation at the Society of Surgical Oncology 2020 International Conference on Surgical Cancer Care.
276. Lucci A, Vicente D, Lee AJ, Hall CS, Vreeland T, Newhook T, Lee JE, Kim MP, Katz M, Hurd M, Alvarez H, Maitra A, Rhim AD, Tzeng CWD. Circulating Tumor Cells and Transforming Growth Factor Beta in Pancreatic Adenocarcinoma. Accepted for Quick Shot Presentation at the 14th Annual Academic Surgical Congress.
277. Lucci A, Hall C, Sarli V, Upshaw J, Meas S, Narendran B, Wang F, Li Y, Ross MM. CTCs AND SENTINEL LYMPH NODE BURDEN IN MELANOMA PATIENTS. Oral Presentation to 2020 Global Academic Program Conference.

Book Chapters

1. Singh, B, Mujoo, K, Lucci, A. Therapeutics of Oxidative Stress and Stemness in Breast Cancer. In: Handbook of Oxidative Stress and Cancer. Springer, 1765-1776, 2022.
2. Liang DH, Hall C, Lucci A. Circulating Tumor Cells in Breast Cancer. In: Recent Results Cancer Res. Springer, 127-145, 2020.
3. Singh B, Mujoo K, Lucci A. Therapeutics of Oxidative Stress and Stemness in Breast Cancer. In: Handbook of Oxidative Stress and Cancer. Springer, 2020.
4. Lucci A, DeSnyder SM, Fayanju OM. Sentinel Lymph Node Biopsy in Breast Cancer. In: Fischer's Mastery of Surgery. 7th, 2018.
5. Partain NS, Lucci A. Alternatives to Tissue Rearrangement: Suture Lattice Technique Combined With Absorable Radiographic 3D Tissue Marker for Cavity Marking and Cosmesis. In: Master Techniques in General Surgery, 443-454, 2018.
6. Fayanju L, Lucci A. Investigational Molecular Prognostic Factors for Breast Carcinoma. In: The Breast. 5th, 2017.
7. Gainer SM, Lodhi AK, Lucci A. Breast Cancer Occult Micrometastasis in Bone Marrow and Blood. In: Advanced Therapy of Breast Disease. 3rd. People's Medical Publishing House, 951-956, 2012.
8. Gainer SM, Yamauchi H, Lucci A. Surgical Therapy for Inflammatory Breast Cancer. In: Inflammatory Breast Cancer: An Update. 1. Springer, 67-74, 2012.
9. Rourke L, Buchholz T, Lucci A. Treatment of Ductal Carcinoma In Situ. In: Advanced Therapy in Surgical Oncology. 1. BC Decker Inc, 482-488, 2007.
10. Rosenkranz K, Lucci A. Surgical Treatment of Breast Cancer during Pregnancy. In: Breast Diseases. IOS Press, 2005.
11. Lucci A, Shoher A. Lymph Node Micrometastases. In: Diseases of the Breast. Lippincott, Williams and Wilkins, 2003.
12. Yamauchi H, Woodward W, Valero V, Alvarez R, Lucci A, Buchholz T, Iwamoto T, Krishnamurthy S, Yang W, Reuben J, Hortobagyi G, Ueno N. Surgical Therapy. In: Inflammatory Breast Cancer: What Do We Know and What Do We Need to Learn?.
13. Lim B, Stauder M, Woodward W, Lucci A, Ueno N. Inflammatory Breast Cancer - How we treat patients at MD Anderson. In: Breast Cancer. 3.

Books (edited and written)

1. Kuerer, H. Kuerer's Breast Surgical Oncology. Ed(s) 1. Harrison's Textbook of Medicine and Schwartz's Principles of Surgery, 2010.